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Abstract 
 
Bones provide mechanical support for movement and normal daily functions, which 
can only be provided when healthy. Bone diseases such as osteoporosis and cancer 
are a worldwide problem affecting millions of people and causing significant financial 
impact. This study should indicate possible solutions that might contribute to 
combatting bone diseases by understanding the expression of bone markers that are 
known to be expressed differentially at different stages of osteoblastic differentiation. 
Thus a reliable, easily available and easy to maintain bone cell model was selected 
using osteosarcoma cell lines (MG-63, TE-85 and SaOS-2). The effect of ATP and 
PTH treatments on the expression of these markers was also tested to determine 
differences with primary osteoblasts (HOBs). We also determined the differential 
expression of miRNAs between the cell lines and HOBs and identified miRNAs 
involved in regulating expression of sclerostin, examining also their effect on the 
properties of trabecular bone in a mouse model. We hypothesized that these models 
were appropriate for studying the biology of osteoblastic cells and that miRNAs could 
control bone cell phenotype. 
 
In the first objective of this study, the expression of seven bone markers actively 
involved in bone development (OPG, ALP, COL1A2, COL6A3, SOST, OSX and 
RANKL) were investigated. The expression of OPG, COL1A2 and COL6A3 were 
significantly higher in the least differentiated cell line, MG-63, while expression of 
ALP, SOST, OSX and RANKL were highest in SaOS-2, the most differentiated. ATP 
and PTH exerted the expected inhibitory or inductive effects on the cells at the 
osteoblastic maturation stage confirming that the cell lines were a suitable model for 
the study of osteoblasts. 
 
MicroRNA profiling of cell lines and HOBs revealed hundreds of differentially 
expressed miRNAs. Six that were predicted to target the regulation of SOST were 
chosen for further validation. Mimics and antagomirs of these were transfected into 
TE-85 and SaOS-2 cells to confirm their involvement in SOST expression regulation. 
SOST gene expression and protein production were quantified by qPCR and ELISA, 
revealing that miR-1231, miR-1254 and miR-1914 decreased SOST protein 
expression in TE-85 and SaOS-2 cells and miR-378a-3p in just TE-85 cells, but these 
effects were not reversed by the corresponding antagomir. Adult and elderly mice 
were treated with miR-378a-3p mimic and antagomir by injection into the tail vein. 
Few differences could be observed in trabecular bone three weeks following 
treatment, except for significantly increased trabecular pattern factor and decreased 
trabecular separation in elderly mice treated with miR-378a-3p mimic. 
 
In conclusion, this thesis demonstrates that ATP and PTH regulate osteosarcoma cell 
lines similarly to HOBs and that miRNAs can be used to control SOST protein 
expression. Potential future studies should investigate miRNAs as novel therapies for 
bone diseases. 
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CHAPTER 1: 
INTRODUCTION 
  
2 
 
1.0 Overview 
Osteoporosis is the commonest metabolic skeletal disease, affecting more than 200 
million individuals worldwide (Pesce et al., 2009). The estimated annual cost of 
treatment for osteoporosis in the US alone is more than $22 billion (Blume & Curtis, 
2011). Osteoporosis is characterized by low bone mass and altered bone quality, 
which causes fragility and fractures. 
 
Bone health is maintained by two major cell types in a delicate balance of active 
bone remodelling through bone resorption by osteoclasts and bone formation by 
osteoblasts. The activities of these bone cells are regulated through dynamic and 
complex genomic and biological functional networks (Krampera et al., 2006; Matsuo 
& Irie, 2008). Therefore, understanding the molecular regulators of these networks 
is essential for developing novel agents to allow early diagnosis and an effective 
therapy for metabolic bone disorders such as osteoporosis. 
 
This research project was directed towards understanding the molecular 
mechanisms regulating the development of bone and differentiation of osteoblasts. 
This provided some understanding of underlying age-related metabolic bone 
disorders such as osteoporosis using modern cellular and molecular biology 
approaches which in the future could provide strategies for enhancing bone 
regeneration in sufferers of metabolic bone disorders. 
 
 
  
3 
 
1.1 HUMAN BONE BIOLOGY 
 
1.1.1 Overview 
Bone is a highly specialised connective tissue which performs many important 
functions. Human bone serves numerous critical roles for the body such as 
protection of the inner body vital organs and tissue, support, movement, housing of 
bone marrow and the major reserve for calcium and phosphorus (Chan & Duque, 
2002; Kini & Nandeesh, 2012; Raisz, 1999). Human bone tissue is composed of 
bone matrix and bone cells. Almost 90% of bone matrix comprises type 1 collagen, 
the remaining 10% being composed of a large number of non-collagenous proteins 
such as osteocalcin, osteonectin, bone sialoproteins and various proteoglycans 
(Arvidson et al., 2011). Osteoblasts, osteoclasts and osteocytes are the three main 
types of bone cell which play the major role in the bone formation process.  
 
 
1.1.2 Bone cells 
There are three types of bone cells: osteoclasts, osteoblasts and osteocytes. 
Osteoclasts are responsible for bone resorption while osteoblasts are cells that form 
new bone and osteocytes maintain bone and the lining cells that cover the surface 
of bone. 
 
 
1.1.2.1 Osteoclasts  
Osteoclasts are highly specialized, multinucleated cells that originate from 
mononuclear macrophage/monocyte-lineage haematopoietic precursor cells which 
are formed in the bone marrow (Boyce, 2013; Kikuta & Ishii, 2013). Mature 
osteoclasts are very large (50-100 µm in diameter), containing 2 – 100 nuclei, 
although normally in the range 10 – 20 (Huijing & Baan, 2003; Duce, 2010; 
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Roodman, 1991). However, Henriksen et al. (2011) and Cheung et al. (2009) 
reported that the size of osteoclasts is increased in Paget’s disease and in 
osteogenesis imperfecta patients. On the other hand, a significant reduction in the 
size of osteoclasts (18 ± 3 µm diameter) and number of nuclei (2 – 3 in each cell) 
have been reported in osteopetrosis patients (Madyastha et al., 2000). 
 
The main ultrastructural characteristics of osteoclasts include an abundance of 
pleomorphic mitochondria, numerous lysosomes, free ribosomes and cytoplasm 
which contains large quantities of granules (Huijing & Baan, 2003; Roodman, 1991). 
Mature osteoclasts are short-lived cells (approximately 2 weeks) and can be found 
on the surface of trabecular and endosteal cortical bone (Edwards & Mundy, 2011). 
 
The main function of mature osteoclasts is to resorb bone via a highly controlled 
process. Mature osteoclasts are the only known cells in the body that are capable of 
removing old and damaged bone (Edwards & Mundy, 2011). Development and 
survival of osteoclasts are controlled and influenced by several hormones (such as 
parathyroid hormone, calcitonin, interleukin 6 and estrogen), osteoprotegerin (OPG) 
and receptor activator of nuclear factor kappa-B ligand (RANKL). Over-expression 
of osteoclasts results in the formation of various bone diseases such as 
osteoporosis, while defective osteoclast formation can culminates in osteopetrosis 
(Boyce, 2013). 
 
 In the past, it was problematic studying osteoblasts due to their low availability and 
labile nature when isolated from bone. However, new techniques have been 
developed, which have contributed to an improved understanding of osteoclast 
biology. Nowadays, increased research effort is being conducted to identify other 
functions of these fascinating cells. A growing number of research studies focus of 
the function of osteoclasts as immune cells. Our understanding of differentiation, 
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fusion, survival, function and apoptosis of osteoclasts in normal and pathological 
conditions may contribute to new findings of better therapies for bone metabolic 
disorders. 
 
 
1.1.2.2 Osteoblasts 
Osteoblasts are mononucleated cells which develop from bone marrow 
mesenchymal stem cells via the canonical Wnt signalling pathway (Logan & Nusse, 
2004). Osteoblasts are single layer cuboidal cells located on periosteal or endosteal 
bone surfaces (Mackie, 2003). Osteoblasts are responsible for the regulation of 
bone formation and indirectly control bone resorption via the secretion of RANKL 
(Logan & Nusse, 2004; Mackie, 2003). Osteoblasts deposit the organic bone matrix 
of osteoid, which mainly comprises type I collagen and then contributes to its 
mineralisation. An osteoid seam, a thin layer of unmineralised bone matrix, 
separates osteoblasts from mineralised bone matrix (Mackie, 2003). However, 
some osteoblasts which are trapped in the bone matrix become osteocytes which 
later gradually stop secreting osteoid. 
 
Other osteoblasts which are not trapped in the bone matrix undergo apoptosis or 
become the lining cells on the surface of the bones (Jilka et al., 1999). Other 
factors, such as hormones, transcription factors and growth factors also have 
regulatory effects on osteoblasts which determine bone growth (Harada & Rodan, 
2003). However, the number of osteoblasts decreases over the years which results 
in the loss of balance between bone formation and bone resorption. Deterioration of 
bone formation activity by osteoblast leads to osteoporosis (D'Ippolito et al., 1999). 
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1.1.2.3 Osteocytes 
Osteocytes are the most abundant cells in bone comprising 95% of bone cells 
(Dallas & Bonewald, 2010; Kini & Nandeesh, 2012; Mackie, 2003). Osteocytes are  
mature osteoblastic cells that lies within a lacuna, a small pit in the calcified matrix 
of fully formed bone (Manolagas, 2000) which acts as a mechanosensor detecting 
environmental changes that affect bone such as an increase or decrease in 
workload. Osteocytes send signals to osteoblasts and osteoclasts informing them 
where and when to reabsorb or form new bone. Osteoblasts, which are embedded 
in bone matrix, differentiate into osteocytes (Divieti Pajevic, 2013). They survive in 
the bone matrix they occupy as long as the bone exists. Osteocytes communicate 
with nearby cells and even distant tissues and organs through small channels that 
penetrate the surrounding bone called canaliculi. Osteocytes secrete substances 
through tentacle-like dendrites within the canaliculi and influence the activity of 
osteoclasts and osteoblasts (Dallas et al., 2013). Osteocytes are also capable of 
sensing mechanical stress and the daily wear-and-tear that occurs in healthy bone. 
Osteocytes then communicates with other osteoblastic cells to undertake the 
necessary repairs or adaptation (Pajevic, 2013). 
 
Mature osteocytes are the only cells that produce sclerostin (SOST), a protein that 
plays a vital role in new bone formation by blocking the Wnt signalling pathway 
(Bonewald, 2011; Brunkow et al., 2001). Thus, when sclerostin secretion from 
osteocytes increases, the production of new bone slows down. Following a bone 
fracture, osteocytes secrete insulin-like growth factor (IGF) that stimulates 
osteoblast activity which accelerates the formation of new bone (Sheng et al., 
2014).  
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1.1.2.4 Lining cells 
Bone lining cells are a relatively inactive form of osteoblasts that cover the surface 
of bone. Lining cells are thinly extended over bone surfaces and contain few 
cytoplasmic organelles (Nakamura, 2007). The precise function of bone lining cells 
is still not well understood. However they seem to be involved in the maintenance of 
bone fluid, responsible for the immediate release of calcium from bone when the 
calcium levels in blood are low and for protecting bone from factors which could 
degrade bone structure. Bone resorption by osteoclasts is not complete as they 
leave some demineralized non-digested bone collagen.  Bone lining cells enter the 
resorption pit and digest the remnants of collagen left by osteoclasts, forming a 
cement line and depositing a thin layer of fibrillar collagen on the cleaned surface 
(Everts et al., 2002). 
 
 
1.1.2.5 Osteosarcoma cell lines 
Osteosarcoma (also called osteogenic sarcoma) is the most common type of 
primary bone malignancy derived from primitive mesenchymal cells (Ritter and 
Bielack, 2010). Osteosarcoma can occur at any age but mostly occurs in children 
and young adults when bone growth is rapid. Osteosarcoma normally occurs in the 
metaphyseal area of long bones with approximately 75% of all cases take place in 
the proximal tibia and distal femur (Longhi et al., 2006). Tumor or sarcoma cell lines 
has been considered as a good in vitro models for studying general cell biology, 
malignancies, drug discovery, the functional characteristics of genes and many 
more. Studies have shown that cell lines adequately represent the tumors they are 
originating from and considered as a good model to study the cell biology as long as 
they are cultured in controlled culture conditions (Drexler et al., 2003). In this study, 
we used 3 osteosarcoma cell lines, MG-63, TE-85 and SaOS-2 as the bone model. 
These three cell lines have been shown to represent different stages of osteoblastic 
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differentiation; MG-63 has been shown to represent osteoblastic cell at the early 
stage of differentiation, TE-85 represent the intermediate differentiation stage and 
SaOS-2 represent the most differentiated cell. These cell lines provide a robust 
model to study bone biology at different stages of osteoblastic differentiation 
(Pacheco-Pantoja et al., 2011). 
 
 
1.1.3 Bone Formation 
There are two processes comprising bone formation: bone remodelling and bone 
modelling. Both processes are highly regulated. Bone remodelling is a continuous 
process which involves bone resorption by multinucleated osteoclasts followed by 
bone formation by osteoblasts. In healthy individuals, a balance in the activity of 
osteoclasts and osteoblasts results in the maintenance of healthy bone mass. 
 
 
1.1.3.1 Bone modelling 
Bone modelling differs from bone remodelling. Bone modelling is a process where 
osteoblasts deposit new bone matrix without prior bone resorption by osteoclasts. 
This process occurs mainly during the growth phase, especially during the early 
developmental stages, before the age of 20 years in humans. Bone modelling 
increases bone size, its strength and modifies bone shape. Bone modelling is an 
adaptive response to the biomechanical force experienced by the bone to prevent 
the occurrence of injury to the bone (Crockett et al., 2011; Martin & Seeman, 2008). 
This explains why the dominant arm of a tennis player has a thicker cortex and a 
larger external diameter than the contralateral radius. However, bone modelling 
normally is less frequent compared to bone remodelling (Brandi, 2009).  
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1.1.3.2 Bone Remodelling  
Bone remodelling is a complex continuous process which involves a series of highly 
regulated sequential steps (Raisz, 1999). Bone remodelling allows the bone to 
grow, repair itself and adapt to environmental signals such as an increase or 
decrease in workload (Orriss et al., 2010). Rapid skeletal growth during the early 
stages of bone development and stable maintenance of bone mass during adult life 
is the result of a careful balance between bone formation by osteoblasts and bone 
resorption by osteoclasts (Bielby et al., 2007). In humans, this process peaks 
around 20 years of age when bone formation exceeds bone resorption. For the next 
40 years, human bone mass remains relatively stable. However, with ageing, the 
stable process of bone formation and resorption is affected by a reduction in 
osteoblast differentiation activity resulting in loss of bone mass (Horowitz et al., 
2001). 
 
The bone remodelling process starts when lining cells on the bone surface move 
apart to expose the bone surface. These lining cells then develop into osteoblasts 
and begin to secrete RANKL, which binds to RANK on the surface of osteoclast 
precursor cells, initiating their fusion and development into mature osteoclasts. 
Osteoblasts continuously secrete RANKL which is essential for the formation, 
function and survival of the osteoclasts. Osteoclasts attach to the bone surface 
creating an acidic seal zone which dissolves bone mineral content. Osteoblasts 
then release matrix-degrading enzymes, hydrogen ions and chloride ions to remove 
the remaining collagen of the bone matrix to complete the bone resorption process 
(Edwards & Mundy, 2011). 
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Figure 1.1: Bone remodelling involves solubilisation of bone mineral and 
degradation of bone matrix by osteoclasts followed by a bone formation phase by 
osteoblasts which produce osteoid matrix 
 
Following resorption, osteoblasts move to the resorption space and deposit an 
organic matrix known as osteoid which mainly comprises collagen. Minerals such as 
calcium and phosphate begin to crystallize around the collagen scaffold and provide 
a strong framework for the bone (Fig. 1.1). 
 
1.1.3.3 Bone repair 
Bone repair is a complex process which involves four overlapping stages; 
inflammatory response, soft callus formation, hard callus formation and bone 
remodelling. Inflammatory process starts immediately after bone injury or fracture 
happens and lasts until bone formation starts. The bleeding at the fracture site is 
contained by the surrounding tissues and develops into a hematoma. Degranulating 
platelets, macrophages and inflammatory cells such as lymphocytes, monocytes 
and granulocytes enter the hematoma to prevent the infection and secrete growth 
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factors and cytokines (Gerstenfeld et al., 2003). In stage 2, pain and swelling start 
to decrease and soft callus is formed. This semi-rigid soft callus provides 
mechanical support to the fracture and act as a template for the growth of the new 
bone. Stage 3 is also known as primary bone formation. At this stage, osteoblast 
activity and the mineralization of bone matrix are at the highest level. The soft callus 
is gradually removed and replaced with new bone known as hard callus. Hard callus 
is normally irregular, woven and under-remodeled. In the final stage, which is the 
bone remodelling stage also known as secondary bone formation, the bone 
remodelling process starts when the fracture has solidly fused with woven bone. 
Lamella bone then slowly replaces the woven bone through the remodelling process 
which involves bone resorption followed by the formation of lamellar bone. This 
process lasts until the bone has completely returned to its original morphology and 
might takes anything from a few months to several years (Gerstenfeld et al., 2003; 
Mulari et al., 2004). 
 
 
1.1.4 Bone diseases  
The maintenance of healthy bone is a result of a delicate balance between bone 
resorption and bone formation (Calvo et al., 1996). However, as age increases and 
after the menopause in women, the balance of this complex process is disturbed by 
a few factors such as changes in the production of hormones and growth factors 
(Silva-Fernandez et al., 2013). After the age of 30, bone resorption increases while 
bone formation starts to slow down. At this stage, bone resorption slightly exceeds 
bone formation leading to a slow but continuous loss of bone. Loss of bone mass 
density reduces bone strength and increases the risk of bone fracture, a condition 
known as osteoporosis (Li et al., 2013). Currently, osteoporosis is the most common 
bone metabolic disorder and is considered a major global health problem (Arvidson 
et al., 2011; Pesce et al., 2009). Osteoporosis is also characterised by a 
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deterioration in microarchitectural bone tissue and the degradation of matrix protein. 
Its incidence increases with age in both women and men and is usually clinically 
symptomless until the occurrence of the first fracture (Stromsoe, 2004). Fractures 
most commonly occur in the hip, ankle, proximal humerus, vertebrae and wrist, 
causing disability to patients and a heavy economic burden for many countries 
(Pesce et al., 2009). Today, bisphosphonates are the most common class of 
antiresorptive medications used for the treatment of osteoporosis. Bisphosphonates 
efficiently inhibit osteoclastogenesis in bone marrow, supressing osteoclast activity 
on the surface of bone and reducing osteoclast life span by the induction of 
apoptosis (Rodan & Fleisch, 1996).  
 
Osteogenesis imperfecta (OI) is another type of bone disease which is 
characterized by bones that break easily. The term “osteogenesis imperfecta” 
means imperfect bone formation. This disease is a rare, inherited skeletal disorder 
which is caused by the mutation involving multiple genes, especially COL1A1 and 
COL1A2 which are responsible for the synthesis of collagen type 1, the most 
abundant protein in the human body that is crucial for the formation of strong bone 
(Pillion et al., 2011). The most distinctive sign of OI is the occurrence of fractures 
even with very minor accident which might happen just a few or as many as 
hundreds of fractures in a lifetime. OI patients can also suffer other symptoms 
including brittle teeth, a curved spine, weak muscles and hearing loss (Cundy, 
2012). Until today, there is no cure for OI. Patients are treated with pain medicine, 
physical therapy, braces, exercise and surgery. 
 
Multiple myeloma is a cancer of the malignant plasma cells in the bone marrow. 
When the cancerous plasma cells grow out of control, a tumor called a 
plasmacytoma is formed which normally develop in a bone, rarely in other tissue 
(Blade et al., 2012). If there is only a single plasma cell tumor, it is called isolated or 
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solitary plasmacytoma. However, when there are more than one plasmacytoma, it is 
called multiple myeloma. Multiple myeloma represents one percent of human 
cancers and contribute to almost two percent of total cancer death (Palumbo and 
Anderson, 2011). Multiple myeloma is normally characterized by low blood counts, 
kidney damage, bone pain, infections and high calcium levels in the blood but the 
bones are weak due to increase in bone break-down by osteoclasts but bone repair 
and growth by osteoblast is suppressed (Khan et al., 2015; Palumbo and Anderson 
2011).  
 
The balance between the activity of osteoblasts and osteoclasts is essential for the 
maintenance of healthy bone mass. Too much bone resorption by osteoclasts leads 
to a weakening of bone. However, if the bone resorption process is too low, bone 
overgrowth is another serious health concern. Osteopetrosis is an inherited genetic 
bone disease where the bone density increases significantly due to failure of bone 
resorption by osteoclasts or a reduced number of osteoclasts, characterised by 
osteosclerosis, obliteration of the medullary canal, calcified cartilage and brittle 
bone (Xie et al., 2015). There are three main types of osteopetrosis, based on 
clinical forms and genetic transmission: infantile malignant (an autosomal recessive 
form) which is early onset and normally causes lethal outcome in the first decade of 
life if no treatment is given; intermediate (another autosomal recessive form) which 
occurs in the first decade of life but with an expectation of a normal life span and 
benign (an autosomal dominant form) which is milder and is late onset (Mikami et 
al., 2016; Palagano et al., 2015; Ye et al., 2013).  
 
Bone cancer is one of the most studied bone diseases. There are two types of bone 
cancer; primary bone cancer and secondary bone cancer. Primary bone cancer 
begins in the bones while secondary bone cancer is the cancer that spreads to the 
bones after developing in another part of the body such as the breast, lung or 
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prostate (Paley et al., 2011). Bone cancers normally develop in the long bones of 
the upper arms and the legs and rarely affect other types of bone. Persistent bone 
pain, noticeable lump over a bone, bone that fractures easily and inflammation over 
a bone are among the main symptoms of bone cancer. Until today, in most cases, 
the reason why a person develops bone cancer is still unknown. However, 
researchers have found that we are more at risk of getting bone cancer if we 
exposed to radiation such as during radiotherapy (Wong et al., 1997). Treatment for 
bone cancer depends on how serious or how far it has spread and the type of the 
bone cancer the person has. Most patients are treated with surgery to remove the 
section of the cancerous bone, chemotherapy and/or radiotherapy where the 
cancerous cells are destroyed using radiation. A study has shown that 
bisphosphonates effectively provide pain relief from pain for bone cancer patients 
even though it can cause side effects such as nausea and vomiting (Wong and 
Wiffen, 2002). 
 
 
1.1.5 Current treatments of bone diseases 
In recent years, there have been important advance achievements and abilities to 
treat and prevent bone related diseases, especially in those suffering fragile bones 
such as osteoporosis, multiple myeloma and osteogenesis imperfecta. Today, 
bisphosphonates are the most commonly used agents for both treatment and 
prevention of these fragile bone diseases. Bisphosphonates, such as alendronate, 
risedronate and ibandronate normally come in tablet form which is taken daily, 
weekly or monthly (Bock and Felsenberg, 2008). Denosumab, another current 
treatment which is widely used is a humanized monoclonal antibody which is given 
to the patients through injection in every 6 months. Compared to bisphosphonate, 
denosumab works differently but has the same effect of slowing the rate of bone 
loss by inhibiting osteoclast activity (McClung, 2017). Other treatments includes 
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strontium ranelate to enhance pre-osteoblastic cells replication (Reginster, 2002), 
hormone replacement therapy using estrogen or progestogen (Shulman, 2008) and 
teriparatide (recombinant human parathyroid hormone (1-34)(PTH[1-34]) that acts 
as an anabolic agent) (Lindsay et al., 2016).  
 
 
1.2 Bone markers 
 
1.2.1 Overview 
Studies of the cellular and extracellular components of skeletal matrix have resulted 
in the development of bone markers that provide information on bone dynamics. 
These bone markers are categorised as either markers of bone formation or 
resorption (Wheater et al., 2013). Bone markers have been used as an early 
diagnosis of bone lesions and for predicting the rate of bone loss in 
postmenopausal woman and evaluation of the risk of future fractures (Terpos et al., 
2010). The advantage of analysing bone markers is their cost effectiveness, the 
speed and non-invasiveness and the significant help they provide in assessing 
disturbances in bone metabolism. In this study, we examined the expression of 
seven bone markers (osteoprotegerin (OPG), alkaline phosphatase (ALP), collagen 
1a2 (COL1A2), collagen 6a3 (COL6A3), receptor activator of nuclear factor Kappa-
B Ligand (RANKL), osterix (OSX) and sclerostin (SOST)) in human osteosarcoma 
cell lines. 
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1.2.2 Bone markers used in this study 
 
1.2.2.1 Osteoprotegerin 
Osteoprotegerin (OPG) is a dimeric glycoprotein belonging to the tumour necrosis 
factor (TNF) receptor superfamily. OPG is also known as osteoblast binding factor 
(OBF), tumour necrosis factor receptor superfamily member 11B (TNFRSF11B) and 
osteoclastogenesis inhibitory factor (OCIF) (Kini & Nandeesh, 2012; Kwon et al., 
1998; Leibbrandt & Penninger, 2008; Perlot & Penninger, 2012). OPG is extensively 
expressed as a soluble protein by osteoblasts and other cells from the spleen, 
heart, liver, kidney and bone marrow (Leibbrandt & Penninger, 2008; Wada et al., 
2006). OPG plays an important role in inhibiting the recruitment, differentiation and 
activation of osteoclasts by inhibiting the binding of RANKL to RANK, thereby 
reducing the bone resorption process by mature osteoclasts and protecting bone 
from excessive bone loss. Imbalance in OPG expression can lead to an increase in 
bone resorption which then results in osteoporosis or other bone metabolic 
disorders (Kini & Nandeesh, 2012). 
 
 
1.2.2.2 Alkaline phosphatase 
Alkaline phosphatase (ALP) is a metalloenzyme present in serum in as different 
isoenzymes in different tissues, such as liver, kidney, placenta, intestine and bone 
(Gomez et al., 1995). However, most ALP isoenzymes derive from the bone and 
liver (Mukaiyama et al., 2015). ALP is expressed in many species (plants, bacteria 
and animals) and functions differently in different organisms and tissues (Golub & 
Boesze-Battaglia, 2007). In this study, we will focus only on bone ALP to investigate 
its role in mineralisation. Bone ALP is one of the most commonly used bone 
formation markers for the study of bone development because of easy measurability 
and its potential use as identifiers for prediction of the potential risk of bone 
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fractures associated with bone metabolism disorders (Havill et al., 2006). Bone ALP 
is a non-collagenous protein secreted by osteoblasts and vital for bone 
mineralisation, which defines ALP as a highly specific marker of osteoblast function 
(Rey et al., 2007). In bone and calcifying cartilage, ALP expression is highest during 
the early stage of development. In the later stages, the expression of ALP declines 
while other genes such as osteocalcin are upregulated, clearly demonstrating that 
ALP fulfils its role during the initial phases of hard tissue formation (Golub & 
Boesze-Battaglia, 2007). 
 
 
1.2.2.3 Collagen 1A2 
Type 1 collagen is the most abundant protein in the skeleton, composed of two α1 
chains and one α2 chain (Phillips et al., 2000). Any mutation in genes encoding type 
1 collagen can cause various bone, cartilage and blood vessel diseases ranging 
from mild to life threatening (Forlino & Marini, 2016). Collagen type 1 α-2 chain is a 
protein that is encoded by the COL1A2 gene and a crucial component of bone 
matrix as it plays a vital role in bone formation and architecture. Mutations in the 
COL1A2 gene are known to cause the autosomal dominant disorder osteogenesis 
imperfecta (OI) characterized by fragile and brittle bones from early childhood and 
low bone mineral density (BMD) (Forlino & Marini, 2016; Styrkarsdottir et al., 2016).  
 
 
1.2.2.4 Collagen 6A3 
Collagen 6 is a microfibrillar protein widely expressed in all connective tissues. It is 
composed of three genetically different subunits or isoforms, α1(VI), α2(VI) and 
α3(VI) encoded by COL6A1, COL6A2 and COL6A3, respectively. Each isoform 
contains a relatively short triple helix structure, about 335 amino acids long 
(Lamande et al., 2006). COL6A3 is known to be involved in fibrosis (Khan et al., 
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2009), metabolic dysregulation in obesity (Pasarica et al., 2009) and is a potential 
diagnosis and prognosis marker of colorectal carcinoma (Qiao et al., 2015). It has 
been shown that deficiency of the α3 subunit in mice leads to decreased muscle 
mass and contractile force (Pan et al., 2013).  
 
1.2.2.5 RANKL 
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) is a type ll 
transmembrane protein which belongs to the tumour necrosis factor (TNF) cytokine 
family. RANKL is also known as TNF-related activation-induced cytokine 
(TRANCE), osteoprotegerin ligand (OPGL) and osteoclast differentiation factor 
(ODF) (Fuller et al., 1998; Lacey et al., 1998; Takami et al., 2005).  RANKL is 
produced mainly by osteoblasts but also in other cell types such as bone marrow 
stromal cells, osteocytes and lymphocytes. However, recent studies have 
suggested that osteocytes embedded in bone express significantly higher quantities 
of RANKL than osteoblasts or other cell types, hence it plays a major role in 
inducing osteoclastogenesis in vitro (Nakashima et al., 2011).  
 
RANKL is responsible for the activation and survival of mature osteoclasts (Fuller et 
al., 1998). RANKL binds to its receptor, Receptor Activator of Nuclear Factor κ B 
(RANK) on the surface of osteoclasts and their precursors. The interaction between 
RANKL and RANK stimulates the differentiation of haematopoietic stem cells into 
mononuclear preosteoclast cells.  These mononuclear preosteoclast cells then fuse 
to form multinucleated cells which are known as osteoclasts (Boyce & Xing, 2007; 
Lian et al., 2012). 
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1.2.2.6 Osterix 
Osterix, also known as SP7, is a novel zinc finger-containing transcription factor for 
embryonic and postnatal osteoblast differentiation and bone formation (Liu et al., 
2015; Zhou et al., 2010). Expression of osterix mRNA and protein is positively 
regulated by the RUNX2 and distal-less homeobox 5 (Dlx5) signalling pathways 
(bone morphogenetic protein-2 (BMP2), mitogen-activated protein kinase (MAPK) 
and insulin like growth factor 1 (Igf1)) and the ER-stress pathway (IRE1a/XBP1). 
Conversely, osterix mRNA and protein is negatively regulated by DNA methylation, 
p53, TNF and microRNAs (Sinha & Zhou, 2013). 
 
Osterix shows anti-tumour activity in mouse osteosarcoma cells transfected with the 
osterix gene where it significantly reduced incidence and volume of tumours in both 
in vitro and in vivo experiments (Cao et al., 2005). Osterix is also involved in the 
regulation of a group of miRNAs which target important genes that are involved in 
osteoblast differentiation and inhibition. Osterix has been shown to down-regulate 
the expression of miR-133a, miR-204 and miR-211 but up-regulate the expression 
of miR-141 and miR-200a. MiR-133a, miR-204 and miR-211 are known to target 
RUNX2, which is an important osteogenic transcription factor. MiR-204 and miR-
211 also target sclerostin and alkaline phosphatase while miR-141 and miR-200a 
has been shown to target transcription factor Dlx5 (Chen et al., 2013). This 
indicates that osterix plays an important role in controlling optimal osteoblast 
differentiation and function by controlling different key proteins.  
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1.2.2.7 Sclerostin 
Sclerostin is an osteocyte-derived glycoprotein coded by the SOST gene that 
functions as a negative physiological regulator of bone formation. Sclerostin was 
first discovered in 2001 as the gene that responsible for causing sclerosteosis, a 
rare and recessively inherited disorder that is characterised by the progressive bone 
overgrowth. Sclerosteosis patients experience symptoms such as facial palsy, 
hearing loss, syndactyly and compression of the cranial nerves which can be fatal 
(William, 2014). Sclerosteosis is caused by the mutation in SOST gene which limits 
the secretion of sclerostin protein by osteocytes. Sclerostin not only inhibits bone 
formation by blocking the canonical Wnt signalling (Monroe et al., 2012) but also 
crucial for osteoclast formation and osteoclast bone resorption function (Wijenayaka 
et al., 2011). This means, low level of sclerostin results in higher bone formation by 
osteoblast and less bone resorption by osteoclast at the same time, resulting in 
excessive bone growth. Before this finding, it was thought that sclerosteosis is 
caused primarily by excessive osteoblastic bone formation rather than the defective 
of osteoclastic bone resorption (Hamersma et al., 2003). The identification of SOST 
gene mutation in sclerosteosis lead to the discovery of mutation that cause Van 
Buchem disease, a very similar disease to sclerosteosis, primarily differentiated by 
syndactyly and tall stature in sclerosteosis patients. Van Buchem disease is caused 
by deletion mutation of a 52-kb regulatory region which is 35 kb downstream of 
SOST gene resulting in reduced SOST expression (Balemas et al., 2002). These 
two findings show that the mutation of SOST gene which limits the SOST protein 
production results in the excessive bone growth, giving the first idea that the 
physiological role of SOST in the suppression of bone formation. Since then, many 
studies have been performed to investigate the role of sclerostin in bone 
development.  A published clinical study showed that sclerostin inhibition using anti-
sclerostin antibody (Scl-Ab) has been shown to efficiently prevent rapid and 
extensive spinal cord injury-induced cancellous and cortical bone loss (Beggs et al., 
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2015). Other study discovered that multiple myeloma cells express high level of 
sclerostin, creating an environment with high sclerostin concentration which might 
contribute to low osteoblastic differentiation in multiple myeloma patients (Brunetti et 
al., 2011). Further investigation showed that combination of Scl-Ab with anti-
myeloma drugs is effective in controlling multiple myeloma and multiple myeloma-
induced bone disease in patients with active multiple myeloma (Delgado-Calle et 
al., 2017). In other study, deletion of the sclerostin gene in mice resulted in a 
significant increase in bone formation and bone strength. Bone densitometry 
analysis revealed the increase of bone mineral density of more than 50 percent. 
Meanwhile micro-CT analysis showed a significant increase of bone volume in both 
trabecular and cortical bones (Li et al., 2008). On the other hand, transgenic mice 
which overexpress sclerostin have been shown to have significantly lower bone 
mass and reduced bone strength (Winkler et al., 2003). These findings confirm the 
role of sclerostin as a negative regulator of bone formation and suggest that 
sclerostin might become a key tool for the development of therapeutic strategies for 
bone diseases.  
 
Recently, there has been increasing interest in the role of microRNAs, a small non 
coding RNA molecule, in bone development. A few miRNAs have been identified to 
negatively regulate sclerostin which antagonize Wnt signalling such as miR-218 
(Hassan et al., 2012), miR-133a and miR-204/211 (Chen et al., 2013). These 
miRNAs have a great potential to be used as a new method of treating bone 
diseases such as osteoporosis. Another finding shows that two bone-specific 
transcription factors, RUNX2 and osterix, activate sclerostin gene expression in a 
co-ordinated manner in vitro using human HEK-293T cells (Perez-Campo et al., 
2016) suggesting another approach that could be used to control bone growth. 
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1.3 Purinergic signalling and the role of Adenosine 5’-triphosphate (ATP) and 
Parathyroid hormone (PTH) in bone development 
 
1.3.1 Purinergic signalling 
Purinergic signalling is an extracellular signalling that regulates various cellular 
functions such as heart rate, coronary flow, liver metabolism, activation of white 
blood cells, nerve cells communication, renal function, and cell proliferation and 
function (Alan and Alexei, 2006; Junger, 2011; Mclntosh and Lasley, 2011; Oliveira 
et al., 2013, Rumney et al., 2012). Purinergic signalling is controlled by purine 
nucleotides and nucleosides which activates purinergic receptors in the cells 
(Praetorius and Leipziger, 2010). There are three different types of purinergic 
receptors, known as P1, P2X and P2Y receptors. Bone cells, osteoblasts and 
osteoclasts express P2X and P2Y receptors to control bone modelling and 
remodelling processes. P2X receptors are ligand-gated ion channel type receptors 
which are activated by ATP, while P2Y receptors, G protein-coupled type receptors, 
are activated by nucleotides such as ATP, ADP, UDP and UTP. Purinergic 
signalling has been shown to involve in the pathophysiology of several bone 
diseases such as osteoporosis. Hence, blocking nucleotides in this signalling 
pathway could be one of the strategy to fight osteoporosis (Rumney et al., 2017). 
 
 
1.3.2 Role of adenosine 5’-triphosphate (ATP) in bone development 
The role of adenosine triphosphate (ATP) in intracellular energy metabolism has 
long been understood. ATP is also now known as an important extracellular 
signalling molecule that is involved in various biological processes. The binding of 
ATP to the purinergic P2X receptors which function as ligand-gated Ca2+ channel 
opens the cationic channels hence increase the intracellular Ca2+ and induce 
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membrane depolarization. The depolarization of the membrane cell makes the 
membrane permeable to large molecules which assist various biological processes 
such as cell metabolism and function (Kumagi et al., 1991). ATP can be released 
into the extracellular environment by any cell type via several physiological 
mechanisms such as necrosis, following membrane damage or by exposure to 
different stress types such as mechanical strain. In the cytosols of cells, ATP 
concentration is normally between 2 and 5 mM (Orriss et al., 2013). In bone cells, 
mechanical loading triggers the increase of ATP release by osteoblast and 
osteoclast cells.  The released ATP and its breakdown products can activate the 
purinergic P2Y or P2X receptors, depending on the concentration of ATP in the 
environment. High concentration of ATP triggers the P2X7 receptors on the 
osteoclast precursors and triggers the fusion and multinucleation of osteoclasts. 
This will result in the increase of mature osteoclast production hence increase the 
bone resorption (Orriss et al., 2010; Rumney et al., 2012). 
 
 
1.3.3 Role of parathyroid hormone (PTH) in bone development 
Parathyroid hormone (PTH), also known as parathormone or parathyrin, is a 
hormone secreted by the parathyroid gland. Its main function is to control plasma 
calcium levels in the blood and to prevent osteoblast and osteocyte apoptosis. A 
decrease in serum calcium levels induces secretion of PTH which increases 
calcium levels, but conversely supresses further PTH release. Intermittent 
administration of low levels of PTH has been shown to have an anabolic effect 
which occurs by activating osteoblast surface receptors, inducing the production of 
growth factors such as insulin-like growth factor 1 (IGF1). This results in an increase 
in the number of osteoblasts, bone formation and bone mass, mainly by increased 
production of trabecular bone (Crockett et al., 2011; Hirsch et al., 2013). There are 
two major pathways that PTH can influence bone development; through protein-
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kinase A (PKA) pathway or through the release of intracellular calcium and 
activation of protein-kinase C (PKC). Activation of PTH1R by PTH increases several 
intracellular signalling molecules such as adenylate cyclase (AC) and 
phospholipase C (PLC). Activation of the AC signalling cascade leads to the 
activation of PKA and phosphorylation of transcription factors that regulate 
transcription of related genes such as RANKL and osterix. Stimulation of PLC 
signalling leads to the accumulation of inositol trisphosphate (IP3) and 
diacylglycerol (DAG) which increase intracellular calcium level and activate PKC 
resulting in the regulation of gene transcription (Datta and Abou-Samra, 2009; 
Swarthout et al., 2002). In both osteoblastic cell lines and primary osteoblast, PTH 
effectively increases c-fos gene transcription (Bowler et al., 1999a). Other study 
revealed that stimulation of P2 receptors by ATP and PTH stimulates synergistic 
increase of c-fos gene expression, suggesting that in the presence of both ATP and 
PTH, bone remodelling could be increased. This could occur via different pathways 
depending on the cell types and which P2 receptor is activated. ATP activates P2Y 
type receptors (either P2Y1 or P2Y2) which results in the intracellular calcium level 
to increase. Meanwhile PTH can react independently to increase the c-fos 
expression by activating the Gs subunit (Gartland et al., 2012). 
 
 
1.4 microRNAs in bone development 
 
1.4.1 Overview 
MicroRNAs (miRNAs) are small, genetically conserved non-coding RNA molecules 
of only approximately 19-25 nucleotides in length (Hupkes et al., 2014). miRNAs are 
produced by all cell types and is secreted into blood by endothelial cells, vascular 
smooth cells, red blood cells and platelets. The same miRNAs can be produced by 
different cell types for different purposes (Navickas et al., 2016). Generally, miRNAs 
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are negative regulators of gene expression through the inhibition of target 
messenger RNA (mRNA) translation (Iorio et al., 2010). However, some miRNAs 
can bind to the 5’ UTR region (coding region) of mRNA and enhance protein 
translation (Orom et al., 2008). 
 
MiRNAs have been identified as regulating major cellular functions such as 
apoptosis, cell proliferation and differentiation (Brennecke et al., 2003; Hupkes et 
al., 2014; Li et al., 2009; Williams et al., 2009). They have also been implicated in 
various human diseases, such as breast cancer (Zhang et al., 2014), brain tumours 
(Catania et al., 2012), oesophageal cancer (He et al., 2012), schizophrenia 
(Forstner et al., 2013; Wang et al., 2014) and osteoarthritis (Wu et al., 2014). Since 
the first discovery of miRNA in 1993 (Lee et. al., 1993), more than 2000 individual 
miRNAs have been identified which are involved in human gene regulation and 
deposited in miRBase, with each miRNA predicted to control hundreds of gene 
transcripts (Hammond, 2015).  However, their role in bone and in the aetiology of 
metabolic bone diseases remains to be established. 
 
 
1.4.2 miRNA biogenesis and function 
Genes encoding miRNAs can be found in various locations within the genome, both 
in introns and exons (Rodriguez et al., 2004). However, in humans, only some of 
the miRNAs are encoded by exons as the majority are encoded by introns of coding 
or non-coding transcripts (Ha & Kim, 2014). The biogenesis of miRNA takes place 
firstly in the nucleus and then continues in the cell cytoplasm. 
 
In the nucleus, RNA polymerase II/III transcribes a long, variable-length hairpin 
RNA known as primary miRNA (pri-miRNA) directly from the miRNA encoding gene. 
This pri-miRNA is processed into ~ 70- to 120-nucleotide long premature stem-loop 
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intermediates known as precursor miRNAs (pre-miRNAs) by the Microprocessor, a 
large complex that includes an RNase III enzyme known as Drosha and the RNA-
binding protein DGCR8. These pre-miRNAs are then transported to the cytoplasm 
by Exportin 5 where the loop region of the pre-miRNAs are cleaved into double 
stranded miRNA by an RNase III enzyme known as Dicer. Transactivation response 
RNA binding protein (TRBP) facilitates the association of the Dicer-miRNA complex 
with RNA-induced silencing complex (RISC) that contains Argonaute 2 (Ago2), 
protein kinase RNA activator (PACT), trinucleotide repeat-containing gene 6A 
(TNRC6A) and other RNA binding proteins. Association of mature miRNA with 
RISC complex induces degradation of the passenger strand. The guide strand then 
recognizes its target site on the 3’ UTR region on the target mRNA. The silencing 
effect of the miRNA is achieved either by degrading the mRNA (in case of perfect 
base complementarity) or inhibiting protein translation (in case of multiple sequence 
mismatch between miRNA and target mRNA) (Bhaskaran & Mohan, 2014; Lee et 
al., 2003). Recent studies have shown that miRNAs can interact with the 5’ UTR 
region of the target gene via complementarity yet inhibit protein translation as 
efficiently as an interaction in the 3’ UTR region (Lytle et al., 2007). The process of 
miRNA biogenesis is illustrated in Fig. 1.2. 
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Figure 1.2: Schematic model of miRNA biogenesis which starts with miRNA 
transcription by RNA polymerase II (Pol II) within the nucleus. 
 
 
1.4.3 miRNA in human diseases and disorders 
As miRNAs play vital roles in many cellular functions, their dysregulation has been 
linked to various diseases and disorders, not surprisingly cancer in many cases 
(Calin & Croce, 2006; Deng et al., 2016; Ha & Kim, 2014). A small change in the 
level of miRNA can cause major or minor cellular effects to both normal and 
aberrant cells. Changes in the expression of miRNAs have been detected during 
the progression of various human diseases, demonstrating the involvement of 
miRNA in human diseases (Mendell & Olson, 2012). Table 1.1 shows examples of 
miRNAs that are involved in human disease. 
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Table 1.1: List of miRNAs involved in human disease 
Locus name  Phenotype/Disease References 
miR-1286, miR-24-1, miR-328, 
miR-548a-1 
Breast cancer (Cordero et al., 2015) 
miR-132, miR-148a, miR-18b, 
miR-34b, miR-34c 
Prostate cancer 
(Formosa et al., 
2013) 
miR-1286, miR-1287, miR-432, 
miR-1290 
Cervical cancer (Yao et al., 2013) 
let-7e, miR-132, miR-34b, miR-
489 
Melanoma (Mazar et al., 2011) 
miR-203 Rheumatoid arthritis 
(Stanczyk et al., 
2011) 
miR-29b Cardiovascular disease (Chen et al., 2012) 
miR-15a, miR-21, miR-155, 
miR-34a, miR-125b 
Lymphomagenesis (Lawrie, 2013) 
miR-185 Schizophrenia (Forstner et al., 2013) 
miR-133a Cardiac fibrosis (Renaud et al., 2015) 
miR-122 Hepatitis C (Jopling et al., 2008) 
 
 
1.4.4 miRNAs in bone development and bone diseases 
Inhibition of protein translation by miRNAs in cells has emerged as an important 
regulator of various cellular functions. Bone formation is a continuous and complex 
process which is controlled and influenced by various factors including miRNAs. 
MiRNAs are involved in every step of bone formation and bone repair from 
embryonic stage to adulthood by regulating the growth, differentiation and function 
of the cells that constitute bone tissue. All miRNAs that are expressed in osteoblast 
lineage cells that are involved in bone regulation are also known as osteomiRs (Lian 
et al., 2012). Studies have shown that different subsets of osteomiRs are expressed 
during different stages of osteoblast and osteoclast maturation indicating 
sophisticated control of bone formation by miRNAs (Lian et al., 2012; Zhang et al., 
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2011). Several miRNAs have been identified as being involved in bone 
development such as miR-125 targets osterix which is required for bone 
mineralisation (Goettsch et al., 2011) and miR-133 inhibits osteoblast differentiation 
by targeting Runx2 (Li et al., 2008). Inhibition of osterix expression by miR-125 and 
suppression of osteoblast differentiation by miR-133 result in weak bone formation 
and could leads to osteoporosis. On the other hand, miR-378 promotes osteoblast 
differentiation, promoting healthy bone formation by regulating nephronectin 
expression, an extracellular matrix protein that plays a critical role in the 
development and function of various tissues (Kahai et al., 2009). Other examples of 
miRNA involved in bone development and disease are shown in Table 1.2. 
 
 
Table 1.2: List of miRNAs involve in bone development and bone diseases. 
Locus name  Function References 
miR-138 
Inhibit osteogenic 
differentiation 
(Eskildsen et al., 2011) 
miR-223 Stimulate osteoclastogenesis  (Sugatani and Hruska, 2009) 
miR-155 Suppress osteoclastogenesis (Mann et al., 2010) 
miR-29 Support osteoblastogenesis (Kapinas et al., 2009) 
miR-103a Inhibit bone formation through 
targeting Runx2 
(Zuo et al., 2015) 
miR-125 Inhibit osterix production (Goettsch et al., 2011) 
miR-133 Inhibit osteoblast 
differentiation 
(Li et al., 2008) 
miR-378 Promote osteoblast 
differentiation 
(Kahai et al., 2009) 
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1.5      Hypothesis 
Our hypothesis are osteosarcoma cell lines (MG-63, TE-85 and SaOS-2) provide a 
useful model to study bone biology and miRNAs have promising potential to be 
used to control healthy bone development as well as a new treatment for various 
bone diseases. 
 
 
1.6 Objectives of this thesis 
 In the first experimental chapter, we wanted to prove if osteoblastic cell 
lines, MG-63, TE-85 and SaOS-2 represent different stages of osteoblastic 
differentiation. To prove this, we studied the expression of several bone 
markers that are known to be expressed differently at different stages of 
osteoblastic differentiation using these cell lines. We also studied the effects 
of ATP and PTH treatment on the expression of these markers to examine if 
these cell lines respond the same way as the primary osteoblastic cell. 
 Once we were confident that these 3 cell lines do represent osteoblastic 
cells at different stages of osteoblastic differentiation, we then studied the 
differential expression of miRNAs in these cell lines to understand the 
differential expression of miRNA at different stages of osteoblastic 
differentiation. 
 The next objective was to identify miRNAs that involve in the regulation of 
sclerostin expression, a major regulator of bone formation in these cell lines 
by using transient transfection method. 
 The final objective was to study the effect of miR-378a-3p transfection (one 
of the miRNAs that we used in the transfection experiment) on bone 
microstructures in mice. 
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CHAPTER 2: 
MATERIALS AND METHODS 
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2.1 Cell culture 
MG-63, TE-85 and SaOS-2 cells were obtained from liquid nitrogen stock. Primary 
human osteoblasts were obtained from patients that had undergone hip 
replacement surgery. The experiments on the primary cells were undertaken under 
approval from the Liverpool Research Ethics Committee, Pathophysiological studies 
to understand the nature of tissue damage in Alkaptonuria (REC reference 
07/Q1505/29). Resurrection of preserved cells, culture of cell lines and primary 
cells, their passage, enumeration and preservation were carried out according to 
established protocols (Gartland et al., 2012). 
 
 
2.1.1 Thawing of cryo-preserved cells 
Frozen vials containing MG-63, TE-85 or SaOS-2 cells were removed from liquid 
nitrogen storage and thawed quickly in a water bath at 37°C with gentle shaking. 
The thawed cell suspensions were wiped with 70% ethanol before being added into 
10 cm culture dishes containing 9 mL Dulbecco’s modified Eagle medium (DMEM) 
(D6429, Sigma-Aldrich) with 10% fetal calf serum (FCS) (FB-1001/500, Biosera) 
and 50 U/mL penicillin - 50 μg/mL streptomycin (P4458, Sigma-Aldrich). The 
cultures were incubated at 37°C in a humidified atmosphere of 95% air and 5% 
CO2. Culture medium was replaced after overnight incubation. 
 
 
2.1.2 Culture of osteosarcoma cell lines 
Osteoblastic cell lines were cultured in DMEM with 10% FCS and 50 U/mL penicillin 
- 50 μg/mL streptomycin. Cells were seeded at different concentrations depending 
on the frequency of use. For maintaining a culture, cells were seeded at between 1 
– 2 x 104 cells per 10 cm culture dish. Cultures were incubated at 37°C in a 
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humidified atmosphere of 95% air and 5% CO2. Cells were passaged when 
confluency reached approximately 70-80%. 
 
 
2.1.3 Culture of primary human osteoblasts 
Femoral heads obtained from patient who had undergone hip replacement were 
transported to the laboratory in PBS on the same day. Trabecular bone was 
removed from the open end of the femoral head using sterile bone rongeurs and a 
solid stainless steel blade with integral handle. The trabecular bone fragments were 
transferred to a clean Petri dish containing 3 mL of PBS and diced into pieces 3-5 
mm in diameter using a scalpel blade and fine scissors. The PBS was removed 
slowly without disturbing the bone sediment. Bone chips were transferred to a 
sterile 30 mL tube containing 20 mL of PBS. The tube was vortex-mixed vigorously 
three times for 10 seconds and left to stand for 30 seconds to allow the bone 
fragments to settle. The supernatant containing haematopoietic tissue and 
dislodged cells was carefully removed. Another 20 mL of PBS were added to the 
tube and vortexed. This step was repeated at least three times until no remaining 
haematopoietic marrow was visible and the bone fragments appeared white. The 
bone fragments were cultured as explants at a density of 0.2-0.6 g of tissue/10 cm 
culture dish in 10 mL DMEM at 37°C in a humidified atmosphere of 95% air, 5% 
CO2. The cultures were incubated for 7 days then the medium replaced carefully 
without dislodging the explants. The outgrowths of cells were checked at day 7-10. 
The medium was changed at day 14 and twice weekly thereafter until the desired 
confluency had been attained. This isolation and culture of primary human 
osteoblast procedures was performed by Dr. Peter Wilson, Musculuskeletal Biology 
Department, Institute of Ageing and Chronic Disease, University of Liverpool. 
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2.1.4 Passage of primary cells 
Bone chips were removed using sterile forceps and discarded. The spent medium 
was removed and the cell layers were gently washed three times with 10 mL of Ca2+ 
and Mg2+-free PBS. The culture dish was incubated with 5 mL of freshly thawed 
trypsin-EDTA for 5 minutes at 37°C. The culture was gently rocked every 30 
seconds to ensure the entire surface of the dish was exposed to the trypsin-EDTA 
solution. The culture was removed from the incubator and examined by light 
microscopy to ensure all cells had dislodged from the dish. The culture that was not 
fully dislodged was incubated for another 5 minutes at 37°C. When all cells had 
detached from the dish, the cells were transferred to an eppendorf tube containing 
10 mL of complete medium. The culture dish was then washed 3 times with serum-
free medium. The washings were pooled with the original cell isolate and 
centrifuged at 250 x g for 5 minutes at room temperature to recover the cells. The 
supernatant was removed carefully by inverting the tube without loosening the cell 
pallet. The cell pellet was then resuspended in 2 mL serum-free medium. The 
number of cells was determined using a Neubauer haemocytometer (section 2.1.6). 
The harvested cells were seeded at a cell density suitable for the required 
experiment at 37°C in a humidified atmosphere of 93% air and 5% CO2. Generally, 
cells were subcultured at a concentration of 5 x 103 – 104 cells/cm2. At this 
concentration, the culture was ≥70% confluent after 24 hours. 
 
 
2.1.5   Passage of cell lines 
Culture medium was removed and the cells washed twice with 5 mL of PBS. Five 
mL of trypsine-EDTA were added and incubated at 37°C for 5 minutes. The cells 
were checked by light microscopy to ensure all had detached from the culture dish. 
They were then transferred to an eppendorf tube containing 10 mL of complete 
medium. The number of cells was determined using a Neubauer haemocytometer 
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(section 2.1.6). The harvested cells were seeded at a density suitable for the 
required experiment at 37°C in a humidified atmosphere of 95% air and 5% CO2. 
For the maintenance purposes, cells were seeded at 1 - 2 x 104 cells per 10 cm 
culture dish. 
 
 
2.1.6    Cell counting 
Twenty µL of the harvested cell suspension were diluted with 80 µL serum free 
medium. One hundred µL of trypan blue solution were added and mixed well. The 
mixture was left for 1 minute before counting viable and nonviable cells using a 
Neubauer haemocytometer. The number of cells in five squares (Fig. 2.1) was 
determined and the cell concentration calculated using the following formula: 
 
Total cells/mL = Total cells counted x (dilution factor ÷ number of squares) x 
10,000 cells/mL  
 
 
 
 
 
 
 
 
 
Figure 2.1: Grid layout of a Neubauer Improved haemocytometer. Cells in four 
corner squares and the middle squares were counted to determine cell 
concentration 
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2.1.7    Cryo-preservation of cells 
Cultures were harvested when confluency had reached approximately 80-90% 
using the same procedure for routine subculture. After performing cell counting, 
cells were centrifuged at 250 x g for 5 minutes and the supernatant was removed. 
The cell pellet was resuspended in an appropriate quantity of freezing medium (0.9 
mL FCS + 0.9 mL dimethyl sulfoxide (DMSO) per sample) to achieve a cell 
concentration of 2 - 4 x 106 cells/mL per cryovial. Cryovials were closed tightly and 
frozen overnight in a -80°C freezer using a Mr. Frosty. Cells were then transferred 
into liquid nitrogen for long term storage. 
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2.2 Molecular biology 
 
2.2.1 Extraction and quantification of total RNA 
Total RNA was extracted from cells using an miRNeasy Mini Kit (Qiagen, Cataloque 
No. 217004) according to the protocol provided by the manufacturer. The purified 
total RNA was quantified using a NanoDrop 2000 spectrophotometer (Thermo 
Scientific). 
 
 
2.2.2 Reverse transcription of RNA 
Reverse transcription of RNA was carried out using a high capacity RNA-to-cDNA 
kit (Applied Biosystems, Catalogue No: 4387406) according to the protocol provided 
by the manufacturer. Reverse transcription mix per 20 µL reaction is shown in Table 
2.1. 
 
Table 2.1: Reverse transcription mix per 20 µL reaction 
Component Volume/Reaction (µL) 
2x RT Buffer 10.0 
20x Enzyme Mix 1.0 
RNA Sample up to 9 µL (1 µg) 
Nuclease-free H2O quantity sufficient for 20.0 µL 
Total per Reaction 20.0 
 
The reaction mix was incubated at 37°C for 60 minutes. The reaction was then 
halted by incubating the reaction mix at 95°C for 5 minutes and held at 4°C. The 
cDNA was diluted 10 times and used for real-time PCR or stored in a -20°C freezer. 
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2.2.3 Designing PCR primers  
Primers for miRNA expression were ordered from Qiagen 
(https://www.qiagen.com/gb/geneglobe) while primers for gene expression study 
were designed using free online software and synthesized by Invitrogen (UK). 
Primer specification and the location of the free software used to design the primers 
were: 
Primer3 (http://frodo.wi.mit.edu/primer3) 
- Product size: 100-150bp 
- Primer size: 18-22bp 
- Primer Tm: 58-62°C 
- Primer GC%: 20-50% 
DNA mfold (http://mfold.bioinfo.rpi.edu/cgi-bin/dna-form1.cgi) 
- Sequence type: Linear 
- Folding temperature: 58-62°C 
- [Na+]: 50 mM, [Mg2+]: 3mM 
Beacon Designer (http://www.premierbiosoft.com/qOligo/Oligo.jsp?PID=1) 
     -    Nucleic acid concentration: 500 nM  
     -    Mono ion concentration: 50 mM 
     -    Free Mg2+ concentration: 3 mM  
 
 
2.2.4 Quantitative reverse transcription PCR (RT-qPCR) of gene expression 
RT-qPCR for gene expression was performed using a CFX Connect™ Real-Time 
PCR Detection System (Bio-Rad). Diluted cDNA samples (1:10) were used as 
templates. RT-qPCR was performed according to the protocol supplied by the 
manufacturer for iQTM SYBR® Green Supermix (Bio-Rad). Primer sequences are 
shown in Table 2.2 and the reaction mix for each reaction in Table 2.3. Reactions 
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were performed using 6 biological replicates and 3 technical replicates for each 
sample, on a 96-well plate.  The reaction conditions are listed in Table 2.4. Relative 
normalized expression was automatically calculated by the Bio-Rad CFX Manager 
3.1 software using the ΔΔCt formula. 
 
Table 2.2: Primer sequences for gene expression 
Primer Sequence 
Col 1a2 forward 5’- GGC ACT CCA GGT CCT CAG-3’ 
Col 1a2 reverse 5’- CCA CAG CAC CAG CAA CAC-3’ 
OPG forward 5’-GCA GCG GCA CAT TGG ACA TG-3’ 
OPG reverse 5’-AGG ATC TGG TCA CTG GGT TTG C-3’ 
Col 6a3 forward 5’-GCT GTC TCC AGC GTT TAT CC-3’ 
Col 6a3 reverse 5’-TCA AGC AGA AAC ACC ACG TC-3’ 
SOST forward 5’-AAG AAT GAT GCC ACG GAA AT-3’ 
SOST reverse 5’-AGC TGT ACT CGG ACA CGT CTT T-3’ 
Osterix forward 5’- CCC ACC TCA GGC TAT GCT AA-3’ 
Osterix reverse 5’- CAC TGG GCA GAC AGT CAG AA-3’ 
RANKL forward 5’- TAT GCC AAC ATT TGC TTT CG-3’ 
RANKL reverse 5’- CTT GGG ATT TTG ATG CTG GT-3’ 
ALP forward 5’-GCT GAA CAG GAA CAA CGT GA-3’ 
ALP reverse 5’-TCA ATT CTG CCT CCT TCC AC-3’ 
Β-actin forward 5’-GGA CCT GAC TGA CTA CCT C-3’ 
Β-actin reverse  5’-GCC ATC TCT TGC TCG AAG-3’ 
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Table 2.3 Reaction mix for each reaction  
Component Volume/Reaction (µL) 
iQTM SYBR® Green Supermix 7.5 
Forward primer 1.0 
Reverse primer 1.0 
RNase-free water 3.5 
Template cDNA 2.0  
Total per Reaction 15.0 
 
Table 2.4: Reaction conditions for RT-qPCR of gene expression 
Polymerase 
activation & 
DNA 
denaturation 
Amplification 
Melt curve 
analysis 
Denaturation 
Annealing/Extensi
on + plate read 
Cycles 
95°C 
3 minutes 
95°C 
30 seconds 
60°C 
30 seconds 
40 
65-96°C 
0.5°C 
increment 
5 seconds/step 
 
 
2.2.5 Total DNA extraction and quantification 
DNA extraction was carried out using a CyQUANT® Cell Proliferation Assay Kit (Life 
Technologies, Catalogue No. C7026) according to the manufacturer’s protocol. 
 
2.2.6    ATP and PTH treatments 
The medium was replaced with serum free DMEM when the culture reached 80 – 
85 percent confluency. Cells were incubated for a further 48 hours. Cells were then 
treated with ATP (final concentration: 5 µg/ml), PTH (final concentration: 10 ng/ml) 
or ATP + PTH (final concentration: 5 µg/ml ATP + 10 ng/ml PTH). In control 
cultures, cells were grown in serum-free DMEM.  
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2.3 miRNA profiling 
 
2.3.1 Extraction of total RNA 
RNA (including miRNA) was extracted using an miRNeasy Mini Kit (Qiagen, 
Catalogue No. 217004) according to protocol provided by the manufacturer.  
 
 
2.3.2 Microarray analysis 
Total RNA samples (free from genomic DNA) were quantified and the quality of 
RNA assessed using an Agilent 2100 Bioanalyser RNA 6000 Nano chip and small 
RNA chips.  Samples were prepared for hybridisation onto Affymetrix miRNA 4.0 
arrays. 1000 ng of total RNA was used as the initial input, and an Affymetrix Flash 
Tag labelling kit used to prepare samples for hybridisation according to the 
manufacturer’s instructions. Biotin-labelled samples were hybridised onto Affymetrix 
GeneChip miRNA 4.0 for 17 hours at 48°C at 60 rpm in an Affymetrix hybridisation 
oven 640. Following hybridisation the arrays were washed using an Affymetrix 
Hybridisation wash and stain kit on a GeneChip Fluidics station 450 using fluidics 
script FS450_0002 and scanned using the Affymetrix GeneChip scanner 3000 7G. 
CEL files were generated using Affymetrix GeneChip Command Console Software, 
and Expression Console software was used to QC array performance. 
 
 
2.3.3 Differential expression of miRNA between cell lines 
Differential expression of miRNAs between all three cell lines and human primary 
osteoblasts was analysed using Mass Profiler Professional Version B.14.5 (Agilent 
Technologies). The estimated log2 fold change (logFC) for the 6 contrasts were 
tested in limma using a t-test. P-values associated with logFC were adjusted for 
multiple testing using the False Discovery Rate (FDR) approach (Benjamini and 
42 
 
Hochberg, 1995). Significantly differentially expressed (DE) miRNAs were defined 
as those with an FDR-adjusted P-value < 5%. 
 
 
2.3.4 miRNA target prediction 
From 6940 miRNAs that were differentially expressed between osteosarcoma cell 
lines and primary human cells, we investigated miRNAs that have the potential to 
inhibit sclerostin expression, a protein that inhibits new bone formation by blocking 
the Wnt signalling pathway. To predict miRNAs that target mRNA coding for 
sclerostin, we use five different online prediction tools: miRWalk 
(http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/), miRanda 
(http://www.microrna.org/microrna/home.do), Pictar (http://www.pictar.org/), RNA22 
(https://cm.jefferson.edu/rna22/) and Targetscan 
(http://www.targetscan.org/vert_71/). MiRNAs that were predicted by a majority of 
the prediction algorithms were chosen for further experimental validation. 
 
 
2.3.5 Reverse transcription of miRNA 
Reverse transcription for miRNAs that were predicted to target the sclerostin gene 
was carried out using miScript® II RT Kit (Qiagen, Catalogue No: 218161) according 
to the protocol provided by the manufacturer. Reverse transcription mix per 20 µL 
reaction is shown in Table 2.5. 
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Table 2.5: Reverse transcription mix per 20 µL reaction 
Component Volume/Reaction (µL) 
5x HiSpec Buffer 4 
10x miScript Nucleic Mix 2 
miScript RT Mix 1 
H2O quantity sufficient to 20.0 µL 
RNA Sample up to 13 µL (1 µg) 
Total per Reaction 20.0 
 
The reaction mix was incubated at 37°C for 60 minutes. The reaction was then 
stopped by incubating the reaction mix at 95°C for 5 minutes and held at 4°C. cDNA 
was diluted 10 times and used for real-time PCR or stored in a -20°C freezer. 
 
 
2.3.6 Quantitative reverse transcription PCR (RT-qPCR) for the validation of 
miRNA expression 
RT-qPCR for gene expression was performed using a CFX Connect™ Real-Time 
PCR Detection System (Bio-Rad). Diluted cDNA samples (1:10) were used as 
templates. RT-qPCR was performed according to the protocol supplied by the 
manufacturer for the miScript® SYBR® Green PCR Kit (Qiagen). The primer 
sequences used are shown in Table 2.6, reaction mix for each reaction is shown in 
Table 2.7 and the reaction conditions shown in Table 2.8. Relative normalised 
expression was automatically calculated by the Bio-Rad CFX Manager 3.1 software 
using the ΔΔCt formula (Livak and Schmittgen, 2001). 
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Table 2.6: Primers used for miRNA expression 
Primer Assay 
Catalogue No. 
(Qiagen) 
Sequence 
hsa-miR-422a MS00004172 5'-ACU GGA CUU AGG GUC AGA AGG C-3’ 
hsa-miR-1231 MS00031290 5'-GUG UCU GGG CGG ACA GCU GC-3’ 
hsa-miR-1254 
MS00042350 
5'-AGC CUG GAA GCU GGA GCC UGC 
AGU-3’ 
hsa-miR-1914-
3p 
MS00016548 
5'-GGA GGG GUC CCG CAC UGG GAG G-
3’ 
hsa-miR-103a-
3p 
MS00031241 
5'-AGC AGC AUU GUA CAG GGC UAU GA-
3’ 
hsa-miR-378a-
3p 
MS00006909 
5'-ACU GGA CUU GGA GUC AGA AGG C-3’ 
RNU6-2 MS00033740 N/A 
 
 
 
 
Table 2.7: The reaction mix for each reaction 
Component Volume/Reaction (µL) 
2x QuantiTect SYBR Green PCR Master Mix 7.5 
10x miScript Universal Primer 1.5 
10x miScript Primer Assay 1.5 
RNase-free water 3.0 
Template cDNA 1.5 
Total per Reaction 15.0 
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Table 2.8: Reaction conditions for RT-qPCR of miRNA expression 
Polymerase 
activation & 
DNA 
denaturation 
3-step amplification 
Melt curve 
analysis 
Denaturation Annealing Extension Cycles 
 
95°C 
15 minutes 
 
94°C 
15 seconds 
55°C 
30 
seconds 
70°C 
30 
seconds 
40 
65-95°C 
0.5°C 
increment 
5 
seconds/step 
 
 
 
2.3.7 Validation of miRNA function - Transfection of cells with miRNA 
mimics and antagomirs 
For miRNA transfection, only TE-85 and SaOS-2 cells were used as sclerostin 
expression was not detected in the MG-63 cell line. Cells were seeded into 6-well 
plates 24 hours before transfection at a density of 1.5 x 105 cells/mL in complete 
DMEM. The culture medium was then removed from each well and replaced with 
fresh DMEM without any supplementation and incubated for 30 minutes. During this 
incubation period, transfection media were prepared. Cells were to be transfected 
with scrambled miRNA, miRNA mimics and miRNA inhibitors (antagomirs). For the 
control cells DMEM only was used. Two 15 mL tubes were prepared for each 
transfection, tube A and tube B. In tube A, 5 µL of Lipofectamine 2000 (Invitrogen) 
were mixed with 500 µL of DMEM for each well. In tube B, 1 µL miRNA mimic, 
antagomir or scrambled miRNA was mixed with 500 µL of DMEM for each well. The 
miRNA mimics, antagomirs and scrambled miRNAs were purchased from Qiagen 
(Table 2.9). Transfection tubes were incubated for 5 minutes at room temperature. 
The contents were then completely mixed and incubated for another 20 minutes. 
Cell culture medium was removed from each well of the 6 well plates and replaced 
with 500 µL of the contents of each of both tubes A and B for the appropriate 
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transfection (n=3). Cells were incubated with these transfection media for 6 hours 
before the transfection media were replaced with complete DMEM. After 48 hours, 
culture media were collected for sclerostin protein analysis and cells were harvested 
for total RNA extraction. 
 
Table 2.9: miRNA mimics, antagomirs and scrambled miRNA used in transfection 
miRNA 
Mimic/Inhibitor 
Catalogue 
No. (Qiagen) 
Nucleotide Sequence of miRNA 
hsa-miR-422a mimic 
MSY000133
9 
5'-ACU GGA CUU AGG GUC AGA AGG 
C-3’ 
hsa-miR-422a inhibitor MIN0001339 5'-ACUGGACUUAGGGUCAGAAGGC 
hsa-miR-1231 mimic MSY000558
6 
5'GUGUCUGGGCGGACAGCUGC 
hsa-miR-1231 inhibitor MIN0005586 5'GUGUCUGGGCGGACAGCUGC 
hsa-miR-1254 mimic MSY000590
5 
5'AGCCUGGAAGCUGGAGCCUGCAGU 
hsa-miR-1254 inhibitor MIN0005905 5'AGCCUGGAAGCUGGAGCCUGCAGU 
hsa-miR-1914-3p 
mimic 
MSY000789
0 
5'GGAGGGGUCCCGCACUGGGAGG 
hsa-miR-1914-3p 
inhibitor 
MIN0007890 5'GGAGGGGUCCCGCACUGGGAGG 
hsa-miR-103a-3p 
mimic 
MSY000010
1 
5'AGCAGCAUUGUACAGGGCUAUGA 
hsa-miR-103a-3p 
inhibitor 
MIN0000101 5'AGCAGCAUUGUACAGGGCUAUGA 
hsa-miR-378a-3p 
mimic 
MSY000073
2 
5'ACUGGACUUGGAGUCAGAAGGC 
hsa-miR-378a-3p 
inhibitor 
MIN0000732 5'ACUGGACUUGGAGUCAGAAGGC 
Inhibitor negative 
control (scrambled 
miRNA) 
1027271 N/A 
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2.3.8 Protein quantification 
Media from treated cell cultures were stored at -80°C until further analysis. The 
quantity of SOST protein secreted into the culture media was measured using a 
Quantikine® Human SOST ELISA (R&D Systems) according to the protocol 
provided by the manufacturer with some modification. Three hundred µL of test 
culture medium were added to the appropriate wells of the ELISA plate and covered 
with an adhesive strip. Plates were incubated for two hours at room temperature on 
a horizontal orbital microplate shaker set at 500 ± 50 rpm. For each well medium 
was then discarded and replaced with another 300 µL culture medium from the 
same sample. Fifty µL of control and fresh media (blank) were added to the ELISA 
plate as controls. Plates were incubated for a further 2 hours on a horizontal orbital 
microplate shaker (500 ± 50 rpm) at room temperature. Each well was then 
aspirated and washed with 400 µL of wash buffer. The washing step was repeated 
three times for a total of four washes. After the last wash, any remaining wash 
buffer was removed by aspirating and the plates were inverted and blotted using 
clean paper towels. Two hundred µL of human SOST conjugate were added to 
each well. Plates were covered with adhesive strip and incubated at room 
temperature on the orbital shaker. After two hours, the washing step was repeated. 
Two hundred µL of substrate solution were added and plates wrapped with 
aluminium foil to protect the samples from light. Plates were incubated for one hour 
at room temperature. Fifty µL of stop solution were added to each well and the 
plates gently tapped to ensure thorough mixing. The colour in the wells changed 
from blue to yellow after positive detection of SOST protein. The optical density of 
each well was determined within 30 minutes using a microplate reader set to 450 
nm. The readings at 450 nm were subtracted from the reading at 570 nm to correct 
optical imperfections in the ELISA plate. 
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2.4 Trabecular bone analysis 
 
2.4.1 miR-378a-3p treatment of mice 
Treatment of mice with miR-378a-3p was done by Muscle Research Group 
members, Department of Musculoskeletal Biology, Institute of Ageing and Chronic 
Diseases, University of Liverpool. Six month old adult mice and old mice aged 2 
years were used to study the effect of miR-378a-3p on the properties of trabecular 
bone. Mice were treated with 2 mg/kg body weight of microRNA mimics or 
inhibitors/antagomirs through tail vein injection over 3 weeks of treatment. Mice 
were culled a week following the last injection and the left hind limbs were 
preserved in 10% phosphate buffered formal saline (PBFS) and used for micro-CT 
scanning. Experiments were performed in accordance with UK Home Office 
guidelines under the UK Animals (Scientific Procedures) Act 1986 and received 
ethical approval from the University of Liverpool Animal Welfare and Ethical Review 
Body (AWERB). 
 
 
2.4.2 Micro-computed tomography (micro-CT) scan of trabecular bone of 
tibial head 
Preserved samples were transferred into micro-computed tomography (micro-CT) 
scanning tubes and scanned using a Skyscan 1272 system in water. The scanner 
was set as follows: voltage = 50kV, source current = 200 μA, filter = Al 0.5 mm, 
resolution = 4032 x 2688, pixel size = 4.5 μm, rotation step (degree) = 0.30 and 
frame averaging = Off. Reconstruction of the bone scans was achieved using 
NRecon software with the following settings: smoothing = 1, misalignment = auto 
value, ring affect reduction = 5 and beam hardening correction = 38%. The 
reconstructed bone image files were then opened using Data Viewer software to 
determine the volume of interest to be used for the analysis of the trabecular bone 
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properties in the head of the tibia. The position of the growth plate half way between 
the two ends was determined as the reference point (Figure 2.2). The volume of 
interest was then measured as the volume of 200 slices of scanned images after 
the first 10 slices of scanned images from the reference point. Properties of the 
trabecular bone were than analysed using CTan software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Growth plate in the head of tibia. 
 
 
2.5 Statistical analysis 
Results were analysed using One-Way Independent ANOVA. The significance level 
was set at p values less than 0.05. Results are presented as mean ± standard error 
of the mean (SEM). 
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CHAPTER 3: 
 
EXPRESSION OF OSTEOBLASTIC BONE MARKERS IN HUMAN 
OSTEOSARCOMA CELL LINES AND THE EFFECTS OF ADENOSINE 
TRIPHOSPHATE (ATP) AND PARATHYROID HORMONE (PTH) ON THE 
EXPRESSION OF THESE MARKERS 
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3.1 Introduction 
The first objective of this thesis was to study the expression of mRNA of selected 
bone markers in the three most commonly used osteosarcoma cell lines: MG-63, 
TE-85 and SaOS-2. The expression of these markers in primary human osteoblast, 
HOB was also studied as a comparison to the cell lines. Each cell line represents 
different stages of osteoblast maturation. MG-63 represents the early stage of 
osteoblast differentiation, TE-85 represents the intermediate stage while SaOS-2 
represents the most differentiated and matured osteoblasts (Pacheco-Pantoj et al., 
2011). We have selected seven bone markers which are alkaline phosphatase 
(ALP), collagen 1a2 (COL1A2), collagen 6a3 (COL6A3), osteoprotegerin (OPG), 
osterix (OSX), RANK ligand (RANKL) and sclerostin (SOST). Each marker plays an 
important role in bone modelling and remodelling processes. To understand the 
expression pattern of these markers, the expression of the mRNA of these markers 
was compared between cell lines to examine the regulation of bone markers at 
different stages of osteoblastic differentiation. 
 
ATP has been shown to inhibit bone mineralisation in primary rat osteoblasts 
(Orriss, Key, Hajjawi, & Arnett, 2013) while the administration of PTH has been 
shown to increase osteoblast number and bone formation (Crockett, Rogers, 
Coxon, Hocking, & Helfrich, 2011). Other study showed combined treatment of ATP 
and PTH significantly increase bone mineral density in ovariectomized female mice 
by increasing bone formation and decrease bone resorption (Syberg et al., 2011). In 
this chapter, we also studied the effect of ATP and PTH treatments in MG-63, TE-
85 and SaOS-2 to identify if these cells respond to the treatment similar to primary 
osteoblast. The findings of this study will help us to understand if MG-63, TE-85 and 
SaOS-2 are good cell models to be used to study bone biology. 
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3.2 Brief methods 
 
3.2.1 Expression of bone markers in osteosarcoma cell lines 
Osteosarcoma cell lines (MG-63, TE-85 and SaOS-2) were cultured in 10 mm cell 
culture dishes until 80-85% confluent (Section 2.1.2). Total RNA was extracted from 
cells using a miRNeasy Mini Kit and purified total RNA quantified using a NanoDrop 
2000 spectrophotometer (Section 2.2.1). cDNA was synthesized using a high 
capacity RNA-to-cDNA Kit (Section 2.2.2). To examine the expression of the bone 
markers, real-time PCR was performed as described earlier (Section 2.2.4). 
 
 
3.2.2    Effect of ATP and PTH treatments on bone marker expression 
Osteosarcoma cell lines (MG-63, TE-85 and SaOS-2) were cultured in complete 
DMEM with 10% FCS in 10 mm cell culture dishes until 80-85% confluent (Section 
2.1.2). Cells were then treated with ATP, PTH or ATP + PTH (Section 2.2.6). Cells 
were incubated overnight before proceeding with total RNA extraction (Bowler et al., 
1999). 
 
Total RNA was extracted from cells using a miRNeasy Mini Kit and purified total 
RNA quantified using a NanoDrop 2000 spectrophotometer (Section 2.2.1). 
Synthesis of the cDNA was performed using a high capacity RNA-to-cDNA Kit with 
a total volume of 20 µL per reaction (Section 2.2.2). The expression of the bone 
markers was analysed using RT-qPCR (Section 2.2.4). Result was analysed using 
One-Way Independent ANOVA.  
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3.3 Results 
3.3.1 Expression of osteoblastic bone markers in human osteoblastic cells 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Expression of selected bone markers in a) MG-63 b) TE-85 
c) SaOS-2 and d) HOB. Value of the mean expression of 5/6 biological 
replicates (n=5/6) are shown on top of each plot. Error bar represent 
standard error of the mean (SE). Data were analysed using One-Way 
Independent ANOVA and LSD Post-Hoc test.  
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The expressions of the seven selected bone markers in cell lines and HOB were 
analysed and compared. The expression of ALP mRNA was compared between 
MG-63, TE-85, SaOS-2 and HOB. ALP mRNA expression was significantly higher 
in SaOS-2 than MG-63, TE-85 and HOB cells (p<0.005). The expression of ALP 
was 47 times higher in SaOS-2 than TE-85, which was 120 times higher than in 
MG-63 (p<0.005). The ALP mRNA expression level was similar in MG-63 and HOB 
(p>0.05). The expression of COL1A2 mRNA was compared between the three 
different osteosarcoma cell lines and HOB. Among the cell lines, the highest 
expression was observed in MG-63 while the lowest was in TE-85. The expression 
of COL1A2 mRNA was 4.6 times higher in MG-63 compared to SaOS-2, which in 
turn was 18 times higher than in TE-85 cells (p<0.05). There was no significant 
different of COL1A2 expression between the HOB and all three cell lines due to big 
standard error value in HOB. The expression of COL6A3 mRNA in MG-63, TE-85 
and SaOS-2 cells was compared using One-Way Independent ANOVA and LSD 
Post-Hoc test. It is apparent that the expression of COL6A3 mRNA was higher in 
MG-63 cells compared to that in the other cell lines. There was no significant 
different of the expression level of COL6A3 between MG-63 and HOB (p>0.05). 
COL6A3 mRNA was expressed 62 times higher in MG-63 cells than in TE-85 cells, 
which was 31 times higher than in SaOS-2 cells (p<0.05). 
 
Expression of OPG mRNA was compared between the three osteosarcoma cell 
lines and HOB. The expression of OPG mRNA was very much higher in MG-63 
cells than in the other cell lines, being expressed 72 times higher than in TE-85 and 
31 times higher than in SaOS-2 cells (p<0.05). The difference between the 
expression of OPG mRNA in TE-85 and SaOS-2 was also significant (p<0.05). The 
expression of OSX mRNA was analysed and compared between all three 
osteosarcoma cell lines. No significant difference was observed between the 
expression of OSX mRNA in MG-63 and TE-85, but it was significantly higher in 
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SaOS-2 than in both MG-63 and TE-85 cells (p<0.05). The expression of RANKL 
mRNA between MG-63, TE-85 and SaOS-2 cells was compared. The expression of 
RANKL in HOB was not studied due to technical difficulties. The expression of 
RANKL mRNA was significantly higher in SaOS-2 cells than in MG-63 and TE-85 
cells (p<0.05). The expression was 27 times higher in SaOS-2 compared to MG-63 
(p<0.05). However, no difference was found between the expression of RANKL 
mRNA in MG-63 and TE-85 (p>0.05).  The expression of SOST mRNA was 
compared between the osteosarcoma cell lines. SaOS-2 expressed the highest 
levels of SOST mRNA while it was not detected in MG-63 cells. The expression of 
SOST mRNA was 5.8 times higher in SaOS-2 than in TE-85 cells (p<0.05). The 
differences in SOST mRNA expression was also significant between SaOS-2 and 
HOB (p<0.05).  
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3.3.2 Effects of adenosine triphosphate (ATP) and parathyroid hormone (PTH) 
on the expression of bone markers 
 
 
 
Figure 3.2: Expression of alkaline phosphatase in osteosarcoma cell lines (MG-63, 
TE-85 and SaOS-2) treated with Adenosine 5’-triphosphate (ATP) and parathyroid 
hormone (PTH). Data are normalized to β-actin. The values of the mean expression 
of the gene are shown on top of each plot. Error bars represent standard error of 
the mean (S.E.M). * indicates significant difference as analysed by One-Way 
Independent ANOVA and LSD Post-Hoc test, p<0.05. 
 
Following treatment by ATP or PTH, the expression of ALP mRNA in all three cell 
lines was compared. ALP mRNA expression was normalised to the expression of β-
actin mRNA. In MG-63, treatment with ATP, PTH and combination of ATP and PTH 
significantly increased the expression of ALP compared to the control, p<0.05. 
Expression of ALP was significantly higher in MG-63 treated with PTH compared to 
MG-63 treated with ATP, (p<0.05). Combination of ATP and PTH treatment in MG-
63 enhanced the expression of ALP significantly compared to control cells and and 
cells treated with ATP (p<0.05). There was no significant difference in the 
expression of ALP between MG-63 treated with PTH alone and combined ATP-
PTH. In TE85 cells however, there was no significant difference of ALP expression 
throughout the treatments. Interestingly, there were significant increases of ALP 
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expression in all treatments using SaOS-2 compared to the control (p<0.05). SaOS-
2 cells treated with ATP and PTH alone equally increased the expression of ALP, 
p>0.05. Meanwhile, the combination of ATP-PTH treatment significantly increased 
the ALP expression compared to control and PTH, p<0.05 but not significantly 
different compared to ATP.   
 
 
 
Figure 3.3: Expression of collagen 1a2 in osteosarcoma cell lines (MG-63, TE-85 
and SaOS-2) treated with Adenosine 5’-triphosphate (ATP) and parathyroid 
hormone (PTH). Data are normalized to β-actin. The values of the mean expression 
of the gene are shown on top of each plot. Error bars represent standard error of 
the mean (S.E.M). * indicates significant difference as analysed by One-Way 
Independent ANOVA and LSD Post-Hoc test, p<0.05. 
 
The expression of COL1A2 mRNA in MG-63, TE-85 and SaOS-2 cells treated with 
ATP, PTH and combined ATP-PTH was analysed and compared. Treatments with 
ATP, PTH and ATP + PTH significantly increased the COL1A2 mRNA in all three 
cell lines (p<0.005) compared to control except in SaOS-2 treated with ATP. 
However, no significant differences were found between cells treated with ATP + 
PTH and cells treated with ATP or PTH alone (p>0.05). COL1A2 mRNA expression 
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was normalised to β-actin mRNA expression. Data are presented as mean from 6 
biological replicates (n=6). Error bars represent standard error of the mean (S.E.M).  
 
 
 
Figure 3.4: Expression of collagen 6a3 in osteosarcoma cell lines (MG-63, TE-85 
and SaOS-2) treated with Adenosine 5’-triphosphate (ATP) and parathyroid 
hormone (PTH). Data are normalized to β-actin. The values of the mean expression 
of the gene are shown on top of each plot. Error bars represent standard error of 
the mean (S.E.M). * indicates significant difference as analysed by One-Way 
Independent ANOVA and LSD Post-Hoc test, p<0.05. 
 
 
COL6A3 mRNA expression in MG-63, TE-85 and SaOS-2 cells treated with ATP, 
PTH and combined ATP-PTH was analysed and compared using One-Way 
Independent ANOVA and LSD Post-Hoc test. Data are presented as mean from 6 
biological replicates (n=6). A significant decrease in the expression of COL6A3 
mRNA in MG-63 was observed following treatment with PTH and combined ATP-
PTH (p<0.005) compared to control. However, there were no significant difference 
between MG-63 treated with ATP + PTH and MG-63 treated with ATP or PTH 
individually (p>0.05) which shows combination of ATP and PTH does not enhance 
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the expression of COL6A3 in MG-63. In TE-85 and SaOS-2 cells, treatment with 
ATP, PTH and combined ATP-PTH decreased COL6A3 mRNA expression 
significantly (p<0.005) significantly. However, there was no significant difference in 
COL6A3 expression in TE-85 or SaOS-2 cells when treatment was with combined 
agonists compared to individual treatment (p>0.05). 
 
 
Figure 3.5: Expression of osteoprotegerin in osteosarcoma cell lines (MG-63, TE-85 
and SaOS-2 cells) treated with Adenosine 5’-triphosphate (ATP) and parathyroid 
hormone (PTH). Data are normalized to β-actin. The values of the mean expression 
of the gene are shown on top of each plot. Error bars represent standard error of 
the mean (S.E.M). * indicates significant difference as analysed by One-Way 
Independent ANOVA and LSD Post-Hoc test, p<0.05. 
 
The expression of OPG mRNA in all three cell lines was compared and analysed. 
Data are presented as mean from 5-6 biological replicates (n=5/6) ± standard error 
of the mean (S.E.M). Treatments with ATP, PTH and combined ATP-PTH 
significantly decreased OPG mRNA expressions in MG-63, TE-85 and SaOS-2 
(p<0.05) compared to control. Further statistical tests revealed that there was no 
significant difference of OPG mRNA expression between cell lines treated with 
individual nucleotides compared to combined ATP and PTH (p>0.05). 
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Figure 3.6: Expression of osterix in osteosarcoma cell lines (MG-63, TE-85 and 
SaOS-2) treated with Adenosine 5’-triphosphate (ATP) and parathyroid hormone 
(PTH). Data are normalized to β-actin. The values of the mean expression of the 
gene are shown on top of each plot. Error bars represent standard error of the 
mean (S.E.M). * indicates significant different as analysed by One-Way 
Independent ANOVA and LSD Post-Hoc test, p<0.05. 
 
The expression of OSX mRNA in all three cell lines was compared. Data are 
presented as mean from 5-6 biological replicates (n=5/6) ± standard error of the 
mean (S.E.M). Treatment with ATP, PTH and ATP-PTH combined significantly 
increased the expression of OSX mRNA in TE-85 and SaOS-2 cells (p<0.05) 
compared to control. There was no significant increase of OSX expression in MG-
63 observed throughout the treatments. Further statistical tests revealed that there 
were no significant difference in OSX mRNA expression in any cell line treated with 
individual nucleotides compared to combined (p>0.05). 
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Figure 3.7: Expression of RANKL in osteosarcoma cell lines (MG-63, TE-85 and 
SaOS-2) treated with Adenosine 5’-triphosphate (ATP) and parathyroid hormone 
(PTH). Data are normalized to β-actin. The values of the mean expression of the 
gene are shown on top of each plot. Error bars represent standard error of the 
mean (S.E.M). * indicates significant difference as analysed by One-Way 
Independent ANOVA and LSD Post-Hoc test, p<0.05. 
 
Prior to and following treatment with ATP and PTH, the expression of RANKL 
mRNA in all three cell lines was compared. In all cell lines, treatment with ATP, PTH 
and ATP-PTH combined increased the expression of RANKL mRNA. However, the 
significant increase of RANKL mRNA expression compared to control was only 
observed in MG-63 and TE-85 treated with PTH and the combination of ATP-PTH 
(p<0.05). In TE-85 cells there was no significant difference in the expression of 
RANKL mRNA between cells treated with ATP or PTH (p>0.05) and between cells 
treated with PTH and ATP-PTH combined (p>0.05). However, RANKL mRNA 
expression was significantly higher in TE-85 treated with combined ATP-PTH 
compared to TE-85 treated with ATP alone (p<0.05). Meanwhile no significant 
difference was observed in SaOS-2 cells treated with ATP, PTH or ATP-PTH 
(p>0.05). Data are presented as mean from 5 biological replicates (n=5) ± SE. 
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Figure 3.8: Expression of sclerostin in osteosarcoma cell lines (MG-63, TE-85 and 
SaOS-2) treated with Adenosine 5’-triphosphate (ATP) and parathyroid hormone 
(PTH). Data are normalized to β-actin. The values of the mean expression of the 
gene are shown on top of each plot. Error bars represent standard error of the 
mean (S.E.M). * indicates significant difference as analysed by One-Way 
Independent ANOVA and LSD Post-Hoc test, p<0.05. 
 
SOST mRNA expression in TE-85 and SaOS-2 cells treated with ATP, PTH and 
ATP-PTH combined was analysed and compared. Data are presented as mean 
from 6 biological replicates (n=6). SOST mRNA expression was not detected in MG-
63 cells. A significant decrease was observed in the expression of SOST mRNA in 
both TE-85 and SaOS-2 cells treated with ATP, PTH and combined ATP-PTH 
(p<0.05) compared to control. However, there was no significant difference in SOST 
mRNA expression in TE-85 and SaOS-2 cells across all treatments (p>0.05). There 
were no significant differences in SOST mRNA expression between cells treated 
with ATP or PTH (p>0.05) and between cells treated with PTH and ATP-PTH 
combined (p>0.05). 
 
  
63 
 
3.4 Discussion 
In the first part of this chapter, we studied the expression of seven bone markers in 
three human osteosarcoma cell lines and primary osteoblast. The selected bone 
markers are ALP, COL1A2, COL6A3, OPG, OSX, RANKL and SOST. We selected 
MG-63, TE-85 and SaOS-2 cells because these cells represent different stages of 
osteoblast differentiation: MG-63 the least differentiated, TE-85 representing the 
intermediate stage and SaOS-2 as the most differentiated or matured osteoblast 
(Pacheco-Pantoja, et al., 2011).  The use of these cell lines has enabled us to study 
the expression of proteins participating in the osteoblastic differentiation process 
which is crucial for normal cell development, growth and survival. 
 
ALP has been used as a bone formation marker by many researchers due to the 
ease of its measurement and its potential for use as an indicator of risk of fracture 
and other bone complications related to disorders of bone metabolism (Havill et al., 
2006). Osteoblasts secrete bone ALP, a non-collagenous protein which is crucial for 
bone mineralisation. High concentrations of ALP have been detected in menopausal 
women experiencing high bone turnover (Mukaiyama et al., 2015) and in 
osteoporosis, Paget’s disease and osteomalacia patients (Gomez et al., 1995). In 
this current study, we found that the expression of ALP mRNA differed significantly 
between cell lines. One interesting finding was the large difference in its expression 
in SaOS-2 cells compared to MG-63 and TE-85 cells. This result may be explained 
by the fact that SaOS-2 cells represent the most differentiated and mature 
osteoblasts, in comparison to MG-63 and TE-85 cells. The same observation, that 
is, the lowest level of ALP mRNA detected at the onset of the osteoblastic 
differentiation in bone marrow stromal cells (BMSC) and higher concentrations at 
the later stages have been reported previously (Prins et al., 2014).  
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Type 1 collagen is the most common and abundant of the collagen family of 
proteins. COL1A2 is especially known to be expressed abundantly in bone as the 
main component of the matrix. Any mutation that affects COL1A2 expression may 
result in genetic bone disorders such as osteogenesis imperfecta which affects 
bone strength (Dalgleish, 1997). It has been shown that type 1 collagens are 
expressed at all stages during development by osteoblastic cells (Kem et al., 2001). 
In this current study, we found that COL1A2 mRNA was expressed in all three cell 
lines. However, the highest expression was detected in MG-63 cells, which 
represent the early stage of osteoblastic differentiation, at 4.6 times higher than 
detected in SaOS-2 cells, the most differentiated osteoblast. This result suggests 
that COL1A2 mRNA expression decreases as osteoblasts differentiate further into a 
more mature form. Other studies have observed the same situation during in vitro 
osteogenic induction of BMSCs. After 12 days, induced BMSCs differentiated into 
mineralized osteoblasts and subsequently expressed very low levels of COL1A2 
(Guo et al., 2016). 
 
A study in 2014 reported that COL6A3-silencing induced the expression of Sfrp2 
(secreted Frizzled-related protein 2), an antagonist of Wnt signalling which 
efficiently suppresses 3D growth in cultured cells. This indicates that COL6A3 plays 
an important role in bone formation by favouring Wnt signalling (Martianov et al., 
2014). However, the expression pattern of COL6A3 in developing bone matrix is still 
not very well understood. Our findings suggest that the expression of COL6A3 
mRNA was highest in MG-63 cells and decreased as the cells became more 
differentiated. The lowest levels of COL6A3 mRNA expression were detected in TE-
85 cells. This result corroborates the finding by the other researcher in our 
laboratory that COL6A3 stabilises the extracellular matrix during bone development 
by providing the initial scaffolding at an early stage of osteoblastic differentiation 
upon which mineralization takes place (unpublished data). 
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OPG is a protein known to regulate osteoclastogenesis by inhibition of both the 
function and differentiation of osteoclasts (Yamaguchi, 2009). In this study, we 
found that the expression pattern of OPG mRNA is quite similar to COL1A2 and 
COL6A3, where the highest expression levels were detected in MG-63 cells. These 
results suggest that osteoblasts at the early stage of differentiation inhibit 
osteoclastogenesis via OPG. This finding however is inconsistent with previous 
reported study which investigated whether osteoclastogenesis depends on the 
stage of osteoblastic differentiation. The study reported an increase of OPG mRNA 
expression in murine primary osteoblast cultures after the onset of mineralization. 
High expression of OPG at the later stage of osteoblastic differentiation caused the 
mature osteoblast to have relatively decreased osteoclastogenic activity (Thomas et 
al., 2001).  
 
OSX mRNA and RANKL mRNA were expressed at significantly higher 
concentrations in SaOS-2 cells compared to MG-63 or TE-85 cells, in which 
expression levels were very similar. OSX is an essential transcription factor for 
osteoblastic differentiation (Cao et al., 2005) while RANKL is essential for 
osteoclastogenesis (Atkins et al., 2003). However, the expression patterns of OSX 
and RANKL at different stages of osteoblastic differentiation in human 
osteosarcoma cell lines have not been reported. Here, we found that OSX and 
RANKL mRNAs were expressed at higher levels in SaOS-2 which represent the 
most matured osteoblastic cell. A similar observation was reported in mice where 
OSX and RUNX2 were reported to independently regulate osteoblastic 
differentiation at a later stage (Yoshida et al., 2012). A further study showed that 
OSX and RUNX2 could activate the expression of SOST in a co-ordinated manner 
in vitro (Perez-Campo et al., 2016). 
 
66 
 
SOST is a locally-derived inhibitor of bone formation which signals through the Wnt 
pathway and thought to be a major regulator of bone modelling and remodelling 
(Moyses & Schiavi, 2015). Consequently, there was much interest in SOST as a 
potential therapeutic target for bone disorders. Our result indicates that the SOST 
mRNA expression profile in the three cells lines was consistent with their reported 
differentiation status. SaOS-2 cells had the highest expression, 5.75 fold higher 
than that in TE-85 cells. Interestingly, SOST mRNA expression was barely 
detectable in MG-63 cells (Fig. 3.7). This result reinforces previous reports on the 
relative differentiation status of these commonly used osteoblastic cell models. The 
robust expression patterns of these bone markers suggest that these cell types do 
indeed represent different stages of the osteoblast / osteocyte lineage and reinforce 
their utility in investigating osteoblast biology. 
 
In the second part of this chapter, we measured the mRNA expression of seven 
selected bone markers: ALP, COL1A2, COL6A3, OPG, OSX, RANKL and SOST, 
with and without ATP and PTH treatments in the three human osteosarcoma cell 
lines: MG-63, TE-85 and SaOS-2 cells. Each cell line was treated with ATP, PTH 
and ATP + PTH for 48 hours before cells were harvested for analysis. 
 
The results of this study indicate that ATP and PTH increase the mRNA expression 
of ALP, COL1A2, OSX and RANKL in all cell lines. Interestingly, the individual 
treatment with ATP or PTH equally increased the mRNA expression of ALP, 
COL1A2, OSX and RANKL with no significant difference between cell lines except 
for ALP mRNA expression in MG-63 cells. MG-63 cells treated with PTH expressed 
significantly more ALP mRNA compared to treatment with ATP. The largest 
increase in ALP mRNA expression was observed with the combined treatment with 
ATP and PTH, although the increase was not significantly higher than in TE-85 cells 
treated only with ATP or PTH. The ability of PTH to increase ALP expression also 
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has been reported in early differentiating MC3TE-E1 mice cells (Rey et al., 2007). 
Similar expression profile was observed for COL1A2 and OSX mRNA in all cell 
lines, where combined treatment with the nucleotide agonists induced expression 
that was not significantly different from cells treated with individual agonists. A 
published study reported that HOBIT cells that were treated with 100 μM of ATP 
showed a significant increase of COL1A2 gene expression (Pines et al., 2003). 
Same result has been observed in a study using primary rat osteoblast which 
showed that OSX mRNA expression increased significantly 12 hours after treated 
with 500 nM of PTH (Wang et al., 2006). Slightly different results were observed in 
RANKL mRNA expression. Combined ATP and PTH treatment on MG-63 cells 
induced significantly higher expression of RANKL mRNA compared with treatment 
with individual agonists. However, RANKL mRNA expression was similar in SaOS-2 
cells regardless the treatment given. The same effect of PTH treatments on RANKL 
mRNA expression has been reported in an in Vivo study using rat. This study 
reported that PTH treatment increased RANKL mRNA expression as much as 27 
folds as early as 1 hour after treatment (Ma et al., 2001). 
 
The inhibitory effect of ATP and PTH was observed on the mRNA expression of 
COL6A3, OPG and SOST genes (Fig. 3.4, Fig. 3.5 and Fig. 3.8 respectively). MG-
63, TE-85 and SaOS-2 cells treated with ATP, PTH and the combination of ATP 
and PTH showed a significant decrease in the mRNA expression of COL6A3, OPG 
and SOST. The combination of ATP + PTH treatment did not induce any further 
significant reduction in COL6A3, OPG or SOST mRNA expression across the cell 
lines except for COL6A3 mRNA expression in MG-63 and SOST mRNA expression 
in SaOS-2 cells. The effect of ATP and PTH treatment in this study is consistent 
with the previous study which reported that PTH treatment dramatically reduces the 
expression of SOST mRNA and sclerostin protein in primary cultures of neonatal 
murine calvaria and osteocytic MLO-A5 cells (Bellido et al., 2005). PTH also has 
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been shown to inhibit OPG expression by 40% when treated with 0.1 ng/ml of PTH 
in murine bone marrow cultures. Complete inhibition of OPG was observed when 
the same cells were treated with 1 ng/ml of PTH (Lee and Lorenzo, 1999). The 
results of this investigation indicate that ATP and PTH increase ALP, COL1A2, OSX 
and RANKL mRNA gene expression and inhibit the mRNA expression of COL6A3, 
OPG and SOST at all stages of osteoblast differentiation.  
 
OPG and RANKL are two critical proteins for osteoclastogenesis. RANKL induces 
osteoclastogenesis by binding to its receptor on the surface of osteoclast 
precursors. On the other hand, OPG inhibits excessive bone resorption by inhibiting 
osteoclast formation by blocking the binding of RANKL to its receptor (Thomas, et 
al., 2001). This finding suggest that ATP and PTH control bone resorption by 
increasing RANKL mRNA expression and inhibiting OPG mRNA expression at all 
stages of osteoblastic differentiation. ATP and PTH also play a role in inhibition of 
bone formation by inhibiting COL6A3 mRNA expression, a protein which creates a 
scaffold for bone mineralisation. 
 
ATP and PTH also favour bone formation by increasing concentrations of proteins 
that are essential for new bone formation, such as ALP and COL1A2 and 
supressing SOST (Cutarelli et al., 2016; Keller and Kneissel, 2005; Pines et al., 
2013). ALP is a protein secreted by osteoblasts which is crucial for bone 
mineralisation while COL1A2 is the main component of bone matrix. Higher OSX 
expression contributes to a higher rate of bone formation because OSX is an 
important transcription factor for osteoblast differentiation. This study has shown 
that ATP and PTH are directly involved in the regulation of proteins that are crucial 
for bone development. This could support the notions that they are involved in bone 
remodelling at all stages of osteoblastic differentiation. As ATP can be released by 
osteoblasts through mechanical stimulation, it would be interesting to investigate 
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techniques that could be used to control ATP production by osteoblasts. 
Identification of the factors which regulate ATP and PTH levels may also contribute 
to the development of new therapeutic approaches to prevent bone loss. 
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3.5     Conclusions 
From the results in this chapter, we conclude that: 
 ALP, OSX, RANKL and SOST mRNAs were expressed highest in SaOS-2 cells 
while COL1A2, COL6A3 and OPG mRNAs were expressed highest in MG-
63cells; 
 SOST mRNA was not detected in MG-63 cells. This is consistent with the fact 
that SOST is only produced by matured osteoblast; 
 The effects of ATP and PTH treatment on the expression of bone markers were 
consistent between cell lines; 
 MG-63, TE85, and SaOS-2 cells were shown to be good models to study 
osteoblastic cells as they express specific proteins and react to ATP or PTH 
treatments in a similar way to primary osteoblast. 
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CHAPTER 4: 
DIFFERENTIAL EXPRESSION OF miRNAs IN HUMAN OSTEOBLASTIC CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
4.1 Introduction 
As described in Chapter 1, microRNAs (miRNAs) are endogenously expressed 
small non-coding RNA molecules that have been demonstrated to play important 
roles in the post-transcriptional regulation of gene expression. To summarise, 
miRNAs are transcribed as a long RNA precursor known as pri-miRNA which is 
then cleaved to pre-miRNA. Pre-miRNA is then further processed into mature and 
functional miRNA that targets complementary mRNA. Mature miRNAs regulate 
protein translation and mRNA cleavage by binding to specific sites within the 3’-end 
region and rarely the 5′-end of the mRNA (Gulyaeva & Kushlinskiy, 2016; Lytle et 
al., 2007). MiRNAs have been linked to numerous biological processes including 
cellular proliferation, differentiation and apoptosis. Over the past decade, studies 
have assessed the expression of miRNA in samples from healthy and diseased 
humans and demonstrated that various health issues, especially cancer (Schulte et 
al., 2010) were the result of variation in normal gene expression as a result of 
changes in the expression of miRNAs. These findings revealed that the miRNA 
expression profile can provide an important tool for better understanding, in addition 
to normal cell physiology, the aetiology and potential treatment options of numerous 
diseases.  
 
We aim to understand the involvement of miRNAs at different stages of osteoblastic 
differentiation. In bone biology, numerous miRNAs have been predicted and 
described as key factors for bone modelling and remodelling. To date, studies of 
miRNAs as regulators of bone development and miRNA as a treatment option for 
bone-related diseases are still scarce. In this chapter, we assessed the miRNA 
expression profile in normal primary human osteoblasts and three osteosarcoma 
cell lines which represent different stages of osteoblastic differentiation: MG-63 
represents the earliest stage of osteoblast differentiation; TE-85 an intermediate 
stage and SaOS-2 the most differentiated or matured osteoblast. We compared 
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miRNA expression profiles by microarray in these cells using cluster analysis to 
identify differentially expressed miRNAs. Identification of miRNAs expressed 
differentially across these four cell lines and variations in expression patterns may 
give insights into the next step of finding the miRNA candidates for tackling issues 
affecting healthy bone maintenance and development. 
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4.2 Brief methods 
4.2.1 Extraction of miRNA 
Total RNA (including miRNA) was extracted using an miRNeasy Mini Kit (Qiagen, 
Catalog No. 217004) according to the protocol provided by the manufacturer. 
 
 
4.2.2 MiRNA analysis of total RNA 
Total purified RNA samples (free from genomic DNA) were sent for Affymetrix 
miRNA profiling using an Affymetrix GeneChip miRNA 4.0. CEL files were 
generated using Affymetrix GeneChip Command Console Software. Expression 
Console software was used for quality control of array performance. Transcriptome 
Analysis Console v2 (Affymetrix) was used to analyse miRNA differential expression 
between cell types. Detailed methods are provided in Section 2.3.2. The estimated 
log2 fold change (logFC) for the 6 contrasts were tested in limma using a t-test. P-
values associated with logFC were adjusted for multiple testing using the False 
Discovery Rate (FDR) approach (Benjamini and Hochberg, 1995). Significantly 
differentially expressed (DE) miRNAs were defined as those with an FDR-adjusted 
P-value < 5%. 
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4.3 Results 
 
Below are the results of miRNAs expression comparisons between two osteoblastic 
cells. 
Table 4.1: Number of differentially expressed (DE) miRNA types. 
 
 
 
 
MG-63 
vs   
HOB 
MG-63 
vs    
TE-85 
MG-63 
vs 
SaOS-2 
TE-85 
vs 
SaOS-2 
TE-85 
vs 
HOB 
SaOS-2 
vs   
HOB 
DE: all 210 132 92 132 314 215 
DE: up-regulated 174 51 49 76 263 174 
DE: down-regulated 36 81 43 56 51 41 
 
Table 4.1 shows the number of differentially expressed miRNAs in different bone 
cell types. Significant differential expression was defined as comparisons with a 
false discovery rate (FDR)-adjusted p-value < 0.05 and miRNA expression fold 
change of at least 2 fold. The highest number of differentially expressed miRNAs 
was observed between TE-85 and HOB with 314 miRNAs. 
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Figure 4.1 shows correlated total miRNA expression levels between the 4 different 
cell types (MG-63, TE-85, SaOS-2 and HOB) and 3 repeats over 12 arrays. There 
was stronger correlation between samples from the same group than between 
samples from different groups. This implies that the variation between groups is 
stronger than the technical variation or variation within the group. 
 
Figure 4.1: Correlation heatmap of miRNA expression in all 12 cell varieties 
and repeats, displaying comparative levels of miRNA expression between 
samples. 
77 
 
 
 
 
 
By performing principal components analysis (PCA) of these data a very clear 
demonstration arises that samples from the same group tightly cluster together (Fig. 
4.2), and supports the finding that the difference between groups is much larger 
than that within any group. Thus, some miRNA molecules can be expected to be 
differentially expressed by different cell types. 
  
Figure 4.2: Principal Components Analysis plot of miRNA expression. PCA plot 
shows clear demonstration that samples from the same groups are tightly cluster 
together. Component 1 differentiates the cell lines from the primary cell and 
component 2 differentiates the cell lines from each other. 
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Figure 4.3: Visualisation of upregulation (red) or downregulation (green) of raw 
miRNA expression data (MA plots) of the six combinations of TE-85 (T), MG-63 (M), 
SaOS-2 (S) and HOBs (H) for Homo sapiens probe sets. 
 
We analysed the comparative expression of each human miRNA across each cell 
type and repeat (Fig. 4.4), in which each line represents a single miRNA, the 
expression of which is compared across each sample in a heatmap, the colour 
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scale illustrating the relative expression level of an miRNA in a specific slide where 
red represents high relative expression and green low relative expression, and so 
each column therefore represents a single repeat for a distinct cell line. The miRNA-
clustering tree is shown on the right and the cell line-clustering tree at the top, 
clustering together the most similar results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Hierarchical clustering showing all 210 differentially expressed miRNA 
levels between MG-63 (M) and primary human osteoblasts, HOBs (H). The 
expression of these same miRNAs in TE-85 (T) and SaOS-2 (S) are also included. 
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Figure 4.5: Volcano plot of the differential expression of miRNAs between MG-63 
and primary human osteoblasts, HOBs. Change in expression is plotted on the x-
axis, log (significance) on y-axis. Blue dots represent human miRNAs which are 
greater than 2 fold different and whose difference is statistically significant (p<0.05). 
 
 
The volcano plot shows that 210 miRNAs show statistically significant difference 
(p < 0.05) with at least 2 fold changes between the two groups and are highlighted 
in blue. The grey data points are either not significant, are expressed at a rate less 
than twice, or more than half, that of the comparative cell line. 
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Figure 4.6 shows a heat map diagram representing the clustering of the 30 miRNAs 
with the largest fold difference between MG-63 cells and HOBs, and in Table 4.2. 
Each row represents a single miRNA and each column represents a cell line. The 
miRNA-clustering tree is shown on the right and the cell line-clustering tree is 
shown at the top. The colour scale illustrates the relative expression level. Red 
represents a high relative expression level and a green a low relative expression. 
  
Figure 4.6: Heat map and hierarchical clustering of the 30 miRNAs with the biggest 
fold difference between MG-63 (M) and HOB (H) cells. The expression of these 
same miRNAs in TE-85 (T) and SaOS-2 (S) are also included. 
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Table 4.2: 30 miRNAs with the greatest differential expression between MG-63 and 
HOBs. 
 
Transcript ID 
(Array Design) 
Fold Change (linear) 
(MG-63 vs. HOB) 
FDR p-value 
(MG-63 vs. HOB) 
hsa-miR-182-5p 754.62 0.000023 
hsa-miR-18a-5p 717.97 0.000606 
hsa-miR-3613-3p 119.46 0.000740 
hsa-miR-18b-5p 108.29 0.000194 
hsa-miR-17-3p 98.43 0.004299 
hsa-miR-4668-5p 92.60 0.000172 
hsa-miR-3200-3p 73.42 0.003241 
hsa-miR-18a-3p 68.80 0.000057 
hsa-miR-183-5p 61.99 0.000569 
hsa-miR-92a-1-5p 61.04 0.000003 
hsa-miR-1244 56.68 0.003722 
hsa-miR-222-5p 56.52 0.000285 
hsa-miR-31-3p 56.23 0.004969 
hsa-miR-106a-5p 53.40 0.000312 
hsa-miR-20b-5p 50.95 0.000308 
hsa-miR-20a-5p 50.38 0.001856 
hsa-miR-328-3p -51.58 0.020834 
hsa-miR-409-5p -56.85 0.038952 
hsa-miR-1290 -71.09 0.003074 
hsa-miR-134-5p -72.06 0.027496 
hsa-miR-543 -95.24 0.040835 
hsa-miR-485-5p -99.44 0.022798 
hsa-miR-143-3p -174.64 0.031891 
hsa-miR-145-5p -204.85 0.017295 
hsa-miR-379-5p -296.10 0.000768 
hsa-miR-382-5p -475.46 0.001411 
hsa-miR-487b-3p -491.07 0.012562 
hsa-miR-432-5p -562.10 0.001010 
hsa-miR-409-3p -665.64 0.006532 
hsa-miR-127-3p -1534.58 0.004035 
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A heat map diagram showing the hierarchical clustering results from all 132 
differentially expressed miRNA between MG-63 (M) and TE-85 (T) is shown in Fig 
4.7, whilst a volcano plot shows the distribution of significantly different expression 
which is greater than double, or less than half, the expression of the comparative 
cell type (Fig 4.8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Hierarchical clustering of all 132 differentially expressed miRNAs 
between MG-63 (M) and TE-85 (T). The expression of these same miRNAs in 
SaOS-2 (S) and HOBs (H) are also included. 
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Figure 4.8: Volcano plot of the differential expression of miRNAs between MG-63 
and TE-85 cells. Change in expression is plotted on the x-axis, log (significance) on 
y-axis. Blue dots represent human miRNAs which are greater than 2 fold different 
and whose difference is statistically significant (p<0.05). 
 
30 miRNAs with the largest difference in expression between MG-63 cells and TE-
85 are displayed in a heatmap in Fig. 4.9 and in Table 4.3.   
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Figure 4.9: Hierarchical clustering shows 30 miRNAs with the biggest fold change 
between MG-63 (M) and TE-85 (T). The expression of the same miRNAs in SaOS-
2 (S) and HOBs (H) are also included. 
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Table 4.3: 30 miRNAs with the greatest differential expression between MG-63 and 
TE-85. 
Transcript ID 
(Array Design) 
Fold Change (linear) 
(MG-63 vs. TE-85) 
FDR p-value 
(MG-63 vs. TE-85) 
hsa-miR-365b-5p 46.91 0.005608 
hsa-miR-24-2-5p 39.02 0.001315 
hsa-miR-23a-5p 23.90 0.022549 
hsa-miR-31-3p 23.23 0.011710 
hsa-miR-27a-5p 22.14 0.003883 
hsa-let-7a-2-3p 18.07 0.022265 
hsa-miR-100-5p 16.80 0.000720 
hsa-miR-125b-2-3p 16.41 0.009027 
hsa-miR-887-3p 13.67 0.009427 
hsa-let-7i-5p 13.55 0.006067 
hsa-miR-199a-5p 11.96 0.000743 
hsa-miR-27a-3p 11.36 0.000743 
hsa-miR-486-5p 10.93 0.014413 
hsa-miR-222-5p 10.86 0.006952 
hsa-miR-378f -9.66 0.004648 
hsa-miR-4521 -10.16 0.004012 
hsa-miR-140-5p -12.29 0.026141 
hsa-miR-133b -13.93 0.002609 
hsa-miR-1307-5p -14.96 0.017638 
hsa-miR-1226-3p -15.77 0.015458 
hsa-miR-6872-5p -18.84 0.004390 
hsa-miR-1304-3p -20.16 0.006861 
hsa-miR-335-5p -21.09 0.010281 
hsa-miR-935 -33.68 0.001982 
hsa-miR-212-3p -35.31 0.004156 
hsa-miR-133a-3p -50.91 0.001982 
hsa-miR-146b-5p -63.30 0.017884 
hsa-miR-708-5p -116.74 0.003135 
hsa-miR-143-3p -512.20 0.000962 
hsa-miR-145-5p -522.54 0.006550 
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A heat map diagram showing the hierarchical clustering results from all 92 
differentially expressed miRNA between MG-63 and SaOS-2 is shown in Fig 4.10, 
whilst a volcano plot shows the distribution of significantly different expression 
which is greater than double, or less than half, the expression of the comparative 
cell type (Fig 4.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Hierarchical clustering shows all 92 differentially expressed miRNAs 
between MG-63 (M) and SaOS-2 (S). The expression of the same miRNAs in TE-85 
(T) and HOBs (H) are also included. 
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Figure 4.11: Volcano plot of the differential epression of miRNAs between MG-63 
and SaOS-2 cells. Change in expression is plotted on the x-axis, log (significance) 
on y-axis. Blue dots represent human miRNAs which are greater than 2 fold 
different and whose difference is statistically significant (p<0.05). 
 
 
30 miRNAs with the largest difference in expression between MG-63 cells and TE-
85 are displayed in a heatmap in Fig. 4.12 and in Table 4.4.  
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Figure 4.12: Hierarchical clustering shows 30 miRNAs with the biggest fold change 
between MG-63 (M) and SaOS-2 (T). The expression of the same miRNAs in TE-85 
(T) and HOBs (H) are also included. 
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Table 4.4: 30 miRNAs with the greatest differential expression between MG-63 and 
SaOS-2. 
Transcript ID 
(Array Design) 
Fold Change (linear) 
(MG-63 vs. SaOS-2) 
FDR p-value 
(MG-63 vs. SaOS-2) 
hsa-miR-155-5p 2842.10 0.000675 
hsa-miR-3200-3p 78.55 0.000701 
hsa-miR-584-5p 64.08 0.013628 
hsa-miR-365b-5p 63.51 0.003607 
hsa-miR-193a-3p 44.47 0.015420 
hsa-miR-497-5p 39.54 0.002704 
hsa-miR-551a 37.38 0.002212 
hsa-miR-3200-5p 35.02 0.013628 
hsa-miR-195-3p 24.73 0.006004 
hsa-miR-193a-5p 18.31 0.001423 
hsa-miR-195-5p 15.32 0.000701 
hsa-miR-887-3p 12.11 0.013506 
hsa-miR-27a-5p 10.94 0.000701 
hsa-miR-296-3p 10.65 0.038422 
hsa-miR-4725-3p 9.92 0.028367 
hsa-miR-601 9.64 0.028235 
hsa-miR-551b-5p -12.06 0.019384 
hsa-miR-181a-2-3p -12.48 0.004937 
hsa-miR-490-5p -12.84 0.012145 
hsa-miR-129-5p -15.23 0.001289 
hsa-miR-34c-5p -19.87 0.005956 
hsa-miR-551b-3p -20.38 0.006004 
hsa-miR-138-5p -28.55 0.002043 
hsa-miR-486-3p -32.46 0.007947 
hsa-miR-1269b -34.75 0.009184 
hsa-miR-1269a -53.55 0.003360 
hsa-miR-105-5p -91.48 0.010815 
hsa-miR-767-5p -151.28 0.001057 
hsa-miR-143-3p -487.53 0.001289 
hsa-miR-145-5p -561.08 0.009482 
 
  
91 
 
A heat map diagram showing the hierarchical clustering results from all 132 
differentially expressed miRNA between TE-85 and SaOS-2 cells is shown in Fig 
4.13, whilst a volcano plot shows the distribution of significantly different expression 
which is greater than double, or less than half, the expression of the comparative 
cell type (Fig 4.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Hierarchical clustering shows all 132 differentially expressed miRNAs 
between TE-85 (T) and SaOS-2 (S). The expression of the same miRNAs in MG-63 
(M) and HOBs (H) are also included. 
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Figure 4.14: Volcano plot of the differential expression of miRNAs between TE-85 
and SaOS-2 cells. Change in expression is plotted on the x-axis, log (significance) 
on y-axis. Blue dots represent human miRNAs which are greater than 2 fold 
different and whose difference is statistically significant (p<0.05). 
 
30 miRNAs with the largest difference in expression between TE-85 and SaOS-2 
cells are displayed in a heatmap in Fig. 4.15 and in Table 4.5.  
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Figure 4.15: Hierarchical clustering shows 30 miRNAs with the biggest fold change 
between TE-85 (T) and SaOS-2 (T). The expression of the same miRNAs in MG-63 
(M) and HOBs (H) are also included. 
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Table 4.5: 30 miRNAs with the greatest differential expression between TE-85 and 
SaOS-2. 
Transcript ID 
(Array Design) 
Fold Change (linear) 
(TE-85 vs. SaOS-2) 
FDR p-value 
(TE-85 vs. SaOS-2) 
hsa-miR-155-5p 1467.24 0.001030 
hsa-miR-935 99.54 0.002489 
hsa-miR-133a-3p 55.35 0.002489 
hsa-miR-296-3p 44.60 0.015201 
hsa-miR-3200-3p 36.34 0.001175 
hsa-miR-146b-5p 32.77 0.021155 
hsa-miR-584-5p 29.91 0.019101 
hsa-miR-1304-3p 29.74 0.002380 
hsa-miR-6872-5p 29.27 0.007516 
hsa-miR-551a 27.43 0.001175 
hsa-miR-378a-5p 25.97 0.006137 
hsa-miR-708-5p 25.43 0.003008 
hsa-miR-378d 24.94 0.033087 
hsa-miR-1226-3p 21.36 0.013405 
hsa-miR-200c-3p 20.94 0.006605 
hsa-miR-378g 20.92 0.002489 
hsa-miR-4521 20.18 0.002516 
hsa-miR-378f 18.89 0.004322 
hsa-miR-378c 18.37 0.001175 
hsa-miR-422a 16.90 0.007975 
hsa-miR-378e 16.58 0.007335 
hsa-miR-378a-3p 16.41 0.002105 
hsa-miR-133b 15.74 0.002516 
hsa-let-7g-5p -19.53 0.021442 
hsa-miR-1269b -34.85 0.007335 
hsa-miR-1269a -56.69 0.002882 
hsa-miR-486-5p -86.23 0.002925 
hsa-miR-486-3p -146.95 0.001426 
hsa-miR-767-5p -173.02 0.000707 
hsa-miR-105-5p -213.34 0.001175 
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A heat map diagram showing the hierarchical clustering results from all 314 
differentially expressed miRNA between TE-85 and HOBs is shown in Fig 4.16, 
whilst a volcano plot shows the distribution of significantly different expression 
which is greater than double, or less than half, the expression of the comparative 
cell type (Fig 4.17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Hierarchical clustering shows all 314 differentially expressed miRNAs 
between TE-85 (T) and HOBs (H). The expression of the same miRNAs in SaOS-2 
(S) and MG-63 (M) are also included. 
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Figure 4.17: Volcano plot of the expression difference in miRNA expression 
between TE-85 and HOBs. Change in expression is plotted on the x-axis, log 
(significance) on y-axis. Blue dots represent human miRNAs which are greater than 
2 fold different and whose difference is statistically significant 
. 
 
30 miRNAs with the largest difference in expression between TE-85 and HOBs are 
displayed in a heatmap in Fig. 4.18 and in Table 4.6. 
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Figure 4.18: Hierarchical clustering shows the 30 miRNAs with the biggest fold 
change between TE-85 (T) and HOBs (H). The expression of the same miRNAs in 
SaOS-2 (S) and MG-63 (M) are also included. 
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Table 4.6: 30 miRNAs with the greatest differential expression between TE-85 and 
HOBs. 
Transcript ID 
(Array Design) 
Fold Change (linear) 
(TE-85 vs. HOBs) 
FDR p-value 
(TE-85 vs. HOBs) 
hsa-miR-18a-5p 2737.90 0.000324 
hsa-miR-378c 1187.84 0.049561 
hsa-miR-378f 855.26 0.036359 
hsa-miR-422a 753.10 0.024589 
hsa-miR-378i 583.22 0.036702 
hsa-miR-18b-5p 448.43 0.000119 
hsa-miR-378d 334.04 0.029608 
hsa-miR-378a-3p 330.63 0.036877 
hsa-miR-378a-5p 257.41 0.016766 
hsa-miR-182-5p 248.22 0.000067 
hsa-miR-18a-3p 221.62 0.000132 
hsa-miR-378g 154.44 0.010146 
hsa-miR-17-3p 143.48 0.002668 
hsa-miR-4417 142.75 0.000254 
hsa-miR-92a-1-5p 138.39 0.000556 
hsa-miR-935 130.16 0.000242 
hsa-miR-106a-5p 129.99 0.000159 
hsa-miR-20b-5p 121.70 0.000556 
hsa-miR-629-3p 120.29 0.000991 
hsa-miR-19a-3p 117.62 0.000530 
hsa-miR-17-5p 111.95 0.000474 
hsa-miR-20a-5p 107.51 0.000917 
hsa-miR-3613-3p 97.74 0.000375 
hsa-miR-485-3p -129.63 0.047197 
hsa-miR-379-5p -251.24 0.000717 
hsa-miR-382-5p -482.67 0.000946 
hsa-miR-487b-3p -494.03 0.009910 
hsa-miR-432-5p -576.58 0.000741 
hsa-miR-409-3p -638.88 0.004593 
hsa-miR-127-3p -1588.00 0.003210 
 
  
99 
 
A heat map diagram showing the hierarchical clustering results from all 215 
differentially expressed miRNA between SaOS-2 and HOBs is shown in Fig 4.19, 
whilst a volcano plot shows the distribution of significantly different expression 
which is greater than double, or less than half, the expression of the comparative 
cell type (Fig 4.20). 
 
 
  
Figure 4.19: Hierarchical clustering shows all 215 differentially expressed miRNAs 
between SaOS-2 (S) and HOBs (H). The expression of the same miRNAs in MG-
63 (M) and TE-85 (T) are also included. 
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Figure 4.20: Volcano plot of the differential expression of miRNAs between SaOS-2 
and HOBs. Change in expression is plotted on the x-axis, log (significance) on y-
axis. Blue dots represent human miRNAs which are greater than 2 fold different and 
whose difference is statistically significant (p<0.05). 
 
 
30 miRNAs with the largest difference in expression between TE-85 and HOBs are 
displayed in a heatmap in Fig. 4.21 and in Table 4.7.  
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Figure 4.21: Hierarchical clustering shows the 30 miRNAs with the largest fold 
change between SaOS-2 (S) and HOBs (H). The expression of the same miRNAs in 
MG-63 (M) and TE-85 (T) are also included. 
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Table 4.7: 30 miRNAs with the greatest differential expression between SaOS-2 
and HOBs. 
Transcript ID 
(Array Design) 
Fold Change (linear) 
(SaOS-2 vs. HOBs) 
FDR p-value 
(SaOS-2 vs. HOBs) 
hsa-miR-182-5p 669.13 0.000037 
hsa-miR-18a-5p 603.60 0.000783 
hsa-miR-3613-3p 253.74 0.005521 
hsa-miR-105-5p 247.29 0.000002 
hsa-miR-767-5p 218.69 0.000085 
hsa-miR-4668-5p 170.22 0.002361 
hsa-miR-18b-5p 116.88 0.000162 
hsa-miR-486-3p 111.54 0.000852 
hsa-miR-20b-5p 104.46 0.000088 
hsa-miR-17-3p 97.33 0.003978 
hsa-miR-19a-3p 77.89 0.000889 
hsa-miR-106a-5p 72.09 0.000346 
hsa-miR-20a-5p 70.34 0.001527 
hsa-miR-17-5p 63.92 0.001053 
hsa-miR-452-5p 60.53 0.000129 
hsa-miR-1269a 58.01 0.000866 
hsa-miR-1269b 55.91 0.001990 
hsa-miR-409-5p -66.98 0.031407 
hsa-miR-493-3p -69.17 0.049419 
hsa-miR-134-5p -72.06 0.026629 
hsa-miR-1290 -89.18 0.002477 
hsa-miR-155-5p -89.25 0.013733 
hsa-miR-543 -93.18 0.043385 
hsa-miR-485-5p -101.01 0.020690 
hsa-miR-379-5p -250.77 0.001349 
hsa-miR-382-5p -473.02 0.001139 
hsa-miR-487b-3p -491.07 0.011292 
hsa-miR-432-5p -566.66 0.000897 
hsa-miR-409-3p -612.18 0.005262 
hsa-miR-127-3p -1459.96 0.003684 
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4.4 Discussion 
In chapter 3, we found that MG-63, TE-85 and SaOS-2 are the good models for 
studying bone biology by studying the expression of 7 bone markers and the effect 
of ATP and PTH treatments on the expressions of these markers. In this chapter, 
we wanted to investigate the differential expression of miRNAs which are the key to 
the gene expression regulation in these cells. Understanding the miRNA expression 
in these cells is the first step toward the identification of miRNAs that can be used to 
control gene expression. 
 
In this chapter, expression profiles of miRNAs were compared between groups of 
osteoblastic cells: primary human osteoblasts (HOBs), MG-63, TE-85 and SaOS-2 
cell lines. Significant differential expression was defined as those with FDR-adjusted 
p-values < 0.05 and miRNA expression change of at least two fold. The highest 
number of differentially-expressed miRNAs was recorded between TE-85 and 
HOBs with 314 miRNAs. Of these, 263 were up-regulated in TE-85 compared to 
HOBs and 51 were down-regulated. The second highest number of differentially 
expressed miRNAs was observed between SaOS-2 and HOBs with 215 miRNAs 
followed by MG-63 and HOBs with 210 miRNAs. A comparison of miRNA 
expression between the different osteosarcoma cell lines identified fewer 
differentially expressed miRNAs: MG-63 and TE-85 (132 miRNAs), MG-63 and 
SaOS-2 (92 miRNAs) and TE-85 and SaOS-2 (132 miRNAs) (Table 4.1). The 
higher number between HOBs and all three human osteosarcoma cell lines might 
be due to cancer-related miRNAs which can play oncogenic or anti-tumour roles in 
the cell lines (Garzon et al., 2010). 
 
The sample correlation heatmap displays the general degree of similarity between 
the 12 libraries (Fig. 4.1). Primary human osteoblasts are clearly different from the 
osteosarcoma cell lines. However, overall miRNA expression is highly correlated 
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between the 12 libraries, the Spearman correlation coefficient being greater than 
0.805. Principle component analysis of the differentially-expressed miRNAs showed 
clearer sample clustering (Fig. 4.2), corroborating the sample correlation heatmap 
result. When we observed the overall comparison of differentially expressed 
miRNAs between each cell type (Fig. 4.3) it was clear that there were a greater 
number of differentially-expressed miRNAs between primary cells and any of the 
cell lines. 
  
Comparison of miRNA expression profiles between MG-63 and HOBs revealed 210 
miRNAs that were differentially expressed (Fig. 4.4). Most of these miRNAs were 
expressed to a higher level in MG-63 with 174 miRNAs. Clearer visualization of the 
differential expression distribution with highly significant differences and greater fold 
change is shown in Fig. 4.5. Out of the 210 differentially-expressed miRNAs, we 
selected 30 that had the largest fold change between (Fig. 4.6 and Table 4.2). One 
miRNA which had a large differential expression was miR-127-3p, which was 
expressed 1530 times higher in HOBs than in MG-63 (p<0.005). An online search 
using miRWalk revealed that miR-127-3p has been validated to target 23 genes, 
namely: ACTR3B, ACTR3C, BCL6, BOLA1, KCNA6, LGALS8, MAPK4, MMP13, 
NBEA, PRDM1, RGMA, SEC31A, SEPT7, SERPINB9, SETD8, SFRP1, SKI, 
SLC29A1, TGM2, USP35, XBP1, ZWINT and DAGLA. Secreted frizzled related 
protein 1 (SFRP1) is involved in the regulation of the Wnt signalling pathway by 
acting as a soluble modulator. Inhibition of this gene leads to deregulated activation 
of the Wnt pathway (Svensson et al., 2008).  
 
Hierarchical clustering clearly shows that miRNA expression in all three cell lines 
was very similar and quite different to that of HOBs. Interestingly, however, we 
found that the expression of miR-145-5p and miR-143-3p were very similar, high in 
TE-85, SaOS-2 and HOBs but very low in MG-63. These miRNAs were expressed 
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205 and 175 times higher in HOBs than in MG-63 cells, p<0.05. The expression of 
these miRNAs appears to be low in the early stage of osteoblastic differentiation 
(MG-63) but very high in the later stages (represented by TE-85 and SaOS-2). This 
finding suggests that miR-145-5p and miR-143-3p might be actively involved in 
gene regulation during the later stages of osteoblastic differentiation. Down-
regulation of miR-145-5p and miR-143-3p in MG-63 cells compared to HOBs was 
also reported in a study published in 2012 (Hu et al., 2012). 
 
Comparison of miRNA expression profiles between MG-63 and TE-85 showed that 
132 miRNAs were differentially expressed. The volcano plot (Fig. 4.8) illustrates the 
distribution of the miRNAs based on fold change and significance of difference. We 
selected the 30 miRNAs with the biggest difference in fold change between MG-63 
and TE-85 (Fig. 4.9, Table 4.3). The miRNA which had the largest difference in 
expression was miR-145-5p which was expressed in TE-85 522.54 times higher 
than in MG-63 cells, p<0.05. MiR-365b-5p was expressed highest in MG-63 
compared to TE-85 cells, which was expressed 46.91 fold higher. Further 
investigation using miRWalk and miRTarBase show this miRNA has been validated 
to target more than 100 genes including Wnt family member 2B (WNT2b), a 
secreted signalling factor crucial for Wnt signalling. However, all of these targets 
were validated using only next generation sequencing, which is considered inferior 
to other validation methods that are considered as robust as reporter assay, 
western blot, ELISA and real-time PCR.  
 
Other miRNA expression profiles we compared relating to osteosarcoma cell lines 
was that in MG-63 compared to SaOS-2 and between TE-85 and SaOS-2. 
Hierarchical clustering indicate that only 92 miRNAs were differentially expressed in 
MG-63 compared to SaOS-2 and 132 between TE-85 and SaOS-2. The volcano 
plots of significance versus relative difference in expression show almost equal 
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numbers of miRs were expressed higher and lower in MG-63 compared to SaOS-2 
(49 and 43 miRNAs respectively). We selected the 30 miRNAs that had the largest 
difference in expression between cell lines. The most striking result to emerge from 
this data is that miR-155-5p expression was 2840 times higher in MG-63 cells than 
in SaOS-2 and 1470 times higher in TE-85 than in SaOS-2, p<0.005. The high 
expression of miR-155-5p in MG-63 and low expression in SaOS-2 suggests that it 
might target proteins that negatively regulate osteoblastic differentiation during the 
early stages of differentiation. Generally, miR-155 is a well-studied multifunctional 
miRNA involved in numerous biological processes such as hematopoiesis and 
associated with various types of cancer, cardiovascular diseases and viral infections 
(Jurkovicova et al., 2014). In bone, miR-155 has been shown to indirectly regulate 
osteoclastogenesis by targeting several essential transcriptional factors such as 
MITF (microphthalmia-associated transcription factor), which is essential for 
osteoclast differentiation (Mann et al., 2010).  
 
Analysis of differential miRNA expression between TE-85 and HOBs identified 314 
miRNAs that were expressed differentially, 263 miRNAs that were up-regulated and 
51 miRNAs were down-regulated in TE-85 compared to HOBs. We selected the 30 
miRNAs that had the largest difference in expression, illustrated by hierarchical 
clustering in Fig. 4.18 and Table 4.6. The three miRNAs with the biggest fold 
changes were miR-18a-5p, miR-127-3p and miR-378c. MiR-18a-5p and miR-378c 
were expressed 2740 and 1190 times higher in TE-85 compared to HOBs while 
miR-127-3p was expressed 1590 times higher in HOBs.  
 
MiR-18a-5p has been shown to enhance vascular smooth muscle cell differentiation 
by inhibiting syndecan4, an inducer of Smad2 expression (Kee et al., 2014). 
Another study showed the involvement of miR-18a-5p in idiopathic pulmonary 
fibrosis (IPF), a chronic progressive lung disease that normally causes respiratory 
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failure and death less than 5 years following diagnosis (Zhang et al., 2016). This 
study shows that inhibition of miR-18a-5p mediates sub-pleural pulmonary fibrosis 
which is the pathological hallmark of IPF through up-regulation its target TGF-β 
receptor II (TGF-βRII). Thus researchers believe that increasing the expression of 
miR-18a-5p might be an effective treatment (Zhang et al., 2016). Using miRWalk 
online software, we found that miR-18a-5p has been validated to target more than 
200 genes including those related to Wnt signalling such as SMAD family member 4 
(SMAD4), cyclin D1 (CCND1), dishevelled associated activator of morphogenesis 2 
(DAAM2) and tumour protein p53 (TP53). 
 
Among the 30 miRNAs that are most different between TE-85 and HOBs, seven 
miRNAs are the family member of miR-378 which is one of the most abundant 
miRNA molecules in all human samples (Lee et al., 2010). The family members of 
miR-378 are miR-378a-3p, miR-378a-5p, miR-378c, miR-378d, miR-378f, miR-378g 
and miR-378i. Although the occurrences of different miRNA family members are 
common, the functional effect and importance of the majority of miRNA variants 
remain to be resolved. 
 
The final comparison of miRNA expression profiles we evaluated was between 
SaOS-2 and HOBs which revealed 215 differentially expressed miRNAs. The 
volcano plot in Fig. 4.20 indicates that 174 miRNAs were up-regulated and 41 
down-regulated in SaOS-2 cells compared to HOBs. The 30 miRNAs whose 
expression varied most between the two cell types were again selected. Among 
these miRNAs, miR-127-3p had the largest fold change, 1460 fold higher in HOBs 
compared to SaOS-2, p<0.005. Expression of this miRNA was much lower in all 
three osteosarcoma cell lines than in HOBs, as discussed earlier, 1530 fold lower in 
MG-63 and 1588 fold in TE-85, p<0.005. Similar observations have been reported in 
the literature in three osteosarcoma cell lines: KHOS, U-2OS and SaOS-2 in 
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comparison to osteoblasts (Duan et al., 2011). An interesting finding is that miR-
127-3p plays a role as a tumour suppressor by inhibiting proliferation and invasion 
of human osteosarcoma cells by targeting the SETD8 gene, which regulates DNA 
replication and the cell cycle. Thus, miR-127-3p could be a potential therapeutic 
target in the treatment of osteosarcoma (Zhang et al., 2016). 
 
In total, there were more than 4600 miRNAs were differently expressed between all 
four different cells used in this study. Table 4.8 shows 10 examples of the miRNAs 
that were expressed with the biggest fold changes between the cells and their 
validated or published targets. Among these miRNAs, miR-378a-3p and miR-422a 
were also predicted to target sclerostin gene by the online prediction tools based on 
the complementary sequences and thermodynamics between these miRNAs and 
the SOST mRNA  These miRNAs were investigated for the regulation of sclerostin 
expression in chapter 5. This shows each miRNA always has more than one targets 
across different species. 
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Table 4.8: List of miRNAs with the biggest fold change between MG-63, TE-85, 
SaOS-2 and primary osteoblast and their targets. 
miRNA Target genes and functions Reference 
hsa-miR-
127-3p 
BCL6 - Regulate cell proliferation and 
senescence. 
BAG5 - Tumor suppressor in epithelial ovarian 
cancer. 
SKI - Inhibits glioblastoma proliferation and 
activates TGF-β signalling. 
(Chen et al., 2013) 
 
(Bi et al., 2016) 
 
(Jiang et al., 2014) 
hsa-miR-
155-5p 
NF-κB p65 – Promotes the transition of 
mesenchymal stem cells to gastric cancer 
tissue derived MSC-like cells. 
ELK3 - Regulate hypoxia response. 
(Zhu et al., 2016) 
 
 
(Robertson et al., 
2014) 
hsa-miR-
18a-5p 
SDC4 – Increase vascular smooth muscle cell 
differentiation. 
TGF-βRII – Inhibit sub-pleural pulmonary 
fibrosis. 
IRF2 – As an oncogene. 
(Kee et al., 201) 
 
(Zhang et al., 
2017) 
(Liang et al., 2017) 
hsa-miR-
378a-3p 
HDAC4 – Inhibit proliferation of myoblast in 
skeletal muscle development. 
WNT10a – Inhibit activation of hepatic stellate 
cell. 
(Wei et al., 2016) 
 
(Yu et al., 2016) 
hsa-miR-
379-5p 
FAK – Inhibit tumor invasion and metastasis 
EIF4G2 – Supress the proliferation, migration 
and invasion of human osteosarcoma cells. 
MDM2 – Inhibit growth and metastasis of 
human bladder tumor. 
(Chen et al., 2016) 
(Xie et al., 2017) 
 
(Wu et al., 2017) 
hsa-miR-
409-3p 
ZEB1 - regulates cell invasion and metastasis. 
As prognostic marker for breast cancer. 
E74-like factor 2 - regulates cell proliferation 
and tumor growth in osteosarcoma. 
(Ma et al., 2016) 
 
(Cao et al., 2016) 
(Zhang et al., 
2017) 
hsa-miR-
422a 
PIK3CA - Tumor suppressor in glioblastoma. 
A potential marker for postmenopausal 
osteoporosis. 
NT53/CD73 - Promotes loco-regional 
recurrence in head and neck squamous cell 
carcinoma. 
(Liang et al., 2016) 
(Cao et al., 2014) 
 
(Bonnin et al., 
2016) 
hsa-miR- 
432-5p 
E2F3 – Inhibit myogenesisthrough 
PI3K/AKT/mTOR signalling pathway. 
P53 - Inhibit the proliferation of neuroblastoma 
cells. 
(Ma, et al., 2017) 
 
(Rihani et al., 
2015) 
hsa-miR-
487b-3p 
GRM3 – Inhibit colon cancer cell growth and 
survival. 
(Yi et al., 2017) 
hsa-miR-
182-5p 
FOXF2, RECK, MTSS1 - Promotes cell 
invasion and proliferation in human prostate 
cancer. 
CASP9 – Induce apoptosis in human breast 
cancer. 
(Hirata et al., 
2013) 
 
(Sharifi and 
Moridnia, 2017) 
 
  
110 
 
4.5   Conclusions 
From the results in chapter 4, we conclude that; 
 MicroRNAs are expressed differentially during osteoblastic differentiation; 
 MicroRNAs that induced the largest fold change between the cells we 
studied were: miR-127-3, miR-155-5p and miR-18a-5p. Each of these 
miRNAs is predicted to target hundreds of different genes which are still 
need to be studied; 
 MicroRNA differential expression profiles provide the first step for the 
identification of specific miRNAs that target our gene of interest. 
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CHAPTER 5: 
IDENTIFICATION OF miRNAs INVOLVED IN THE REGULATION OF 
SCLEROSTIN EXPRESSION 
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5.1 Introduction 
Important regulators of protein production by cells are miRNAs. MiRNA molecules 
inhibit the expression of many genes by binding within the 3’UTR of the targeted 
mRNA and therefore block translation and/or induce the degradation of mRNA 
molecules, thereby reducing protein levels. miRNAs has been used as a therapeutic 
approach to treat various human diseases, especially cancer, as they play a vital 
role in the regulation of tumour cell differentiation, proliferation, cell cycle 
progression, invasion and metastasis (Rothschild, 2013). In chapter 4, we studied 
the differential expression of miRNAs between the osteosarcoma cell lines and 
primary osteoblast. We found that miRNA expression level of certain miRNAs 
changed greatly between cells to suit the biological and physiological function of the 
cells. Then, in this chapter, we focused on the miRNAs that are involved in the 
regulation of the protein of our interest, sclerostin (SOST). We studied this protein 
because SOST plays a key role in limiting bone formation by blocking Wnt signalling 
pathway. Hence, inhibiting or limiting the overexpression of SOST by osteoblastic 
cells could help to control or limit the inhibitory effect of SOST against new bone 
formation. This method could be another approach to treat bone diseases. In the 
first part of this chapter, we have utilised online prediction tools to predict the 
potential miRNAs which could target SOST. Many miRNA targets that have been 
predicted using prediction software based mainly on nucleotide sequences and 
thermodynamics of the miRNA-mRNA interaction have been experimentally 
validated in very limited numbers. 
 
Thus we have selected multiple putative miRNAs that might target SOST, and have 
transfected TE-85 and SaoS-2 cells with the selected miRNA mimics, antagomirs 
and scrambled miRNA using Lipofectamine 2000. Theoretically, when an miRNA 
mimic is transfected into a cell, it mimics natural miRNA by binding target mRNA 
and inhibits or reduces protein translation (Kuhn et al., 2008). On the other hand, 
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antagomir binds to its related miRNA and inhibits the binding to its target mRNA 
therefore blocking its inhibitory effect (Stenvang et al., 2012). To verify the function 
of the selected miRNAs, quantitative analysis of SOST mRNA and protein levels by 
ELISA was performed. 
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5.2 Brief methods 
 
5.2.1 miRNA target prediction – Bioinformatic analysis 
To identify potential miRNAs that target sclerostin mRNA, we used five different 
online prediction tools: miRWalk, miRanda, Pictar, RNA22 and Targetscan. The six 
miRNAs that were predicted by the majority of the prediction algorithms were 
chosen for further experimental validation (section 2.3.4). 
 
 
5.2.2 Transient transfection of cells with miRNA mimics and inhibitors 
TE-85 and SaOS-2 cells were transfected with scrambled miRNA as a negative 
control, miRNA mimics and anti-miRNA/antagomir using Lipofectamine 2000 in 
medium free of serum and antibiotics. After 6 hours of incubation, culture medium 
was replaced with medium containing 10% FCS. Cells were incubated at 37°C for a 
further 48 hours before being harvested for total DNA and RNA extraction and the 
culture medium collected for sclerostin protein quantification. The detailed 
procedure is described in section 2.3.7. 
  
 
5.2.3 Total RNA extraction and protein quantification  
Total RNA (including miRNA) was extracted using an miRNeasy Mini Kit (Qiagen, 
Catalogue No. 217004) according to the protocol provided by the manufacturer. 
Culture medium from treated cells was stored at -80°C until further analysis. Protein 
secreted into the culture medium was quantified using a Quantikine® human SOST 
ELISA (R&D Systems) according to the protocol provided by the manufacturer with 
some modifications (section 2.3.8). 
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5.2.4 Total DNA extraction for sclerostin protein normalisation 
DNA extraction was carried out using a CyQUANT® cell proliferation assay kit (Life 
Technologies, Catalogue No.C7026) according to the manufacturer’s protocol. The 
total quantity of DNA was used to normalise the SOST protein secreted by TE-85 
and SaOS-2 cells. 
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5.3 Results 
 
5.3.1 miRNA target prediction – Bioinformatic analysis 
We used five different online prediction algorithms (miRWalk, miRanda, Pictar, 
RNA22 and Targetscan) to identify miRNA candidates that might target the protein 
of our interest, sclerostin. Based on the predictions, six miRNAs (hsa-miR-1231, 
hsa-miR-103a-3p, hsa-miR-1914, hsa-miR-1254, hsa-miR-378a-3p and hsa-miR-
422a) were selected for further investigation. Table 5.1 shows the prediction of the 
miRNAs by all five prediction algorithms. The expression of these sclerostin 
targeting miRNAs was not investigated in MG-63 due to undetectable level of 
sclerostin mRNA in MG-63 as we reported in chapter 3. 
 
 
Table 5.1: miRNAs expressed in TE-85 and SaOS-2 cells that are predicted to 
target sclerostin mRNA using different prediction tools (miRWalk, miRanda, Pictar, 
RNA22 and Targetscan). 1 denotes predicted, 0 denotes not predicted. 
miRNA miRWalk miRanda Pictar RNA22 Targetscan SUM 
hsa-miR-1231 1 1 1 1 1 5 
hsa-miR-103a-3p 1 1 0 1 1 4 
hsa-miR-1914 1 1 0 1 1 4 
hsa-miR-1254 1 1 0 1 1 4 
hsa-miR-378a-3p 0 1 0 1 1 3 
hsa-miR-422a 0 1 0 1 1 3 
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Figure 5.1: Expression of the selected miRNAs that were predicted to target 
sclerostin in osteosarcoma cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
The expression of the selected miRNAs in the cell lines clearly shows that all of 
these miRNAs were expressed higher in TE-85 compared to MG-63 and SaOS-2. 
High expression of these miRNAs could result in lower expression of one of the 
target genes, SOST. This result is consistent with the result from chapter 3 where 
SOST expression was significantly lower in TE-85 compared to SaOS-2. We were 
unable to compare the expression of SOST in MG-63 because SOST is not 
expressed in MG-63 as shown in chapter 3.The expression of these selected 
miRNAs that are predicted to target SOST in MG-63 is because each miRNA may 
involve in the regulation of many genes as its targets and one gene may be 
controlled by many miRNAs (Hashimoto et al., 2013). Hence, we believe that the 
expression of these miRNAs in MG-63 is to regulate the expression of other genes. 
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Table 5.2: Putative miRNA binding sites on SOST mRNA predicted by the chosen 
algorithms.  
 
Predicted consequential pairing of target 
region (top) and miRNA (bottom) 
Position 355-361 of SOST 3' 
UTR 
  
hsa-miR-378a-3p 
5'  ...GUGUGGGAGUGGGAAAGUCCAGG... 
                                                 |  |  | |  |  |  |  
3'        CGGAAGACUGAGGUUCAGGUCA 
Position 1567-1574 of SOST 3' 
UTR 
  
hsa-miR-378a-3p 
5'   ...AGUCUGUUCUUCCAGAGUCCAGA... 
                                                 |  |  | |  | |  |  
3'        CGGAAGACUGAGGUUCAGGUCA 
Position 355-361 of SOST 3' 
UTR 
  
hsa-miR-422a 
5'   ...GUGUGGGAGUGGGAAAGUCCAGG... 
                                                  |  |  | |  | |  |  
3'         CGGAAGACUGGGAUUCAGGUCA 
Position 1567-1574 of SOST 3' 
UTR 
  
hsa-miR-422a 
5'   ...AGUCUGUUCUUCCAGAGUCCAGA... 
                                                 |  |  | |  | |  |  
3'        CGGAAGACUGGGAUUCAGGUCA 
Position 826-832 of SOST 3' 
UTR 
  
hsa-miR-103a-3p 
5'      ...CUCCUGGAAGAAGCUAUGCUGCU.
.. 
                                                    |  |  | |  |  | |  
3'         AGUAUCGGGACAUGUUACGACGA 
Position 1299-1306 of SOST 3' 
UTR 
  
hsa-miR-1231 
5' ...UUUUGAAAAUCAUUUCCAGACAA... 
                                              |  |  | |  |  | |  
3'          CGUCGACAGGCGGGUCUGUG 
Position 137-143 of SOST 3' 
UTR 
  
hsa-miR-1254 
5'   ...AGGGGGCUGAGACCUUCCAGGCC... 
                     |  |  |  |                   |  |  | |  |  |  |  
3'  UGACGUCCGAGGUCGA-AGGUCCGA 
Position 870-876 of SOST 3' 
UTR 
  
hsa-miR-1914 
5'    ...UGUUUGGCUACCUCCACCCCUCC... 
                                                  |  |  |  |  | |  |  
3'         GGAGGGUCACGCCCUGGGGAGG 
 
Table 5.2 shows the putative binding sites of the miRNAs on the sclerostin mRNAs. 
Two of the miRNAs, miR-378a-3p and miR-422a were predicted to bind to two 
different sites. The binding site or the nucleotide sequence where the binding of 
miRNA and mRNA occurs is also known as seed region. 
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5.3.2 Transient transfection of cells with miRNA mimics and inhibitors and 
sclerostin protein secretion 
 
Figure 5.2: Expression of miR-103a-3p in SaOS-2 transfected with scrambled 
miRNA, miR-103a-3p mimic and antagomir. The expression of miR-103a-3p was 
normalised to the expression of RNU6-2. Data is presented as mean expression of 
6 biological replicates (n=6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
 
Figure 5.3: Expression of miR-103a-3p in TE-85 transfected with scrambled miRNA, 
miR-103a-3p mimic and antagomir. The expression of miR-103a-3p was normalised 
to the expression of RNU6-2. Data is presented as mean expression of 6 biological 
replicates (n=6) ± SE. * indicates a significant difference compared to the negative 
control as analysed by One-Way ANOVA and LSD Post-Hoc test (p<0.05). 
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Figure 5.4: Expression of sclerostin gene in SaOS-2 transfected with scrambled 
miRNA, miR-103a-3p mimic and antagomir. The expression of sclerostin was 
normalised to the expression of ß-actin. Data is presented as mean expression of 6 
biological replicates (n=6) ± SE. * indicates a significant difference compared to the 
negative control as analysed by One-Way Independent ANOVA and LSD Post-Hoc 
test (p<0.05). 
 
Figure 5.5: Expression of sclerostin gene in TE-85 transfected with scrambled 
miRNA, miR-103a-3p mimic and antagomir. The expression of sclerostin was 
normalised to the expression of ß-actin. Data is presented as mean expression of 6 
biological replicates (n=6) ± SE. * indicates a significant difference compared to the 
negative control as analysed by One-Way Independent ANOVA and LSD Post-Hoc 
test (p<0.05). 
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Figure 5.6: Expression of sclerostin in media from SaOS-2 transfected with 
scrambled miRNA, miR-103a-3p mimic and antagomir. The expression of sclerostin 
was normalised to the total DNA content. Data is presented as mean expression of 
6 biological replicates (n=6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
 
Figure 5.7: Expression of sclerostin in media from TE-85 transfected with scrambled 
miRNA, miR-103a-3p mimic and antagomir. The expression of sclerostin was 
normalised to the total DNA content. Data is presented as mean expression of 6 
biological replicates (n=6) ± SE. * indicates a significant difference compared to the 
negative control as analysed by One-Way Independent ANOVA and LSD Post-Hoc 
test (p<0.05). 
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Figure 5.8 Expression of miR-378a-3p in SaOS-2 transfected with scrambled 
miRNA, miR-378a-3p mimic and antagomir. The expression of miR-378a-3p was 
normalised to the expression of RNU6-2. Data is presented as mean expression of 
6 biological replicates (n=6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
 
Figure 5.9 Expression of miR-378a-3p in TE-85 transfected with scrambled miRNA, 
miR-378a-3p mimic and antagomir. The expression of miR-378a-3p was normalised 
to the expression of RNU6-2. Data is presented as mean expression of 6 biological 
replicates (n=6) ± SE. * indicates a significant difference compared to the negative 
control as analysed by One-Way Independent ANOVA and LSD Post-Hoc test 
(p<0.05). 
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Figure 5.10: Expression of sclerostin gene in SaOS-2 transfected with scrambled 
miRNA, miR-378a-3p mimic and antagomir. The expression of sclerostin was 
normalised to the expression of ß-actin. Data is presented as mean expression of 6 
biological replicates (n=6) ± SE. * indicates a significant difference compared to the 
negative control as analysed by One-Way Independent ANOVA and LSD Post-Hoc 
test (p<0.05). 
 
Figure 5.11 Expression of sclerostin gene in TE-85 transfected with scrambled 
miRNA, miR-378a-3p mimic and antagomir. The expression of sclerostin was 
normalised to the expression of ß-actin. Data is presented as mean expression of 6 
biological replicates (n=6) ± SE. * indicates a significant difference compared to the 
negative control as analysed by One-Way Independent ANOVA and LSD Post-Hoc 
test (p<0.05). 
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Figure 5.12: Expression of sclerostin in media from SaOS-2 transfected with 
scrambled miRNA, miR-378a-3p mimic and antagomir. The expression of sclerostin 
was normalised to the total DNA content. Data is presented as mean expression of 
6 biological replicates (n=6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
 
Figure 5.13: Expression of sclerostin in media from TE-85 transfected with 
scrambled miRNA, miR-378a-3p mimic and antagomir. The expression of sclerostin 
was normalised to the total DNA content. Data is presented as mean expression of 
6 biological replicates (n=6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
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Figure 5.14: Expression of miR-422a in SaOS-2 transfected with scrambled miRNA, 
miR-422a mimic and antagomir. The expression of miR-422a was normalised to the 
expression of RNU6-2. Data is presented as mean expression of 6 biological 
replicates (n=6) ± SE. * indicates a significant difference compared to the negative 
control as analysed by One-Way Independent ANOVA and LSD Post-Hoc test 
(p<0.05). 
 
 
Figure 5.15: Expression of miR-422a in TE-85 transfected with scrambled miRNA, 
miR-422a mimic and antagomir. The expression of miR-422a was normalised to the 
expression of RNU6-2. Data is presented as mean expression of 6 biological 
replicates (n=6) ± SE. * indicates a significant difference compared to the negative 
control as analysed by One-Way Independent ANOVA and LSD Post-Hoc test 
(p<0.05). 
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Figure 5.16: Expression of sclerostin gene in SaOS-2 transfected with scrambled 
miRNA, miR-422a mimic and antagomir. The expression of sclerostin was 
normalised to the expression of ß-actin. Data is presented as mean expression of 6 
biological replicates (n=6) ± SE. * indicates a significant difference compared to the 
negative control as analysed by One-Way Independent ANOVA and LSD Post-Hoc 
test (p<0.05). 
 
Figure 5.17: Expression of sclerostin gene in TE-85 transfected with scrambled 
miRNA, miR-422a mimic and antagomir. The expression of sclerostin was 
normalised to the expression of ß-actin. Data is presented as mean expression of 6 
biological replicates (n=6) ± SE. * indicates a significant difference compared to the 
negative control as analysed by One-Way Independent ANOVA and LSD Post-Hoc 
test (p<0.05). 
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Figure 5.18: Expression of sclerostin in media from SaOS-2 transfected with 
scrambled miRNA, miR-422a mimic and antagomir. The expression of sclerostin 
was normalised to the total DNA content. Data is presented as mean expression of 
6 biological replicates (n=5-6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
 
Figure 5.19: Expression of sclerostin in media from TE-85 transfected with 
scrambled miRNA, miR-422a mimic and antagomir. The expression of sclerostin 
was normalised to the total DNA content. Data is presented as mean expression of 
6 biological replicates (n=6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
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Figure 5.20: Expression of miR-1231 in SaOS-2 transfected with scrambled miRNA, 
miR-1231 mimic and antagomir. The expression of miR-1231 was normalised to the 
expression of RNU6-2. Data is presented as mean expression of 6 biological 
replicates (n=6) ± SE. * indicates a significant difference compared to the negative 
control as analysed by One-Way Independent ANOVA and LSD Post-Hoc test 
(p<0.05). 
 
Figure 5.21: Expression of miR-1231 in TE-85 transfected with scrambled miRNA, 
miR-1231 mimic and antagomir. The expression of miR-1231 was normalised to the 
expression of RNU6-2. Data is presented as mean expression of 6 biological 
replicates (n=3-6) ± SE. * indicates a significant difference compared to the negative 
control as analysed by One-Way Independent ANOVA and LSD Post-Hoc test 
(p<0.05). 
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Figure 5.22: Expression of sclerostin gene in SaOS-2 transfected with scrambled 
miRNA, miR-1231 mimic and antagomir. The expression of sclerostin was 
normalised to the expression of ß-actin. Data is presented as mean expression of 6 
biological replicates (n=5-6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
 
Figure 5.23: Expression of sclerostin gene in TE-85 transfected with scrambled 
miRNA, miR-1231 mimic and antagomir. The expression of sclerostin was 
normalised to the expression of ß-actin. Data is presented as mean expression of 6 
biological replicates (n=6) ± SE. * indicates a significant difference compared to the 
negative control as analysed by One-Way Independent ANOVA and LSD Post-Hoc 
test (p<0.05). 
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Figure 5.24: Expression of sclerostin in media from SaOS-2 transfected with 
scrambled miRNA, miR-1231 mimic and antagomir. The expression of sclerostin 
was normalised to the total DNA content. Data is presented as mean expression of 
6 biological replicates (n=6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
 
Figure 5.25: Expression of sclerostin in media from TE-85 transfected with 
scrambled miRNA, miR-1231 mimic and antagomir. The expression of sclerostin 
was normalised to the total DNA content. Data is presented as mean expression of 
6 biological replicates (n=6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
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Figure 5.26: Expression of miR-1254 in SaOS-2 transfected with scrambled miRNA, 
miR-1254 mimic and antagomir. The expression of miR-1254 was normalised to the 
expression of RNU6-2. Data is presented as mean expression of 6 biological 
replicates (n=5-6) ± SE. * indicates a significant difference compared to the negative 
control as analysed by One-Way Independent ANOVA and LSD Post-Hoc test 
(p<0.05). 
 
Figure 5.27: Expression of miR-1254 in TE-85 transfected with scrambled miRNA, 
miR-1254 mimic and antagomir. The expression of miR-1254 was normalised to the 
expression of RNU6-2. Data is presented as mean expression of 6 biological 
replicates (n=5-6) ± SE. * indicates a significant difference compared to the negative 
control as analysed by One-Way Independent ANOVA and LSD Post-Hoc test 
(p<0.05). 
132 
 
 
Figure 5.28: Expression of sclerostin gene in SaOS-2 transfected with scrambled 
miRNA, miR-1254 mimic and antagomir. The expression of sclerostin was 
normalised to the expression of ß-actin. Data is presented as mean expression of 6 
biological replicates (n=5-6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
 
Figure 5.29: Expression of sclerostin gene in TE-85 transfected with scrambled 
miRNA, miR-1254 mimic and antagomir. The expression of sclerostin was 
normalised to the expression of ß-actin. Data is presented as mean expression of 6 
biological replicates (n=6) ± SE. * indicates a significant difference compared to the 
negative control as analysed by One-Way Independent ANOVA and LSD Post-Hoc 
test (p<0.05). 
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Figure 5.30: Expression of sclerostin in media from SaOS-2 transfected with 
scrambled miRNA, miR-1254 mimic and antagomir. The expression of sclerostin 
was normalised to the total DNA content. Data is presented as mean expression of 
6 biological replicates (n=5-6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
 
Figure 5.31: Expression of sclerostin in media from TE-85 transfected with 
scrambled miRNA, miR-1254 mimic and antagomir. The expression of sclerostin 
was normalised to the total DNA content. Data is presented as mean expression of 
6 biological replicates (n=6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
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Figure 5.32: Expression of miR-1914 in SaOS-2 transfected with scrambled miRNA, 
miR-1914 mimic and antagomir. The expression of miR-1914 was normalised to the 
expression of RNU6-2. Data is presented as mean expression of 6 biological 
replicates (n=6) ± SE. * indicates a significant difference compared to the negative 
control as analysed by One-Way Independent ANOVA and LSD Post-Hoc test 
(p<0.05). 
 
Figure 5.33: Expression of miR-1914 in TE-85 transfected with scrambled miRNA, 
miR-1914 mimic and antagomir. The expression of miR-1914 was normalised to the 
expression of RNU6-2. Data is presented as mean expression of 6 biological 
replicates (n=3) ± SE. * indicates a significant difference compared to the negative 
control as analysed by One-Way Independent ANOVA and LSD Post-Hoc test 
(p<0.05). 
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Figure 5.34: Expression of sclerostin gene in SaOS-2 transfected with scrambled 
miRNA, miR-1914 mimic and antagomir. The expression of sclerostin was 
normalised to the expression of ß-actin. Data is presented as mean expression of 6 
biological replicates (n=6) ± SE. * indicates a significant difference compared to the 
negative control as analysed by One-Way Independent ANOVA and LSD Post-Hoc 
test (p<0.05). 
 
Figure 5.35: Expression of sclerostin gene in TE-85 transfected with scrambled 
miRNA, miR-1914 mimic and antagomir. The expression of sclerostin was 
normalised to the expression of ß-actin. Data is presented as mean expression of 6 
biological replicates (n=6) ± SE. * indicates a significant difference compared to the 
negative control as analysed by One-Way Independent ANOVA and LSD Post-Hoc 
test (p<0.05). 
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Figure 5.36: Expression of sclerostin in media from SaOS-2 transfected with 
scrambled miRNA, miR-1914 mimic and antagomir. The expression of sclerostin 
was normalised to the total DNA content. Data is presented as mean expression of 
6 biological replicates (n=6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
 
Figure 5.37: Expression of sclerostin in media from TE-85 transfected with 
scrambled miRNA, miR-1914 mimic and antagomir. The expression of sclerostin 
was normalised to the total DNA content. Data is presented as mean expression of 
6 biological replicates (n=6) ± SE. * indicates a significant difference compared to 
the negative control as analysed by One-Way Independent ANOVA and LSD Post-
Hoc test (p<0.05). 
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5.4 Discussion 
 
5.4.1 miRNA target prediction – Bioinformatic analysis 
In order to identify potential miRNAs that target sclerostin mRNA, we used five 
different miRNA target prediction tools: miRWalk, miRanda, Pictar, RNA22 and 
Targetscan. Each tool uses different characteristics of the interaction between 
miRNAs and target genes to predict miRNA targets: (1) miRWalk searches for 
perfect complementarities in the seed region of the miRNA-mRNA interaction and 
then extends it until a mismatch is found; (2) miRanda predict miRNA targets by 
using nucleotide sequence matching, miRNA and mRNA duplex stability and 
conservation of the target site; (3) Pictar is an abbreviation of “probabilistic 
identification of combination of target sites”. Pictar predicts miRNA targets based on 
complementarity of the seed region, conservation of the sequence between species 
and the thermodynamics of the entire miRNA-mRNA duplex; (4) RNA22 creates a 
prediction based mainly on complementarities in the seed region and 
thermodynamics of the miRNA-mRNA duplex. RNA22 does not consider cross-
species sequence conservation which are parameters utilised by miRanda, Pictar 
and Targetscan; (5) Targetscan predicts mammalian miRNA targets based on seed 
region complementarities and thermodynamics to predict conserved miRNA binding 
sites among different species (John et al., 2004; Tabas-Madrid et al., 2014; Xia et 
al., 2009). We used all these miRNA prediction algorithms to increase the chance of 
finding an miRNA that very effectively targets sclerostin mRNA. MiRNAs that were 
predicted by the majority of the tools were thus chosen for further experimental 
analysis. 
 
In this study, we identified several miRNAs which were predicted to interact with 
sclerostin mRNA. Six of these miRNAs were chosen for further analysis for 
verification of their functionality: hsa-miR-1231, hsa-miR-103a-3p, hsa-miR-1914, 
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hsa-miR-1254, hsa-miR-378a-3p and hsa-miR-422a (Table 5.1). Two of these 
miRNAs, miR-378a-3p and miR-422a were predicted to bind to sclerostin mRNA at 
two different sites each while miR-1914, miR-103a-3p, miR-1231 and miR-1254 
were predicted to have only one binding site, all binding sites being 7-8 nucleotides 
long (Table 5.2). Mimics and inhibitors of these miRNAs were then transfected into 
TE-85 and SaOS-2 cells to evaluate the involvement of these miRNA in the 
regulation of sclerostin synthesis.  
 
 
5.4.2 Validation of miRNA function  
In this chapter, the expression of each miRNA in transfected TE-85 and SaOS2 
cells was analysed using real-time PCR to evaluate whether miRNA transfection 
was successful. Theoretically, miRNA levels increase in cells transfected with 
miRNA mimics and decrease in cells transfected with miRNA inhibitor/antagomirs. 
To validate the function of selected miRNAs as negative sclerostin regulators, 
sclerostin gene expression was measured using real-time PCR and the sclerostin 
protein secreted into culture medium was measured using ELISA. It is anticipated 
that sclerostin gene expression and protein secretion would decrease in cells 
transfected with miRNA mimics and increase in cells transfected with antagomirs. 
 
 
5.4.2.1 miR-103a-3p transfection in SaOS-2 and TE-85 cells 
The expression of miR-103a-3p level in SaOS-2 cells transfected with miRNA mimic 
was significantly higher and in cells transfected with antagomir it was significantly 
lower compared to the negative control and cells with scrambled miRNA. The 
results for TE-85 cells broadly mirrored those for SaOS-2 cells, where miR-103a-3p 
expression in cells transfected with miRNA mimic was significantly higher compared 
to negative control and scrambled miRNA, and significantly lower when transfected 
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with antagomir compared to the negative control and scrambled miRNA. This result 
demonstrates that the miRNA transfections were successful, entering the cells and 
exerting their function.  
 
Sclerostin gene expression and protein secretion was also measured. In SaOS-2, 
sclerostin gene expression was significantly decreased in cells transfected with 
scrambled miRNA, miRNA mimic and antagomir compared to the negative control. 
However, there was no significant difference in the quantity of sclerostin protein 
secreted into the culture medium in any treatment group compared to the negative 
control. In TE-85 cells, there was no significant difference in sclerostin gene 
expression and amount of sclerostin protein secreted into culture media in all 
treatments compared to the negative control.  
 
As scrambled miRNA does not bind to any known mammalian mRNA, we did not 
expect to see any significant difference in sclerostin gene or protein expression and 
in cells transfected with it compared to the negative control. However, in this 
experiment sclerostin gene expression in both SaOS-2 transfected with scrambled 
miRNA were significantly lower compared to negative control, p<0.05. It can 
therefore be assumed that miR-103a-3p alone might not efficiently inhibit sclerostin 
production by osteosarcoma cell lines. 
 
 
5.4.2.2 miR-378a-3p transfection in SaOS-2 and TE-85 cells 
Transfection of miR-378a-3p mimic significantly increased its expression in both 
SaOS-2 and TE-85 cells compared to the negative control and scrambled miRNA. 
Cells transfected with miR-378a-3p antagomir demonstrated a significant decrease 
in miR-378a-3p expression in SaOS-2 and TE-85 cells compared to the negative 
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control and scrambled miRNA. These results show that the transfection process 
was efficient and thus we proceeded with gene expression analysis. 
 
Sclerostin gene expression was not significantly reduced in SaOS-2 transfected 
with miRNA mimic compared to negative control and scrambled miRNA. There was 
a small, but not significant increase in sclerostin gene expression in SaOS-2 
transfected with antagomir. However, miRNA mimic transfection in TE-85 showed a 
significant decrease in sclerostin gene expression compared to the negative control 
and scrambled miRNA. A significant decrease in sclerostin gene expression was 
also detected in TE-85 transfected with antagomir compared to negative control and 
scrambled miRNA. 
 
Sclerostin protein quantification using ELISA showed that there was no significant 
difference in the quantity of sclerostin secreted into culture media by SaOS-2 cells 
between treatment groups and the negative control. What is interesting about this 
finding is that in TE-85, there was a significant reduction in sclerostin protein 
expression in cells transfected with miRNA mimic compared to the negative control 
and scrambled miRNA. This demonstrates that miR-378a-3p binds to sclerostin 
mRNA and is able to inhibit sclerostin protein translation. In TE-85 transfected with 
antagomir, there was an increase, although not significant, in sclerostin protein 
detected. This might be due to the nature of the antagomir which has moderate 
affinity to the related miRNA sequence and has to be used in relatively high 
concentrations compared to the miRNA mimic. Hence, we believe that by increasing 
the concentration of antagomir, its inhibitory effect would be significant. 
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5.4.2.3 miR-422a transfection in SaOS-2 and TE-85 cells 
SaOS-2 cells transfected with miR-422a mimic showed a significant increase of 
miR-422a expression compared to the control. Similar results were observed in TE-
85 cells where a significant increase in miR-422a levels were detected in cells 
transfected with mimic and a significant decrease in cells transfected with 
antagomir, indicating successful miRNA transfection.  
 
Transfection of miR-422a significantly reduced sclerostin gene expression in SaOS-
2 compared to the control. Transfection of antagomir did not increase or decrease 
sclerostin expression level in SaOS-2. Meanwhile in TE-85, there was no change in 
sclerostin expression in all treatment groups compared to the control. 
 
ELISA analysis showed that there was no significant different between the amount 
of sclerostin protein secreted into culture media by SaOS-2 transfected with miRNA 
mimic and antagomir compared to control. Same observation was recorded in TE-
85 cells. 
 
5.4.2.4 miR-1231 transfection in SaOS-2 and TE-85 cells 
The expression of miR-1231 and its antagomir in SaOS-2 and TE-85 cells 
demonstrated successful transfection, indicated by a significant increase in miR-
1231 in cells transfected with miRNA mimic and significant decrease in antagomir 
transfection compared to the control. 
 
There was no significant difference in the expression of sclerostin gene in SaOS-2 
transfected with scrambled miRNA, miR-1231 mimic and antagomir compared to 
control. However, sclerostin gene expression in TE-85 was significantly lower in TE-
85 transfected with miRNA mimic. Surprisingly, there was no significant different in 
sclerostin gene expression in SaOS-2 and TE-85 transfected with antagomir 
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compared to control. Theoretically, the expression of the sclerostin gene in cells 
transfected with antagomir should increase compared to the negative control. 
However, our findings again show that it was significantly decreased in both SaOS-
2 and TE-85 transfected with antagomir compared to the negative control. As 
discussed previously, this could be due to the lower affinity of the antagomir to its 
miRNA target compared to that of the miRNA mimic. 
 
Interestingly, the amount of sclerostin protein secreted into the culture media was 
significantly lower in both SaOS-2 and TE-85 transfected with miR-1231 mimic 
compared to control. This result suggests that miR-1231 could reduce the sclerostin 
protein translation by blocking the mRNA transcript for sclerostin. 
 
 
5.4.2.5 miR-1254 transfection in SaOS-2 and TE-85 cells 
A significant increase in miR-1254 expression was detected in SaOS-2 and TE-85 
transfected with miRNA mimic compared to the negative control, indicating that 
transfection was achieved efficiently. 
  
In SaOS-2 cells, transfection with miRNA mimic did not significantly reduce 
sclerostin gene expression. Meanwhile, in TE-85 transfected with miRNA mimic a 
significant decrease of sclerostin gene expression was observed compared to the 
negative control.  
 
Analysis by ELISA showed that there was a significant decrease in sclerostin 
protein secretion by both SaOS-2 and TE-85. However, transfection with antagomir 
did not increase sclerostin protein secretion in both cells. This result indicates that 
miR-1254 mimic was able to inhibit sclerostin production by osteosarcoma cell lines 
by inhibition of the translation of sclerostin mRNA. 
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5.4.2.6 miR-1914 transfection in SaOS-2 and TE-85 cells 
In SaOS-2 cells transfected with miRNA mimic, the expression of miR-1914 was 
significantly higher compared to the negative control, while that in cells transfected 
with antagomir was lower compared to the negative control but not significantly so. 
Those observations were mirrored in TE-85 cells transfected with miRNA mimic and 
antagomir compared to negative control. 
 
Sclerostin gene expression was significantly lower than the negative control in 
SaOS-2 cells transfected with scrambled miRNA, miRNA mimic and antagomir. As 
scrambled miRNA does not bind to any known mammalian mRNA, gene expression 
in cells transfected with it should not be significantly different from the negative 
control. While in TE-85 cells, there was no significant difference in expression when 
transfected with scrambled miRNA compared to the negative control. A significant 
decrease in sclerostin gene expression was observed in TE-85 transfected with 
miRNA mimic and antagomir. 
 
Analysis by ELISA showed a significant decrease in sclerostin protein secreted into 
the culture medium in SaOS-2 transfected with scrambled miRNA, miRNA mimic 
and antagomir. The quantity of sclerostin protein secreted by TE-85 cells 
transfected with miRNA mimic was also significantly lower compared to the control. 
This result demonstrates that miR-1914 has the potential to inhibit sclerostin protein 
production in SaOS-2 and TE-85 cells. To further validate SOST as the target of 
these miRNAs, in vivo test using mice is a most popular approach used by 
researchers. However, due to budget and time constrains, we only had the 
opportunity to study in vivo effect of miR-37a-3p on trabecular bone in mice which is 
reported in chapter 6. 
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5.5 Conclusions 
In this chapter, the aim was to identify miRNAs involved in the regulation of SOST 
using well-characterised osteosarcoma cell lines. The main research findings are: 
 
 miR-378a-3p decreased SOST protein expression in TE-85. miR-1231, 
miR-1254 and miR-1914 decrease SOST protein expression in both SaOS-
2 and TE-85.  
 surprisingly, transfection of antagomirs of all selected miRNAs, did not 
significantly increase SOST mRNA in either TE-85 or SaOS-2 cells. This 
might be due to the fact that antagomir has lower affinity to its target 
compared to miRNA mimic. Hence, increasing antagomir concentration 
used for the treatment might enhance the effect of antagomir. 
 
Based on our results, the use of antagomirs appears to be less effective compared 
to miR mimics which have higher affinity to bind to their mRNA targets. The findings 
of this study suggest that miR-378a-3p, miR-1231, miR-1254 and miR-1914 mimics 
might be used for limiting the over-production of SOST protein in patients suffering 
low bone mass density. Although a great deal further in vivo validation and stringent 
clinical assessment would need to be performed before these miRNAs could be 
used as potential therapies, we are optimistic that miRNA has promising potential in 
the future. The inhibition of SOST expression by ATP and PTH as shown in chapter 
3 could be combined with miRNA treatment to increase the efficiency of the 
regulation of SOST expression. However, further study is needed to investigate any 
potential unwanted effect as too much SOST inhibition could lead to other issue 
such as bone overgrowth. 
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CHAPTER 6: 
EFFECTS OF miRNA-378a-3p TRANSFECTION ON BONE MICROSTRUCTURE 
IN MICE 
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6.1 Introduction 
In chapter 5, using online prediction tools, we selected several miRNAs that were 
predicted to target sclerostin for in vitro validation using miRNA mimics and miRNA 
antagomirs. One miRNAs that we selected for the in vitro validation was miR-378a-
3p. From a separate series of experiments conducted by Muscle Research Group 
members, Department of Musculoskeletal Biology, Institute of Ageing and Chronic 
Diseases, University of Liverpool, we had access to the hind legs of both aged and 
adult mice that had been treated with miR-378a-3p mimic and antagomir. 
 
We used microcomputed tomography (micro-CT), to study the effect of miR-378a-
3p treatment on trabecular bone properties in mice. Micro-CT, is a high-resolution 
imaging technique widely used to measure bone mass and architecture in animal 
and human models. It’s key advantage is the non-destructive nature of this 
scanning technique and following analysis, samples then can be investigated by 
techniques such as histology or immunostaining (Bouxsein et al., 2010). Bone 
researchers have used micro-CT for more than a decade to study bone structure-
function relationships and disease progression.  
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6.2 Brief methods 
 
6.2.1 miR-378a-3p treatment via tail vein injection 
Treatment of mice with miR-378a-3p was done by Muscle Research Group 
members, Department of Musculoskeletal Biology, Institute of Ageing and Chronic 
Diseases, University of Liverpool. Adult (6 months old) and elderly (2 year old) mice 
were treated with miR-378a-3p mimics or inhibitors/antagomirs through tail vein 
injection. Mice were sacrificed 3 weeks after the treatment and the left hind limbs 
removed, preserved in 10% PBFS and used for micro-CT scanning, histology and 
fibre type analysis (Section 2.4.1).  
 
 
6.2.2   Micro-computed tomography (micro-CT) scan of trabecular bone of 
tibial head of treated mice  
Samples were transferred into micro-computed tomography (micro-CT) scanning 
tubes and scanned using a Skyscan 1272 system in water. The cross-section 
reconstruction was performed using NRecon software. Volumes of interest were 
determined using Data Viewer software and the properties of the trabecular bone 
were analysed using CTan software (Section 2.4.2).  
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6.3       Results 
 
6.3.1 Micro-computed tomography (micro-CT) scan of trabecular bone of tibial 
head 
 
Figure 6.1: Micro-CT analysis of the trabecular bone of tibial head of six month old 
adult mice and two year old elderly mice. Graph shows trabecular bone 
volume/tissue volume (BV/TV) in adult and elderly mice, untreated, treated with 
miR-378a-3p mimic and treated with anti-miR-378a-3p/antagomir. Data are 
expressed as mean ± SE. * indicates significant different compared to control. Data 
was analysed using One-Way Independent ANOVA and LSD Post-Hoc test. Adult 
control, n=8; adult miRNA mimic, n=18; adult antagomir, n=6; elderly control, n=7; 
elderly miRNA mimic, n=9; elderly antagomir, n=8.  
 
Fig. 6.1 shows the bone volume/tissue volume (BV/TV) ratio in adult and elderly 
mice, untreated, treated with miR-378a-3p mimic and with antagomir at a dose of 2 
mg/kg body weight through tail vein injection. Three  weeks after treatment there 
was no significantly change in the BV/TV ratio in treated compared to control mice 
for both adult and elderly animals, p>0.05. However, bone volume in untreated 
adults was 2.7 times higher than in untreated elderly mice, p<0.05. 
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Treatment with miR-378a-3p mimic or its antagomir also did not significantly affect 
trabecular thickness in either adult or elderly mice compared to untreated animals, 
p>0.05 (Fig. 6.2). Surprisingly, there was no significant difference in trabecular 
thickness between untreated adult and untreated elderly mice either, p>0.05. 
 
 
Figure 6.2: Micro-CT analysis of the trabecular bone of tibial head of six month old 
adult mice and two year old elderly mice. Graph shows trabecular thickness (Tb.Th) 
in adult and elderly mice treated with miR-378a-3p mimic and anti-miR-378a-
3p/antagomir. Data are expressed as mean ± SE. Data was analysed using One-
Way Independent ANOVA and LSD Post-Hoc test. Adult control, n=8; adult miRNA 
mimic, n=18; adult antagomir, n=6; elderly control, n=7; elderly miRNA mimic, n=9; 
elderly antagomir, n=8. 
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Treatment of adult and elderly mice with miR-378a-3p mimic and its antagomir does 
not significantly change total bone porosity compared to control mice for both adult 
and elderly animals, p>0.05 (Fig. 6.3). As expected, total bone porosity in untreated 
elderly mice is significantly higher than that in untreated adult mice, p<0.05. 
 
 
Figure 6.3: Micro-CT analysis of the trabecular bone of tibial head of six month old 
adult mice and two year old elderly mice. Graph shows total bone porosity (%) in 
untreated mice, mice treated with miR-378a-3p mimic and with anti-miR-378a-
3p/antagomir. Data are expressed as mean ± SE. * indicates significant different 
compared to control. Data was analysed using One-Way Independent ANOVA and 
LSD Post-Hoc test. Adult control, n=8; adult miRNA mimic, n=18; adult antagomir, 
n=6; elderly control, n=7; elderly miRNA mimic, n=9; elderly antagomir, n=8. 
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There was no significant difference in the mean number of trabeculae per millimetre 
(trabecular number) of bone in the tibial head of adult and elderly mice treated miR-
378a-3p mimic and its antagomir compared to untreated animals (Fig. 6.4), p>0.05.  
Untreated adult mice had 2.5 times more trabecular bone compared to elderly mice, 
p<0.05. 
 
 
Figure 6.4: Micro-CT analysis of the trabecular bone of tibial head of six month old 
adult mice and two year old elderly mice. Graph shows the number of trabeculae 
per mm in adult and elderly mice, untreated, treated with miR-378a-3p mimic and 
treated with anti-miR-378a-3p/antagomir. Data are expressed as mean ± SE. * 
indicates significant different compared to control. Data was analysed using One-
Way Independent ANOVA and LSD Post-Hoc test. Adult control, n=8; adult miRNA 
mimic, n=18; adult antagomir, n=6; elderly control, n=7; elderly miRNA mimic, n=9; 
elderly antagomir, n=8. 
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There was no significant difference in trabecular pattern factor in adult mice treated 
with miR-378a-3p mimic or anti-miR-378a-3p/antagomir compared to untreated 
mice, p>0.05 (Fig. 6.5). However, the trabecular pattern factor in old mice treated 
with miRNA mimic was significantly higher compared to the control, p<0.05. 
Generally, trabecular pattern factor is 54% higher in untreated elderly mice 
compared to untreated adult mice, p<0.05, indicating poor connectedness of the 
trabecular bone in elderly mice, contributing to weakening of the bone. 
 
 
Figure 6.5: Micro-CT analysis of the trabecular bone of tibial head of six month old 
adult mice and two year old elderly mice. Graph shows trabecular pattern factor 
(/mm) in adult and elderly mice, untreated, treated with miR-378a-3p mimic and with 
anti-miR-378a-3p/antagomir. Data are expressed as mean ± SE. * indicates 
significant different compared to control. Data was analysed using One-Way 
Independent ANOVA and LSD Post-Hoc test. Adult control, n=8; adult miRNA 
mimic, n=18; adult antagomir, n=6; elderly control, n=7; elderly miRNA mimic, n=9; 
elderly antagomir, n=8. 
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The was no significant change to trabecular separation in adult mice treated with 
miR-378a-3p mimic and it’s antagomir. Compared to untreated mice, p>0.05 (Fig. 
6.6). There was no significant difference in trabecular separation between elderly 
mice treated with miR-378a-3p mimic and antagomir compared to untreated mice. 
In general, trabecular separation in elderly mice was 1.8 times higher than that of 
adult mice, p<0.05. 
 
 
Figure 6.6: Micro-CT analysis of the trabecular bone of tibial head of six month old 
adult mice and two year old elderly mice. Graph shows trabecular separation (mm) 
in adult and elderly mice, untreated, treated with miR-378a-3p mimic and with anti-
miR-378a-3p/antagomir. Data are expressed as mean ± SE. * indicates significant 
different compared to control. Data was analysed using One-Way Independent 
ANOVA and LSD Post-Hoc test. Adult control, n=8; adult miRNA mimic, n=18; adult 
antagomir, n=6; elderly control, n=7; elderly miRNA mimic, n=9; elderly antagomir, 
n=8. 
 
 
 
  
154 
 
Figure 6.7 shows images from the micro-CT scan of the tibial head of adult and 
elderly mice treated with miR-378a-3p mimic and its antagomir. Bones were 
scanned at a high resolution of 4.5 µm. There is a clear difference between the 
trabecular bones of adult (Fig. 6.7a-c) and elderly (Fig. 6.7d-f) mice. Adult mice had 
significantly higher trabecular bone volume and trabecular number compared to 
elderly mice, p<0.05 (Fig. 6.1 and Fig. 6.4). From these images also we can see 
clearly that elderly mice have higher trabecular separation and bone porosity 
compared to adult mice.  
 
 
Figure 6.7: micro-CT scan images of the proximal tibia and fibula of the mice hind 
limb. (a) Adult mice, untreated control; (b) Adult mice, treated with miR-378a-3p 
mimic; (c) Adult mice, treated with antagomir; (d) Elderly mice, untreated control; (e) 
Elderly mice, treated with miR-378a-3p mimic; (f) Elderly mice, treated with 
antagomir. 
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6.4 Discussion 
In the first part of this chapter, we analysed the effect of miR-378a-3p mimic and its 
antagomir treatment on trabecular bone in adult and elderly mice. Parameters of 
trabecular bone such as bone volume fraction,r bone volume density (BV/TV), bone 
thickness (Tb.Th), total porosity, trabecular number (Tb.N), trabecular pattern factor 
(Tb.Pf) and trabecular separation (Tb.Sp) were measured to evaluate the effect of 
the treatment on the condition of the bone. The values of these parameters depend 
on the species, type of bone, location within it and the health status of the subject. 
 
BV/TV is the ratio of segmented bone volume to the total volume of the region of 
interest and is normally presented as percentage. Tb.Th is the mean thickness of 
the trabeculae which is a key measure for characterising the three-dimensional (3D) 
structure of trabecular bone. It can be used to compare the thickness of a trabecular 
structure but it is unable to describe all structural changes. For example, if one 
sample were composed of struts of uniform thickness and another sample had 
thicker vertical struts but interconnected with much thinner horizontal trabeculae, 
the two samples could have similar Tb.Th but with very different bone strength. 
Total porosity is the volume of all open and closed pores presented as a percentage 
of the total volume of interest.  
 
Another parameter of trabecular bone we measured was Tb.N which conveys the 
mean number of trabeculae per unit length (normally per mm) within the selected 
volumetric region of interest. Assessed using a direct 3D method, Tb.Sp is the 
mean distance between trabeculae. Tb.Th and Tb.Sp can be used as a powerful 
parameter to characterize the shape of a complex trabecular structure. The last 
parameter of trabecular bone we studied was Tb.Pf which describes the 
connectedness of the bone based on the relationship between convex and concave 
surfaces. When there are many convex surfaces present, trabecular bone is 
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considered badly connected whereas if there are more concave structures, the 
bone becomes more connected. Briefly, a lower Tb.Pf signifies better connectivity 
while a higher value indicates poor connectivity between the trabeculae (Chen et 
al., 2013; Hahn et al., 1992; Legrand et al., 2000).  
 
Our result indicate that three weeks after treatment with miR-378a-3p mimic or its  
antagomir the anatomy of adult mice were not affected in terms of BV/TV, Tb.Th, 
total porosity, Tb.N, Tb.Pf or Tb.Sp. In elderly mice, similar results were recorded 
for BV/TV, Tb.Th, total porosity and Tb.N. However, there were a significant change 
in Tb.Pf and Tb.Sp following treated with miR-378a-3p mimic compared to the 
control, p<0.05. Tb.Pf was significantly higher (33.59±1.60) compared to the control 
(27.36±1.02), p<0.05. This result suggests that, miR-378a-3p significantly reduces 
the connectivity of trabecular bone in elderly mice but not in adult mice. A higher 
value of Tb.Pf indicates that there are more convex than concave surfaces in the 
trabeculae, reducing the connectivity of the trabecular bone. Lower connectivity 
contributes to the weakening of the bone structure. 
 
In parallel with this result, Tb.Sp was significantly lower in adult mice treated with 
miR-378a-3p mimic (0.28±0.01) compared to the control (0.32±0.01), p<0.05. In 
general, Tb.Sp continuously increases with ageing. This result suggests that 
treatment with miR-378a-3p mimic has the potential for use in reducing the rate of 
increasing Tb.Sp as we age. The inhibitory effect of miR-378a-3p on bone formation 
might be less clear in adult mice due to a higher natural bone formation rate 
compared to elderly mice. Comparison between untreated adult and elderly mice 
showed that BV/TV and Tb.N significantly decreases with ageing while total 
porosity, Tb.Pf and Tb.Sp significantly increases. However, there was no significant 
difference in Tb.Th between adult and elderly mice. Tb.Th does not have a big 
impact on bone strength compared to Tb.N and Tb.Sp (Chen et al., 2013). 
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The age of the mice is an important factor in an experimental design as it could 
increase the experimental variability if the choice of age is inconsistent. In this 
study, we used 2 age groups of mice, six months old adult male mice and two years 
old elderly male mice. At the age of six months, mice are fully grown and their bone 
mass is at the peak while two years old mice are considered as aged mice and their 
bone mass is decreasing (Brodt et al., 1999, Halloran, et al., 2002). Since this 
treatment was performed by our fellow researchers from Muscle group, mice were 
treated with miR-378a-3p for three weeks at this period of time is enough to see any 
change in muscle prior to the treatment. However, in term of trabecular bone, a 
study have shown that four weeks of treatment was enough to cause significant 
increase in trabecular bone volume, trabecular number, and trabecular separation 
(Eom et al., 2013). Mice model was chosen to study human bone because their 
genome is easy to manipulate and their skeleton is similar to human which exhibit 
trabecular cortical bone loss as they aged that is caused by inadequate new bone 
formation by osteoblast. Furthermore, mice models of atherosclerosis also 
experience loss of bone which is common in osteoporotic individuals. This suggests 
that atherosclerosis and osteoporosis share the same pathophysiological pathways. 
However unlike human skeleton, after puberty the mice murine skeleton continues 
to grow slowly and lacks osteonal remodelling of cortical bone (Robert, 2013).  
 
It should be noted that there are limitations to our study. We studied the effect of the 
inhibition and introduction of selected miRNAs (miR-1231, miR-103a-3p, miR-1914-
3p, miR-1254, miR-378a-3p and miR-422a) on the gene and protein expression in 
osteosarcoma cell lines (MG-63, TE-85 and SaOS-2) in vitro. However, the in vivo 
effects, were not examined except only for one miRNA, miR-378a-3p. Another 
limitation was the concentration of the miRNA mimics and miRNA 
inhibitors/antagomir used was only one concentration. Using a few different 
concentrations or a series of concentration could give us more interesting finding to 
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understand the optimum concentration for both miRNA mimics and antagomirs. 
Also, for the in vivo study, miR-378a-3p transfection was conducted for three 
weeks. Extending this treatment period might reveal the actual effect of miRNA 
treatment on the trabecular bone.  
 
In general, there are two different approaches of miRNA therapeutics; miRNA mimic 
and miRNA inhibitor/antagomir. The use of miRNA mimic is also known as ‘miRNA 
replacement therapy’ where the specific miRNA is introduced into unhealthy or 
diseased cells that are normally expressed in healthy cells. The reintroduction of 
this miRNA into the cells helps to reactivate the pathways that are important for 
normal cell function and prevent those that cause the disease. On the other hand, 
antagomir acts by blocking the inhibition of protein translation by miRNAs. Hence, 
antagomir could be used to enhance the expression of proteins that are crucial for 
normal cell survival and functions. Compared to anti-sclerostin antibodies, the use 
of miRNA therapeutics to treat human diseases is still relatively new. In 
osteoporosis treatment by using anti-sclerostin antibody, the antibody specifically 
binds to sclerostin and prevents the binding of sclerostin to LRP5/6 and co-receptor 
frizzled. Therefore, Wnt is able to bind to LRP5/6 and co-receptor frizzled and 
activates the Wnt signalling pathway which is important for bone formation (Suen 
and Qin, 2016). The use of miRNA therapeutics however, might have unwanted 
side effect as each miRNA could have many different target genes. Hence, efficient 
delivery of miRNA to the desired target is still the biggest challenge in miRNA 
therapeutic research. However, a few miRNAs have entered the preclinical and 
clinical stage and are expected to be available in the market in the next few years 
(Christopher et al., 2016). 
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6.5      Conclusions 
 
The main findings of chapter 6 are: 
 
 Treatment using miR-378a-3p mimic and its antagomir did not have an effect 
on bone volume, trabecular thickness, total porosity or trabecular number in 
either adult or elderly mice; 
 MiR-378a-3p mimic increased the trabecular pattern factor in elderly mice. It 
has no effect in adult mice; 
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CHAPTER 7: 
GENERAL DISCUSSION 
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7.1 Summary of findings 
In chapter 3, the principal objective was to identify the mRNA expression patterns of 
several bone markers at different stages of osteoblastic differentiation using the 
osteosarcoma cell lines MG-63, TE-85 and SaOS-2. The behaviour of these cell 
lines has been shown to reflect their stage of osteoblastic differentiation, MG-63 
cells representing osteoblasts at an early stage, TE-85 an intermediate stage and 
SaOS-2 the most matured or differentiated osteoblast (Pacheco-Pantoja et al., 
2011). Our results showed that ALP, OSX and SOST mRNAs were expressed 
highest in SaOS-2, which is the most differentiated cell line. ALP, OSX and SOST 
are regarded as important bone markers and are highly expressed in mature 
osteoblasts. A study has shown that clonal bone marrow stromal cells (BMSCs) with 
in vivo bone forming capacity express their lowest level of ALP during the early 
stages of osteoblastic differentiation and a level more than 8.2 times higher at later 
stages (Prins et al., 2014). OSX and SOST have also been reported to be involved 
in regulation at a later stage of osteoblastic differentiation in murine and human 
bone (Poole et al., 2005; van Bezooijen et al., 2004; Yoshida et al., 2012). 
Interestingly, the expression of SOST mRNA was not detected in MG-63 cells, the 
least differentiated cells. This result corroborates the finding that SOST is secreted 
by osteocytes, a matured cell, to inhibit or limit new bone formation (Winkler et al., 
2003).  
 
The results provide an overview of differential expression of crucial bone markers at 
different stages of osteoblast maturation. Identification of the factors which regulate 
the induction or inhibition of these bone markers will help us to better understand 
the complex process of osteoblast development. The expression pattern of mRNAs 
of the selected bone markers in different cell lines also provide further evidence that 
MG-63, TE-85 and SaOS-2 cells are good models for the study of osteoblastic cell 
biology.  
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The effect of treating these cell lines with ATP, PTH and ATP combined with PTH 
for 48 hours on the expression of bone marker mRNA was investigated. It was 
found that treatment with ATP, PTH and ATP and PTH combined, significantly 
increased the expression of ALP, COL1A2, OSX and RANKL in all three cell lines. 
Conversely, these treatments significantly decreased the expression of COL6A3, 
OPG and SOST in all cell lines. Our findings indicate that these treatments exerted 
the same inhibitory or inductive effect on osteoblastic cells at all stages of 
differentiation or maturation.  
 
The expression of bone markers is controlled by various factors. Researchers have 
found that control of the expression of these markers by small non-coding RNA 
molecules, miRNAs, makes a very important contribution to overall expression. The 
discovery of miRNAs altered our understanding of gene regulation in various 
diseases. Over the preceding ten years, the study of miRNAs in various animal and 
plant species has steadily accelerated so that thousands of mature functional 
miRNAs and their targets have now been identified. In chapter 4, by studying MG-
63, TE-85, SaOS-2 cells and HOBs, the identity of individual miRNA molecules that 
were differentially expressed were ascertained in order to provide a better 
understanding of miRNA expression patterns at different stages of osteoblastic 
differentiation. Our investigation also provided data that identified miRNA 
candidates that are specific to osteosarcoma cell survival and function. Because of 
the capacity of miRNA molecules to simultaneously target multiple genes, I am 
optimistic that further investigations of these miRNAs will help to facilitate the 
identification of promising and novel early diagnostic/prognostic markers that may 
be potentially powerful therapeutic agents/targets. However, to fully exploit miRNAs 
in diagnostic or therapeutic practice, many more studies will need to be performed, 
in particular to identify every gene that a single miRNA can target, and to create 
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efficient methods of delivery of miRNAs to their target cells and tissues to avoid 
potentially unwanted side effects. 
 
In chapter 5, several miRNAs were identified which are predicted to regulate SOST 
expression in osteoblastic cells by use of an online prediction tool. From hundreds 
of miRNAs that were predicted to target the SOST gene, six miRNAs were selected 
for further experimental validation: miR-1231, miR-103a-3p, miR-1914, miR-1254, 
miR-378a-3p and miR-422a. To validate the roles of these miRNAs in SOST 
regulation, we transfected miRNA mimics and antagomirs of these miRNAs into TE-
85 and SaOS-2 cells. MG-63 cells were not used in this transfection assay as our 
findings in chapter 3 demonstrated that SOST is not expressed in this cell line. In 
this miRNA transfection experiment, SOST gene expression and protein secretion 
into the culture media were measured. From these results it was found that miR-
378a-3p, miR-1231, miR-1254 and miR-1914 significantly reduced the amount of 
SOST protein secreted into the culture media. 
 
Theoretically, antagomirs bind to their complementary miRNA hence blocking its 
binding to the specific mRNA target. Thus antagomirs increase the expression of 
that protein as the mRNA molecule is free to proceed with protein translation. 
However, surprisingly, transfection of antagomirs of all the selected miRNAs did not 
significantly increase SOST mRNA in TE-85 or SaOS-2 cells. This could be due to 
the low affinity of the antagomirs to their respective miRNAs. Increasing the 
concentration of antagomir used in the transfection experiment might be required to 
illicit the expected effect. Thus, miR-378a-3p, miR-1231, miR-1254 and miR-1914 
mimics may be promising therapeutic options for controlling the over-production of 
SOST. 
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Subsequently, the trabecular bone properties of tibial heads from adult and elderly 
mice treated with miR-378a-3p mimic and its antagomir were analysed. Anatomical 
observation of the mice 3 weeks after treatment did not provide evidence for an 
effect on bone volume, trabecular thickness, total porosity, trabecular number, 
trabecular pattern factor or trabecular separation in adult mice. In elderly mice, the 
only effects that were observed due to these treatments were in trabecular pattern 
factor in mice treated with miR-378a-3p mimic. An observation of increased 
trabecular pattern factor indicates a reduction in trabecular bone connectivity which 
results in a reduction in the strength of the bone. Overall bone strength will have 
been influenced by these contradictory effects. Comparison of untreated adult and 
elderly mice clearly showed that adult mice had significantly higher bone volume 
and trabecular number and significantly lower bone porosity, trabecular pattern 
factor and trabecular separation than did elderly mice. All these parameters suggest 
that the trabecular bones in adult mice are generally much stronger than in elderly 
mice. Trabecular thickness however was not significantly different in adult and 
elderly mice.  
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7.2 Discussion of research findings 
The expression pattern of selected bone markers throughout the osteoblastic 
differentiation process in this study corroborate previous reports on the utility of 
human osteosarcoma cell lines in studying osteoblastic cells (Pacheco-Pantoja et 
al., 2011). MG-63 cells are widely used to study osteoblastic cells because they 
retain many osteoblastic properties such as the synthesis of bone-specific proteins 
(osteocalcin and alkaline phosphatase) as a response to 1,25-dihydroxyvitamin D3 
(1,25-(OH)2D3) and PTH treatments (Lajeunesse et al., 1990). Various studies also 
show that the osteoblastic phenotypes of SaOS-2 cells have high levels of alkaline 
phosphatase activity and respond to PTH and 1α,25-dihydroxyvitamin D3 to induce 
the synthesis of osteonectin (Franceschi et al., 1985; Murray et al., 1987). Effects of 
ATP and PTH treatments on the expression of bone markers in MG-63, TE-85 and 
SaOS-2 cells were consistent in all cell lines. A significant increase in ALP, RANKL 
and COL1A2 expression and a decrease in OPG and SOST expression following 
ATP and PTH treatments have also been reported in various studies using different 
cell types (Bellido, 2006; Huang et al., 2004; Keller & Kneissel, 2005; Orriss et al., 
2013; Pines et al., 2003).  
 
The expression of these bone markers are not only controlled by direct factors such 
as ATP and PTH but also by indirect factors. An interesting study has reported that 
osteoblastic cells release ATP as a response to induced mechanical stress 
(Romanello et al., 2001) and ATP has been shown to affect the expression of vital 
proteins for bone development. This shows that bone development is a very 
complex continuous process, involving various factors which have synergistic 
effects.  
 
Another important factor that has an important role in controlling bone formation is 
the regulation of protein expression by miRNAs. Over the preceding decade, 
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miRNAs have been very popular with researchers studying the regulatory aspects 
of human health and disease. Hundreds of miRNAs that were differentially 
expressed between MG-63, TE-85, SaOS-2 cells and HOBs were identified. The 
differential expression of miRNAs between these cells provides a platform to further 
investigate other miRNAs that target proteins of interest that may be involved in 
enhancing osteoblastic differentiation and growth. In this study, six miRNAs were 
selected that were predicted to target the protein of interest, SOST, a protein that 
negatively regulates bone formation via inhibition of Wnt signalling (Poole et al., 
2005). The online database (miRWalk) indicates that, as of now, three human 
miRNAs have been validated to target SOST: miR-335-5p, miR-218-5p and miR-
204-5p.  
 
Our transient transfection experiment of miRNA mimics and their antagomirs 
suggests that miR-378a-3p, miR-1231, miR-1254 and miR-1914 mimics have 
potential for use as negative regulators of SOST expression in osteoblastic cells. 
We found that the use of antagomirs was less effective in the inhibition of miRNAs 
as they have lower affinity to their target miRNAs compared to the affinity of miRNA 
mimics with their mRNA targets. In this study, a final concentration of mimics and 
antagomirs of 100 nM was used. Increasing the concentration of antagomirs might 
increase their effectiveness. One study showed that antagomirs at a concentration 
of 0.125 to 1 µM significantly inhibited their target miRNA in primary B and T 
lymphocytes by up to 99.5% without affecting cell viability (Haftmann et al., 2015).  
 
Treatment of adult and elderly mice with miR-378a-3p did not affect trabecular bone 
volume. The treatment only affected trabecular pattern factor in elderly mice using 
miR-378a-3p mimic. One can speculate that the poor effects of miRNA treatment in 
our mice samples might be due to the low concentration of mimic and antagomir 
used in the treatment, which was 2 mg/kg of body weight. Increasing the 
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concentration of mimic and antagomir might increase the effects of miR-378a-3p 
treatment on bone. A study showed that the use of a much higher antagomir 
concentration, 80 mg/kg of body weight, via three tail vein infusions efficiently 
silenced miR-16 in mice (Krutzfeldt et al., 2005). A major challenge in miRNA 
research is the efficient delivery of the oligonucleotides to specific cells or tissues of 
interest. Thus efficient delivery is a determining factor in the development of 
miRNA-based therapeutics. One miRNA molecule always has more than one target. 
Inefficient delivery might result in unwanted alteration of the expression of other 
genes leading to serious side effects. One of the best approaches for efficient 
nucleotide delivery appears to be through chemical modification of mimic and 
antagomir oligonucleotides which show good pharmacokinetic properties, good 
tissue uptake and high stability in vivo.   
 
 
7.3 Limitations in this study and future investigations 
Following the results of the expression pattern of bone markers at different stages 
of osteoblastic differentiation and the effect of ATP and PTH on their expression, 
identification of other factors such as hormones or stimulants, might help to better 
understand the complex process of bone formation. Identification of these factors 
might enable us to control bone formation by manipulating these factors. In this 
study, only one concentration of ATP and PTH was used to treat the cells. Using a 
range of concentration of ATP and PTH might give us a clearer idea of the optimum 
concentration of ATP and PTH to exert their effect on the cells.  
 
Identification of miRNAs that control the protein of interest is an interesting research 
project. However, the short sequence of the seed region of miRNAs enables one 
miRNA to bind to many different targets. For example, an online validated miRNA 
database (miRTarBase) shows that miR-155-5p has been validated to target 
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hundreds of different genes in different species. This also means that one target 
gene can be controlled by several different miRNAs. In this study only one miRNA 
was transfected at a time to determine the individual role of miRNA molecule has 
towards the regulation of SOST protein. It would be interesting to investigate 
whether transfection of more than one miRNA mimic or antagomir into the same cell 
line might have greater effects on SOST gene expression. The use of higher 
concentrations of antagomirs might also show a stronger effect in miRNA silencing. 
Identification of miRNAs that control SOST expression could become a novel 
therapy for low or excessive bone mass-related disease. However, the biggest 
challenge is still to avoid off-target effects of miRNA therapeutics by developing 
efficient delivery of the miRNAs to the desired specific target. 
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7.4 Conclusions 
Overall it can be concluded that: 
 The effects of ATP and PTH treatment on the expression of bone markers are 
consistent at different stages of osteoblastic differentiation; 
 SOST expression was not detected in the least differentiated osteoblastic cell, 
MG-63; 
 MG-63, TE-85 and SaOS-2 cells are good models for studying osteoblastic cell 
biology; 
 Hundreds of miRNAs were differentially expressed at different stages of 
osteoblastic differentiation; 
 MiR-378a-3p, miR-1231, miR-1254 and miR-1914 mimics might be promising 
therapeutic options for limiting the over-production of SOST protein; 
 The effect of transient transfection of miRNA mimics and antagomirs was 
greater in TE-85 cells than in SaOS-2 cells; 
 Treatment with miR-378a-3p mimic and antagomir did not have any effect on 
bone volume, trabecular thickness, total porosity or trabecular number in either 
adult or elderly mice. However, it did increase trabecular pattern factor in 
elderly mice treated with miR-378a-3p mimic. 
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